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Abstract
DNA double-strand breaks (DSB) are one of the major mediators of chemotherapy-induced
cytotoxicity in tumors. Cells that experience DNA damage can initiate a DNA damage-mediated cell-cycle
arrest, attempt to repair the damage and, if successful, resume the cell-cycle (arrest/repair/resume).
Cells can also initiate an active cell-death program known as apoptosis. However, it is not known what
"formula" a cell uses to integrate protein signaling molecule activities to determine which of these paths
it will take, or what protein signaling-molecules are essential to the execution of that decision. A better
understanding of how these cellular decisions are made and mediated on a molecular level is essential
to the improvement of existing combination and targeted chemotherapies, and to the development of
novel targeted and personalized therapies. Our goal has been to gain an understanding of how cells
responding to DSB integrate protein signaling-molecule activities across distinct signaling networks to
make and execute binary cell-fate decisions, under conditions relevant to tumor physiology and
treatment.
We created a quantitative signal-response dataset, measuring signals that widely sample the
response of signaling networks activated by the induction of DSB, and the associated cellular phenotypic
responses, that together reflect the dynamic cellular responses that follow the induction of DSB. We
made use of mathematical modeling approaches to systematically discover signal-response relationships
within the DSB-responsive protein signaling network. The structure and content of the signal-response
dataset is described, and the use of mathematical modeling approaches to analyze the dataset and
discover specific signal-response relationships is illustrated.
As a specific example, we selected a particularly strong set of identified signal-response
correlations between ERK1/2 activity and S phase cell-cycle phenotype, identified in the mathematical
data analysis, to posit a causal relationship between ERK1/2 and S phase cell cycle phenotype. We
translated this posited causal relationship into an experimental hypothesis and experimentally test this
hypothesis. We describe the validation of an experimental hypothesis based upon model-derived signal-
response relationships, and demonstrate a dual role for ERK1/2 in mediating cell-cycle arrest and
apoptosis following DNA damage.
Directions for the extension of the signal-response dataset and mathematical modeling
approaches are outlined.
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Chapter 1: Introduction
This thesis investigates the signaling mechanisms governing the cellular response to DNA
damage and DNA double-strand breaks (DSB), through the use of quantitative experimental, and
computational, molecular and cell biology approaches. This chapter contains background and
motivating information for this work, including a contextualization of this work within the questions of
the cancer biology field, and an overview of DNA damage- and DSB signaling, the role of inflammatory
cytokines in the etiology and treatment of cancer, and systems biology methods and models that we
make use of, and extend, within the scope of this thesis.
DNA damage and DSB: cancer cause and cure
The chromatin integrity network is a highly conserved response, found in all eukaryotes, that is
critical to maintaining genomic integrity. Failure of cells to appropriately respond to DNA damage
facilitates tumorigenesis [1, 2]. In fact, many mutations commonly found in tumors target and derange
the DNA damage response. A failure to respond appropriately to DNA damage also leaves tumor cells
susceptible to cell-killing by DNA-damaging agents; these agents are thus used in the clinic to target
tumors cells [3-9].
Of the many lesion types that constitute DNA damage, the most lethal is the DNA double-strand
break (DSB), and DSB are one of the major mediators of chemotherapy-induced cytotoxicity in tumors
[2, 10]. Following induction of DSB, cells respond on a molecular level by activating protein signaling
molecules in the core chromatin integrity network or DNA double-strand break response pathway, and
in pathways governing general stress response , cell-survival , cell-death and cell-cycle control (Figure
1-1). On the cellular level, the integration of these protein signaling-molecule activities translates into
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one of several cell-fate decisions, including induction of cell-cycle arrest, initiation of DNA repair,
activation of transcriptional programs, and either apoptosis, necrosis or cell senescence [2, 11]. The two
major cellular responses that are explored in this thesis include that of 1) DNA damage-mediated cell-
cycle arrest and 2) cell-death via apoptosis.
survival stress chromatin intearitv stress
apoptosis cell-cycle control
apoptosis stress DNA damage response
Cell cycle regulation survival
Figure 1-1. A schematic DNA damage response signaling network demonstrating the intersection and
integration of multiple distinct signaling networks governing the chromatin-integrity response, and
general stress, survival, cell-death and cell-cycle regulatory responses.
'------, . 11 ...- ..:::: : - :: --- 'V - I - - - - . :: ::.:::: _ . - - - ::::- -, . ... . ... ........
Proximal DSB signaling
Following induction of a DSB, inactive ATM dimers in the nucleoplasm auto-phosphorylate, fall
apart into active monomers and localize to the site of the break [12, 13]. A complex of three proteins,
MRE11, Rad50 and Nbs1, known as the MRN complex, also localizes to the site of the break [14, 15].
Once at the site of the break, ATM phosphorylates the histone variant H2AX at areas surrounding the
break and many other chromatin-associated and nucleoplasmic substrates [16-19]. ATM also directly
associates with the MRN complex via Nbsl [20, 21], and ATM and Nbsl act in a mutual fashion to
further, or maintain, the activation status of the other [22-28]. The activation and localization of ATM
and Nbs1 to break sites, and of yH2AX to areas surrounding break sites, is required for subsequent
recruitment and retention of DNA repair factors, to the site of the break and for activation of
downstream signaling molecules necessary for induction of DNA damage mediated cell-cycle arrest and
cell-death processes following DNA damage [18, 29]. A few of the better characterized ATM substrates
include Chk2 and p53 [30-33]. Chk2 is a checkpoint signaling protein that leads to induction of DNA
damage mediated cell cycle arrest via phosphorylation and inactivation of Cdc25A/C phosphatases [34].
p53 is a signaling protein and transcription factor that can lead to maintenance of DNA damage
mediated cell cycle arrest via upregulation of the cyclin dependent kinase inhibitor (cki) p21, or to
induction of apoptosis via transactivation of pro-apoptotic Bcl-2 protein family members [35-40].
Mutations in many of the proteins involved in the proximal signaling response to DSB, including
ATM, H2AX, Chk2, Nbsl and p53, are commonly found in various cancers and are often clearly
associated with increased risk of cancer in mutation-carriers [41, 42].
Other molecular signals in the DSB response
MAPKs
p38, JNK and ERK kinases are all members of the MAPK (Mitogen Activated Protein Kinase)
family. While MAPK family members are not traditionally thought of as part of the specific DNA
damage, or DSB, response, these important cellular proteins are widely accepted to be key elements in
the regulation of cell fate decisions such as cell cycle control and apoptosis in nearly all cell types. These
MAPKs have been shown to be activated by induction of DSB, and they undoubtedly play a role in
regulation of cell fate following genotoxic stress.
The MAPK family of signaling pathways is eukaryotic-specific and highly conserved [43-45]. This
family of signaling pathways consists of several specific pathways all sharing a general three-kinase
signal cascade format in which a MAPKKK (MAPK kinase kinase) serine/threonine kinase is activated,
dually phosphorylates and activates a MAPKK (MAPK kinase) dual specificity kinase, that, in turn, dually
phosphorylates and activates a MAPK (MAP kinase) serine/threonine kinase on a TXY motif in the MAPK
activation loop [44, 46]. MAPKs are serine-threonine kinases with a repertoire of at least 80 substrates
consisting of transcription factors, protein kinases and cytoskeletal components [47]. There are just five
MAPKs, the best characterized in mammals being p38, JNK, and ERK1/2. However, they are involved in
the mediation of such wide-ranging and key cellular processes as cellular growth, differentiation,
adaptation to stress, survival and death in response to such diverse stimuli as growth factors, cytokines,
cellular adherence status and hypoxic and genotoxic stress [43, 44]. The ability of these few kinases to
respond to such a wide variety of stimuli is not fully understood, but is probably facilitated by the MAPK
cascade set-up and the ability of several MAPKKK to initiate each cascade [44].
ERK1/2 is usually thought of as a "survival" kinase. It is the MAPK downstream in the three-
kinase MAPK pathway consisting of Raf/MEK/ERK [48]. ERK is activated by dual phosphorylation at
T202/Y204 by the MAPK kinases MEK1 and MEK2, in response to such growth factors as EGF and PDGF
[44, 49]. A role for ERK1/2 in the promotion of cell-survival and proliferation in response to various
growth factors and mitogenic signals is well established. However, it is also implicated in both cell cycle
control and protection from cell death in some cell types [44, 49], and it is activated in cells following
treatment with several genotoxic agents [48, 50].
p38 is usually thought of as a "general stress" kinase. It is a MAPK family member that is
activated by dual phosphorylation at T180/Y182 by the MAPK kinases MEK3 and MEK6 [49] in response
to cellular stresses, such as genotoxic and osmotic stress, and inflammatory cytokines, such as TNF-a
and IL-1 [51]. Its known substrates include the transcription factor ATF2 and the protein kinase MAPK
activated protein kinase-2 (MAPKAPK2/Chk3) [51, 52]. p38 has a role in mediating cytokine production
and apoptosis [44, 45], as well as in cell cycle checkpoint induction and apoptosis following DNA damage
[47, 52]. It has been shown recently by the Yaffe lab and the Fornace lab that the p38 SAPK pathway is
activated following UV treatment, and it has been proposed that p38 activation of MAPKAPK2/Chk3 acts
as another branch in the DNA damage response, in analogy to the ATM-Chk2 and ATR-Chkl branches.
Indeed, MAPKAPK2/Chk3 shares a high functional similarity to the other Chk effector kinases in
mediating cell cycle arrest following UV [52]. MAPKAPK2/CHK3 has been shown to phosphorylate
CDC25B/C following UV, generating the 14-3-3 binding site necessary for cytoplasmic sequestration, and
it has been shown that loss of MAPKAPK2/Chk3 results in an inability to sustain a G2/M or a G1/S
checkpoint following UV-induced DNA damage [52].
JNK is usually thought of as a "general stress" or "death" kinase. It is a MAPK family member
that is activated by dual phosphorylation at T183/Y185 by the MAPK kinases MEK4 and MEK7 [49] in
response to such cellular stresses as genotoxic (eg UV light, y-irradiation) and osmotic stess, and in
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response to inflammatory cytokines, such as TNF-a and IL-1) [45, 47, 48, 50, 53]. Its known substrates
include the Jun-family transcription factors (c-Jun, c-Fos, ATF2) [44, 47]. JNK is implicated in the
induction of apoptosis in several cell types .
Non-MAPKs
Akt, also known as Protein Kinase B (PKB), is a kinase involved in promotion of survival and
regulation of insulin signaling [54, 55]. It is phosphorylated by PDK1 and mTOR-rictor following
activation of P13K by activated RTKs (receptor tyrosine kinases) and requires phosphorylation on T308
and S473 for activity [56-59]. Substrates include FOXO isoforms, BAD, and GSK3. Akt may positively
regulate ERK1/2 signaling via GSK3 [60-63]. Mutations that affect Akt regulation are commonly found in
cancer, including mutations of PTEN, a negative regulator of Akt, and of P13K, a positive regulator of Akt
[64-67].
NFKB is a transcription factor that is implicated both in promoting survival in response to a wide
variety of stresses, including genotoxic stress, and in initiation of inflammatory responses [68-70].
Under normal cellular conditions, NFKB is sequestered in the cytoplasm by the regulatory protein IKBa.
When IKK (IKBa kinase, a multi-subunit kinase consisting of two catalytic subunits, IKKa and IKKP and a
non-catalytic subunit, IKKy or NEMO) is activated, it phosphorylates IKBa, leading to the ubiquitination
and degradation of IKBa, and the release of NFKB and its subsequent nuclear translocation [71, 72].
Following DNA damage, ATM may play a key role in activation of NFKB by directly phosphorylating the
IKK subunit, NEMO, leading to its activation[73-75].
Cellular responses to DNA damage/DSB
Apoptosis: Programmed cell-death
Apoptosis is an important cellular response to DNA damage that can prevent the propogation of
cells that have sustained irreparable chromatin changes [76-80]. It is an active form of "programmed"
cell-death in which cell-elements are broken down and contained in apoptotic membrane-bound
vacuoles or blebs. This break-down and containment of cellular elements prevents their release into the
surrounding extracellular matrix [78, 81]. Apoptosis does not normally provoke an inflammatory
response, as may occur in a relatively unordered and messy alternate mode of cell-death known as
necrosis [82-84]. As opposed to other forms of cell-death such as necrosis, or as opposed to non-cell
death outcomes such as senescence, apoptosis is the goal cellular outcome of chemotherapeutic
treatment regimens as it is thought to be the cellular outcome that most effectively leads to tumor
regression [85-87].
Apoptosis can be mediated by two distinct pathways, the extrinsic and intrinsic pathways. In
extrinsic pathway activation extracellular ligands bind to death receptors (e.g. TNF/TNFR1) and activate
a cascade of intracellular signals, leading to the activation of the initiator caspase 8. In intrinsic pathway
activation, dysfunction of intracellular organelles (e.g. mitochondrial cytochrome c release) due to
various cellular stresses leads to activation of the initiator caspase 9 [88-90]. Activation of the initiator
caspases via the extrinsic and intrinsic pathways converge to activate the effector cystein protease
caspase-3 [91].
Apoptosis is dysregulated in cancer and its dysregulation leads to cancer development and
progression [80, 92].
Cell cycle checkpoints
Cell cycle check-points constitute an essential cellular response to DNA damage that can prevent
cells from replicating while DNA damage remains unrepaired, thus preventing damaged cells from
passing on mutagenic chromatin changes [93, 94]. Cell cycle regulatory elements are commonly
dysregulated in cancer and the dysregulation of these elements promotes cancer development and
progression [95, 96].
Modulation of cell-cycle regulators may be useful in tumor treatment regimens, alone, or in
conjunction with traditional DNA damaging chemotherapeutics. One possible mode of interference is
disruption of cell-cycle checkpoints, as bypass of cell-cycle checkpoints normally initiated by DNA
damage in tumor cells can lead to cell-death [97-103].
Doxorubicin
Doxorubicin (Dox) is a naturally occurring, bacterially-derived anthracycline, and is one of the
most widely therapeutically applied DNA damage-inducing chemotherapeutics for the treatment of solid
and hematopoietic tumors [104-106]. It is a topoisomerase 11 inhibitor that leads to the induction of
DNA double-strand breaks (DSB).
Topoisomerase II is a multifunctional endogenous enzyme that can act as a helicase, nuclease
and DNA-religase. It participates primarily during DNA synthesis, but also during transcription, to
unwind and cut super-helical DNA, allow DNA and RNA polymerases to pass, and then to relegate DNA
following polymerase passage. Doxorubicin binds to topoisomerase II on the DNA and locks it into a
conformation that is competent for DNA cleavage, but incompetent for DNA re-ligation. The result is an
accumulation of so-called "cleavable-complexes" (ternary complexes of Doxorubicin-topoisomerase ll-
DNA) marking the sites of protein-linked DNA double-strand breaks [107-109].
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Doxorubicin can also mediate cell-killing via oxygen radical production and via DNA intercalation
and inhibition of DNA and RNA polymerase [110-113]. Doxorubicin's mode of cytotoxicity has been
shown to be dose dependent; at doses above 3 ptM the balance shifts from direct strand breaks to
oxygen radical production (superoxide production probably results from the transfer of electrons to
molecular oxygen by the doxorubicin semiquinone after reduction of the drug by sarcosomal
NADPH:cytochrome P-450 reductase; this reaction is accompanied by accumulation of hydrogen
peroxide). However, it has been shown that DSB induction (but not SSB induction) is correlated with the
cytotoxicity of Doxorubicin [114-117].
Role of inflammation and inflammatory cytokines in cancer
Tumor cells express and secrete high levels of inflammatory cytokines, including TNF-a, and
increased expression of inflammatory cytokines in tumor cells is highly correlated with tumor grade for
several tumor types, and is associated with poor prognosis [118-121].
Additionally, some alleles of inflammatory cytokines (TNF) are associated with familial cancers
or cancer-prone conditions [122, 123] and suppression of TNF activity or expression in mouse models of
cancer has been shown to prevent the development of tumors [124]. Therefore inflammation and
inflammatory cytokines are strongly associated with tumor initiation or promotion and tumor
progression.
However, TNF has also been shown to have tumoricidal properties. Local high-dose
administration of TNF is under investigation as a treatment for some solid tumors [125-127].
Molecular-Targeted cancer therapeutics: Goals and Challenges
Molecular biological studies have accumulated detailed knowledge about some of the proximal
responders to DNA double strand breaks, as well as about signaling molecules that participate
canonically in signaling pathways distinct from chromatin-integrity signaling pathways, and that are
known to influence the cellular response to DSB (eg signaling molecules that participate in general
stress, survival, cell-death regulatory and cell-cycle regulatory pathways). Some of this understanding
has led to dramatic, if limited, success in developing targeted cancer therapies.
The most compelling targeted therapy story thus far is perhaps the use of the drug Gefitinib
(Iressa) in NSCLS patients. This drug is an EGFR inhibitor and leads to dramatic tumor regression in
NSCLC patients whose tumors express EGFR with one of two well-characterized activating mutations. In
patients whose tumors do not express a mutated EGFR, Iressa does not lead to substantial tumor
regression [128, 129].
Inhibition of signaling from the EGFR leads to inhibition of ERK and Akt signaling, two signaling
pathways that lie downstream from the EGFR. Both of these pathways are canonically involved in
promoting survival and proliferation. Therefore, that the inhibition of these pathways in cells leads to
tumor regression (involving both slowed proliferation and tumor cell death) is a straightforward
outcome [130, 131]. However, the signaling networks involved in mediating cell decisions such as that
of life versus death are complex, involving positive and negative feedback on many levels, and the
outcome obtained from inhibiting a single signaling molecule is often not straightforward [132].
EGFR family member receptors and ligands have been shown to be major drivers of the
pathology and progression of breast tumors. However, a large proportion of breast tumors are resistant
to treatment with tyrosine kinase inhibitors (TKIs) that target these family members. Mutations in
regulatory elements of the Akt signaling pathway are the source of this resistance in some tumors.
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Following treatment with TKIs such as Iressa, sensitive tumor cell-lines exhibit decreased
phosphorylation/activation of EGFR, ERK and Akt whereas resistant cell-lines exhibit decreased
phosphorylation/activation of EGFR and ERK, but maintain Akt signal activation. Loss of PTEN, a
negative regulator of Akt, has been shown to result in loss of sensitivity to TKIs. Restoration of PTEN
function to PTEN null cells, or direct pharmacologic inhibition of the P13K/Akt signaling pathway, confers
sensitivity to TKIs. In this instance, the context of Akt signaling function (wild-type vs. mutated) is a
determining factor between tumor sensitivity and tumor resistance to a targeted chemotherapeutic
agent (TKIs) [133-136].
Chemical inhibition of ATM, a master regulator of the DNA damage response, has been
proposed as a means to sensitize tumors to treatment with IR and other radiomimetic
chemotherapeutic agents [137, 138]. Primary cells from A-T patients and ATM knockout mice are
hypersensitive to ionizing radiation (IR) and chemotherapy-induced DNA double strand breaks (DSBs)
[139-141]. Additionally, ATM-deficient tumors have been shown to be sensitive to DNA DSB-inducing
cancer treatments [142] and some reports show loss of ATM in tumors correlates with beneficial clinical
outcomes in patients undergoing chemotherapeutic regimens with DNA damaging agents. However, a
large number of studies show the opposite result; certain studies suggest that loss of ATM may correlate
with resistance to DNA-damaging chemotherapy and poor patient survival [143-145]. Jiang, Reinhardt
et al. have recently shown that the mutation status of p53 and ATM, two of the most commonly
mutated genes in tumor cells, are crucial elements that interact to determine sensitivity or resistance to
DNA damaging chemotherapeutic regimens. Thus, tumors harboring mutations in both p53 and ATM
are highly sensitive to the cytotoxic effects of DNA damaging agents, while single mutants in either p53
or ATM are highly resistant. Chemical inhibition of ATM may then be expected to sensitize tumor cells
to DNA damaging chemotherapy in the context of a tumor already bearing a p53 mutation. However, in
p53 wild-type tumors, adjuvant chemical inhibition of ATM may actually be expected to confer
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resistance to the traditional regimen. In tumors already bearing both ATM and p53 mutations, adjuvant
ATM inhibition may be expected to not materially contribute to therapeutic outcome.
We do not have a clear understanding of how the integrated signaling response to DNA damage
works as a system to make a decision between the alternate cell-fates following DNA damage of cell
cycle arrest/repair/ resume or induction of cell death, and to mediate that decision. A better
understanding of how these cellular decisions are made and mediated on a molecular level is essential
to the improvement of existing combination and targeted chemotherapies, and to the development of
novel targeted and personalized therapies. Detailed quantitative systems-level studies of the molecular
signaling pathways involved in the cellular decision process following DNA damage are expected to
reveal context-dependencies in signaling and cellular decision outcomes. These context dependencies
represent crucial knowledge that may reconcile conflicting data in the literature regarding the role of
single signaling molecules in the life-death decision following DNA damage. The importance of context
to the cellular outcome obtained from a treatment has been demonstrated in many studies, and the
relevance to implementation of effective targeted chemotherapeutic regimens is clear [146-149].
System-biology models to investigate signal-response relationships in
cue-responsive biological networks
The collection of systems-level, quantitative signal-response data-sets is an essential step in
gaining insight into dynamic, context-dependent signaling mechanisms that may be exploited in design
of targeted chemotherapeutic regimens. Just as important is an appropriate analysis methodology for
these data. A wide range of computational modeling approaches have been used to study molecular
signaling and its regulation of cellular phenotypes. These approaches fall into two broad categories;
mechanistic modeling methods and data-driven modeling approaches.
Ordinary differential equation based physicochemical models are a popular implementation of a
mechanistic modeling approach. Such models require a detailed knowledge of the mechanisms of
interaction among signaling elements modeled that is not available in the context of many studies. The
applicability of these models to the analysis of relationships between molecular signaling and resulting
cellular phenotype is therefore practically limited [150-153].
Data-driven, relational modeling approaches, including regression analysis approaches such as
Partial Least Squares regression (PLSR), Bayesian network analysis and decision tree analysis methods,
have been used with success to discover signal-response relationships from quantitative signal-response
datasets in the study of biological networks with ill-defined structure that are, therefore, not amenable
to modeling in a more explicit fashion using ODE-based modeling approaches.
In PLSR analysis, signaling measurements are cast as a matrix of independent variables, X, across
several observations or treatment conditions, and cellular response measurements are cast as a matrix
of dependent variables, Y, across the same observations or treatment conditions. The analysis is based
on the hypothesis that the measured cellular responses are a definable quantitative function of the
measured molecular signaling [151, 154]. Due to technical, time and cost constraints, the number of
observations available for analysis is small and generally much smaller than the number of signals we
would like to relate to the cellular responses under investigation, prohibiting the calculation of a unique
regression solution to the hypothesized relationship Y = f(X).
PLSR reduces the explanatory variable set substantially to an effective explanatory variable set
that is made up of orthogonal latent variables, or Principal components (PCs). PCs are linear
combinations of the original model independent variables that simultaneously maximally capture
variance in the independent variable space and covariance with the dependent variable space. The
number of PCs necessary to capture the majority of the variance in the explanatory (independent)
variable set is much smaller than the number of original explanatory variables, and smaller than the
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number of observations available for analysis. The PCs serve as effective explanatory variables. This
effective reduction in the number of explanatory variables allows PLSR to find a unique solution for the
signal-response functional relationship [155, 156].
PLSR can be used to identify single signaling elements and combinations of signaling elements
that strongly correlate with cellular response. Additionally, it can be used to predict cellular responses
to additional treatments or conditions (e.g. following pharmacologic perturbations), using newly
measured and/or estimated signaling data. The quality of the model and any predictions it produces
rely upon the the original data-set having included: 1) measurements of all essential signaling molecules
for the cellular response decision under investigation, 2) measurements across treatment conditions
that produce large quantitative changes in activation of signaling elements, and 3) measurements across
treatment conditions that produce large qualitative changes in activation of signaling elements [157,
158]. PLSR models have been generated using quantitative molecular signaling and cellular response
data from and have been successful at interpreting and predicting signal-response relationships in
various contexts, including cytokine- and pathogen-induced epithelial cell apoptosis-survival [154, 157,
159], receptor agonist-induced T-cell and B-cell cytokine release [160, 161], and growth factor-induced
mammary epithelial cell proliferation and migration [162].
Stepwise regression (SWR) is a regression method that has been widely used in fields such as
sociology and has been used in biology for the analysis of genomic datasets. To our knowledge, it has
not been applied for the analysis of network level molecular signaling datasets. Stepwise regression is
an iterative algorithm that searches for a subset of explanatory variables, from an original larger set of
explanatory variables, that together best explain the variation in the response variable. Sometimes such
a subset can be manually chosen by the investigator, to coincide with some explicit hypotheses about
the system. A stepwise algorithm can be used to automatically pick out a subset of explanatory
variables in the case that there is no a priori hypothesis about which of the possible explanatory
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variables might actually best explain the variability in the response variable. Basically, the stepwise
technique will take a set of independent variables and put them into a regression one at a time, in a
specified manner, until a specified criterion has been met. The criterion is usually one of statistical
significance or the improvement in the explained variance. Depending on the strategy used for adding
variables to the regression model, multiple stepwise procedures can be used, such as forward,
backward, maximum R, etc [163, 164].
The stepwise procedure we use in the analysis of the measured data is a forward stepwise
approach. We start with no explanatory variables in the model. We first run all possible univariate
regressions, regressing the response variable on each of the possible explanatory variables in turn. For
each of these univariate regressions, we determine the significance level of the calculated regression
coefficient by calculating first the F statistic, or the ratio of the mean suare deviation between the model
and the mean and the mean square deviation between the data and the model. We then calculate the
corresponding p-value, or probability that the regression coefficient for that explanatory variable is
actually zero given the value of the F statistic, by means of an F-test. If we calculate a p-value less than
0.05 for just one of the univariate regression models, that explanatory variable is added to the model. If
we calculate a p-value less than 0.05 for more than one of the univariate regression models, the
explanatory variable for which the univariate regression model p-value is lowest is added to the model.
Next, all two-variable models that include the first selected explanatory variable are calculated, by
adding each of the remaining variables one at a time. For each of these pair-wise regressions, the
stepwise procedure determines the significance level of the new variable's ability to explain additional
variability in the response variable, by calculating the F statistic for each additional variable, and the p-
value, or probability that the regression coefficient for the new variable is actually zero given the F
statistic obtained, by means of an F-test. Again, if we calculate a p-value less than 0.05 for more than
one of the pair-wise regression models, the new explanatory variable for which the p-value is lowest is
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added to the model. This continues, next for all three-variable models, then four-variable models, etc.
The procedure stops when all the explanatory variables that satisfy the p-value criterion have been
included in the model.
In this thesis, we make use of Stepwise regression within a framework that was developed in the
process of analyzing our time-dependent signal-response data and is described in detail in Chapter 3.
The development of data-driven modeling analysis methods for the inference and
investigation of network-level signaling and relationship between signaling and cellular phenotype, and
for prediction of cellular phenotype under novel treatment conditions, is a rapidly growing area of
research. In this thesis, we apply accepted PLSR analysis methods and we develop a novel
implementation of another accepted analysis method, SWR, for the discovery of time-dependent
network level signaling and signal-response relationships (explained in detail in Chapter 3).
Thesis Overview
Using quantitative experimental and data-driven computational modeling approaches of a
quantitative signal-response data-set, this thesis investigates the relationship between molecular
signaling and cellular response phenotype resulting from exposure to DNA damage, and induction of
DSB, in a physiologically relevant, inflammatory context.
Chapter 2: A Systems Approach to DNA Damage Signaling
Identifies Phospho-ERK1/2 as a Binary Switch Between S-Phase
Progression and Apoptosis
Introduction
DNA damage and DSB: cancer cause and cure
The chromatin integrity network is a highly conserved response, found in all eukaryotes, that is
critical to maintaining genomic integrity. Failure of cells to appropriately respond to DNA damage
facilitates tumorigenesis . In fact, many mutations commonly found in tumors target and derange the
DNA damage response. But the failure to respond appropriately to DNA damage also leaves tumor cells
susceptible to cell-killing by DNA-damaging agents. These agents are thus used in the clinic to target
tumors cells.
The DNA double-strand break (DSB) is the most lethal of the many lesion types that constitute
DNA damage. DSB are also one of the major mediators of chemotherapy-induced cytotoxicity in tumors.
Following induction of DSB, cells respond on a molecular level by activating protein signaling molecules
in the core chromatin integrity network or DNA double-strand break response pathway, and in
pathways governing general stress response , cell-survival , cell-death and cell-cycle control (Figure 1-
1). On the cellular level, the integration of these protein signaling-molecule activities translates into one
of two cell-fate decisions. Cells that have experienced DNA damage can initiate a DNA damage-
mediated cell-cycle arrest, attempt to repair the damage and, if successful, resume the cell-cycle
(arrest/repair/resume). Cells can also initiate an active cell-death program known as apoptosis.
However, it is not known what "formula" a cell uses to integrate protein signaling molecule activities in
order to determine which of these paths it will take, or what protein signaling-molecules are essential to
the execution of that decision. A better understanding of how these cellular decisions are made and
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mediated on a molecular level is essential to the improvement of existing combination and targeted
chemotherapies, and to the development of novel targeted and personalized therapies. The goal of this
work was to gain an understanding of how cells responding to DNA damage (DSB) integrate protein
signaling-molecule activities across distinct signaling networks to make and execute binary cell-fate
decisions, under conditions relevant to tumor physiology and treatment.
DNA Damage signaling and proximal response to DSB
A large body of research has been devoted to the study of the upstream signaling components
in the DNA double strand break response pathway in the 15 years since ATM, a critical first-responder to
DSB, was cloned. Following induction of a DSB, inactive ATM dimers in the nucleoplasm auto-
phosphorylate, fall apart into active monomers and localize to the site of the break. A complex of three
proteins, MRE11, Rad50 and Nbs1, known as the MRN complex, also localizes to the site of the break.
Once at the site of the break, ATM phosphorylates the histone variant H2AX at areas surrounding the
break and many other chromatin-associated and nucleoplasmic substrates. ATM also directly associates
with the MRN complex via Nbs1 and ATM and Nbs1 participate to mutually further activate, or maintain
the activation status of, the other. The activation and localization of ATM and Nbsl to break sites, and
of yH2AX to areas surrounding break sites, is required for subsequent activation and recruitment of DNA
repair factors, to the site of the break and for activation of signaling molecules necessary for induction
of DNA damage mediated cell-cycle arrest and cell-death processes following DNA damage. A few of the
better characterized ATM substrates include Chk2, a checkpoint signaling protein that leads to induction
of DNA damage mediated cell cycle arrest via phosphorylation and inactivation of Cdc25A/C
phosphatases, and p53 , a signaling protein and transcription factor that can lead to maintenance of
DNA damage mediated cell cycle arrest via up-regulation of the cyclin dependent kinase inhibitor (cki)
p21, or to induction of apoptosis via trans-activation of pro-apoptotic Bcl-2 protein family members.
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Despite some detailed knowledge about some of the proximal responders to DNA double strand breaks,
we have an extremely limited understanding of how other distinct signaling pathways and proteins
known to influence the response to DSB (e.g. general stress, survival, cell-death regulatory and cell-cycle
regulatory pathways) integrate into the pathway. We also have no clear understanding of how this
integrated signaling response works as a system to make a decision between the alternate cell-fates
following DNA damage of cell cycle arrest/repair/ resume or induction of cell death, and to mediate that
decision.
DNA Damage signaling network and Linear Regression - a data driven approach to
identifying signal-response relationship in a system with ill-defined structure
The goal of this work was to improve our very limited understanding of the signal to signal, and
of the signal to cellular response connectivity in this network, as a whole. Our strategy was to
investigate the network biology of the molecular signaling and cellular response to DSB, and to find a
systematic way to discover signal-response relationships that are crucial to the cellular response to DSB.
As a first step, we created a quantitative signal-response dataset by measuring a set of signals that
widely sample the dynamic response of signaling networks activated by the induction of DSB, and the
associated cellular responses that together reflect the relevant cell-fate decisions and the cellular
phenotypic responses that are mediated, following the induction of DSB, in a physiologically relevant
context. In a second step, we made use of mathematical modeling approaches to systematically
discover signal-response relationships within the DSB-responsive protein signaling network. Because
this network has an as-yet ill-defined structure, we chose to use two data-driven, relational modeling
approaches in complement, Partial Least Square Regression (PLSR) and a hypothesis-based, Time-
Interval Stepwise Regression analysis (TI-SWR). Both PLSR and TI-SWR can be implemented without a
requirement for any imposed structure that is defined by pre-existing knowledge of network
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relationships (signal-signal or signal-response), and can be used effectively in complement to identify
signal-response relationships in this network. We describe the experimental signal-response dataset
and the mathematical modeling approaches used to analyze the data in the following sections.
Experimental system: Design and Details
The goal of the experimental effort was to develop a quantitative signal-response dataset, by
measuring signals that widely sample the response of signaling networks activated by the induction of
DSB, and the associated cellular phenotypic responses that together reflect the dynamic cellular
responses that follow the induction of DSB in a physiologically relevant context.
A pre-requisite for this approach is that we define a system that is biologically and clinically
relevant and amenable to mathematical modeling approaches, within which we are able to study and
measure the dynamic integrated protein signaling involved in mediating and making the decision
between the cellular responses of cell-cycle arrest/repair/resume and cell-death in cells responding to
DSB.
We chose to perform this study in U2OS human osteosarcoma cells, which originate from a solid
tumor etiology. These cells are p53 wild-type and therefore have intact cell-cycle checkpoints, an
important consideration for our study.
In designing our experimental system, there were several important factors we considered critical to
allow the acquisition of a dataset that is both clinically relevant and that is amenable to rigorous analysis
via quantitative, data-driven mathematical modeling approaches. We considered it critical to include:
- Cues that are biologically, and preferably clinically, relevant to the problem at hand
- Cues that result in large variations in both the signaling molecules of interest and the cellular
responses of interest
- Multiple cues to elicit combinatorial signaling relevant to the variation in possible physiological
start states of cells experiencing the cue in vivo
- Quantitative measurements of molecular signals and cellular responses
Therefore, we chose two biologically/clinically relevant cues- Doxorubicin and TNF-a - that display
synergistic effects in mediating cellular response to DSB in vitro to use in tandem to investigate the
molecular signaling and cellular response to DSB. Doxorubicin is a topoisomerase 11 inhibitor that leads
to the formation of DNA double strand breaks. It is used extensively as a chemotherapeutic agent in the
clinic for the treatment of solid tumors, such as osteosarcoma.
TNF-a is an inflammatory cytokine that is up-regulated in many solid tumors and in the tumor micro-
environment and is well correlated with tumor grade in some tumor-types. It is a known context-
dependent modulator of cell-survival under various physiologic conditions. In fact, the use of TNF-a as a
chemotherapeutic agent in its own right has been explored, and though the side-effects resulting from
its systemic administration are far too severe to make it a useful treatment, methods of using TNF in a
localized or targeted fashion for the treatment of some tumor types are currently being explored. In our
own studies, we observe that exposure of cells to TNF-a alone does not cause cell-death. But when cell
populations are simultaneously exposed to Doxorubicin and TNF-a, cell-death is dramatically increased
as compared to that observed when cell populations are exposed to Doxorubicin alone. This increase in
cell-death in populations treated with Dox plus TNF-a versus populations treated with Dox alone is
supra-additive, or synergistic (Supplementary Figure 2-1).
To study the integration of signals across distinct signaling pathways known to contribute to the
cellular response decision following DNA damage and their relation to subsequent cellular response,
under conditions relevant to tumor physiology and treatment, U2OS human osteosarcoma cells were
treated with varying doses of Doxorubicin (at 0, 2, and 10 pM) alone, or in combination with TNF-a, as
illustrated in Table 2-1.
Cue-combination treatments:
Dox (p M) TN F-a
1 0 pM -----
2 0 pM 100 ng/ml
3 2 pM---
4 2pM 100 ng/mi
5 10 pM -----
6 10pM 100 ng/ml
Table 2-1. Table of all 6 cue-combination treatment conditions
Following the exposure of U2OS cells to the 6 distinct cue combination treatment conditions of
Dox and TNF-a shown in Table 2-1, cell extracts were collected for quantitative molecular signaling
measurements at 10 time-points over 24 hr following treatment. The measurement time points are
shown in Table 2-2.
Table 2-2. Time points at which cell extracts were collected for molecular signaling
measurement
Whole cell samples were collected and fixed for cellular-response measurements at 4 time-points
over 48 hr following treatment, as shown in Table 2-3. These conditions define our experimental system
going forward.
Table 2-3. Time points at which cell samples were collected for cellular response measurement
Experimental Measurements
We chose a subset of 17 signals to measure that we consider information-rich and/or "strategic"
signals in the signaling network (Table 2-4). These signals broadly sample the distinct signaling pathways
that are involved in making cell-fate decisions and mediating the cellular response to DSB (Figure 1-1).
We included measures of signal activity (via measurement of activating phosphorylation sites, or via
direct activity ELISA assay) in many cases, and measures of signal level in others (Table 2-4). Assays for
quantitative measurement of these signals were developed and validated. The linear and dynamic
ranges for these assays were evaluated, and assays were used for signal measurement in the dataset
only if these parameters were deemed satisfactory (Appendix A). From collected cell extracts, we
obtained quantitative measurements of 17 signals at each of 10 time-points over 24 hr following
treatment (Table 2-2), where all 17 signals measured at each time-point were measured from one cell-
extract sample, for each of 6 distinct cue combination treatments shown in Table 2-1. Including
replicates, this dataset includes more than 2,500 signaling measurements (Figure 2-1B).
Signaling molecule Measurement Measurement assay Measurement time-points
pATM (S1981) activity quantitative western 0.25, 0.5,1, 1.5,2,4,8,12,16, 24hr
pH2AX (S139)** activity quantitative western 0.25, 0.5,1,1.5, 2,4, 8,12,16, 24hr
pNbsl (S343)** activity quantitative western 0.25, 0.5,1,1.5, 2,4, 8,12,16, 24hr
pp53 (S15)** activity quantitative western 0.25, 0.5,1,1.5, 2,4, 8,12,16, 24hr
pp38 (T1 80/Y182)** activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
pJNK (T1 83/Y185)** activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
pERK1/2 (T202/Y204)** activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
pAkt (S437)** activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total H2AX* level quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total Nbs1* level quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total p53** level/activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total JNK* level quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total ERK1* level quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total Akt* level quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total Cyclin A* level/activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
total Cyclin B* level/activity quantitative western 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
NFkB** activity ELISA 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24hr
included in both PLSR example model and example TI-SWR analysis
included only in example TI-SWR analysis
Table 2-4. Table of protein signals measured, by what assay they were measured, and at what time-
points following treatment they were measured, for the quantitative signal-response dataset compiled.
We also chose a subset of cellular responses to measure (Table 2-5) that we believe to capture
well the relevant cell-fate decisions and mediated cellular responses resulting from exposure to DSB in
the context of physiologically relevant inflammatory cytokines.
Cellular response Measurement Measurement assay Measurement time-point
Cell cycle: % G1* level FACS 6,12, 24,48 hr
Cell cycle: % S** level FACS 6, 12, 24, 48 hr
Cell cycle: % G2-M* level FACS 6, 12, 24, 48 hr
Cell cycle: % pH3 activity FACS 6,12, 24,48 hr
Apoptosis: %CC3+CParp+** activity FACS 6,12, 24,48 hr
Apoptosis: %CC3-CParp-* activity FACS 6,12, 24,48 hr
Apoptosis: %CC3+ activity FACS 6,12, 24,48 hr
included in PLSR example model and individually in example TI-SWR analyses
included only in example PLSR model
Table 2-5. Table of cellular responses measured, by what assay they were measured, and at what time-
points following treatment they were measured, for the quantitative signal-response dataset compiled.
From collected whole-cell, fixed samples, we obtained quantitative measurements of four
measures of cell-cycle phenotypic response and three measures of cell-death/survival phenotypic
response (Table 2-5) at each of 4 time-points over 48 hr following treatment shown in Table 2-3.
Including replicates, this dataset includes more than 500 cellular response measurements (Figure 2-1B).
The resulting quantitative signal-response dataset provides a comprehensive description of the
dynamic response of the cell signaling network following the induction of DSB and forms the biological
information foundation for identifying relevant signal-response relationships. We used two distinct
data-driven, linear regression analysis modeling approaches, Partial Least Squares Regression (PLSR) and
a hypothesis-based, Time-Interval Stepwise Regression analysis (TI-SWR), in complement to identify
signal-response relationships from the quantitative signal-response dataset, and to aid in the
interpretation of response-response relationships. These mathematical modeling and analysis
approaches are described in the following sections. As a specific example, we selected a particularly
strong set of identified signal-response correlations between ERK1/2 activity and S phase cell-cycle
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phenotype, identified in a TI-SWR analysis, to posit a causal relationship between ERK1/2 and S phase
cell cycle phenotype. We translated this posited causal relationship into an experimental hypothesis
and then experimentally test this hypothesis. In the following sections we also describe the validation of
the experimental hypothesis based upon model-derived signal-response relationships, and demonstrate
a role for ERK1/2 as a context-dependent switch between cell-cycle arrest and apoptosis following DNA
damage.
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Figure 2-1. (A) Experimental time-line; U20S cells were seeded at 1.2x106 in media containing 10%
FBS (fetal bovine serum) in 10 cm2 tissue culture dishes and incubated for 24 hr. Cells were then treated
+/- Dox (0, 2, or 10 pM) and +/- TNF-a (0 or 100ng/ml) and allowed to incubate for 4 hr. Immediately
. . . . .. . . . ... ............ .  ..  .
following treatment, cell-extract and sample collection commences, and proceeds, at appropriate times.
4 hr following treatment, media is aspirated and replaced with media containing 1% FBS. From this
point on, cells are NOT further exposed to Dox or TNF-a. Cell-extracts collected for the 4 hr time-point
signaling measurements do NOT experience a media change. Cell-extracts for signal measurement were
collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16 and 24 hr following treatment. Whole cell samples were
collected and fixed for cellular-response measurements at 6, 12, 24 and 48 hr following treatment. (B)
Signaling data heatmap and cellular-response data heatmap for all 6 cue-combination treatment
conditions investigated. Signaling data heatmap; 1) Within each single signal measurement set, across
the 6 conditions, the 10 time-point measurements of the signal are in consecutive time-order from top
to bottom within each column, 2) Within each single signal measurement set, across the 6 conditions, all
signal measurement values were normalized to the maximum signal measurement value (the max value
ever observed for the measurement of that signal, across conditions and across time-points), such that
all values are between 0-1, with dark red denoting high values close to 1 and dark blue denoting low
values close to 0. Cellular-response data heatmap; 1) Apoptosis section: Within each time-point at
which apoptosis is measured, across the 6 conditions, 4 measures of apoptosis are represented in order
from top to bottom within each column. These 4 measures of apoptosis are: a) % of cells staining
positively for both apoptotic markers measured (CC3+CParp+), b) % of cells staining positively for only
one of the markers (CC3+), c) % of cells staining negatively for both apoptotic markers (CC3-CParp-) and
d) % of cells staining positively for one apoptotic marker (CC3+), without consideration for the status of
staining for the other apoptotic marker (CParp+/-), 2) Cell-cycle section: Within each time-point at
which cell-cycle is measured, across the 6 conditions, 3 measures of cell-cycle are represented in order
from top to bottom within each column. These 3 measures of cell-cycle are: a) % of cells in G1 phase of
the cell-cycle, b) % of cells in S phase of the cell-cycle, and c) % of cells in G2-M phase of the cell-cycle.
Data is not normalized and colors are representative as shown in the color-bar at right. All data are
means of replicates. Signaling data: n = 2-3. Cellular response data: n = 4-10.
Materials and Methods
Cell Culture -- U20S cells were maintained in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum, penicillin, streptomycin, 2 mM L-glutamine. Cells were
passaged to maintain sub-confluent cell density.
Cell Stimulation -- U20S cells were seeded at 1.2 x 106 on 10 cm2 tissue-culture dishes in 10 mL DMEM
supplemented with 10% fetal bovine serum, penicillin, streptomycin, 2 mM L-glutamine and incubated
20-24 hr. Prior to stimulation, the volume of media left after over-night evaporation was determined for
one representative plate; over-night evaporation was almost always 1 mL, leaving a pre-treatment
media volume of 9 mL. Cells were stimulated with either 0 or 100 ng/ml TNF-a by spiking in 9 ptL of
carrier (water) or of 1000x TNF-a stock (stock is 100 ptg/mL TNF-a in water; Peprotech). Cell were also
stimulated with 0, 2 or 10 ptM Doxorubicin by spiking in 9 lpL of carrier (water) or of 1000x Doxorubicin
stock (for 10 lpM treatment), or of a 1:5 dilution of Doxorubicin stock (for 2 pM treatment; 1000x stock is
10 mM Doxorubicin in water; Sigma). Stimulation was always in the order 1) TNF-a and 2) Doxorubicin.
Stimulation was accomplished in waves, starting with cells to be collected at latest time-points. Time of
stimulation was recorded so that collection-time of samples could be appropriately adjusted to account
for treatment-time. Stimulation waves each consisted of equal numbers of plates such that all cells
experienced equal amount of time outside of incubation conditions. Cells were incubated for 4 hr
following stimulation, and samples were removed as necessary during this time (for treatment time-
points before and including the 4 hr time-point). Treatment media was then aspirated and replaced
with 8 mL of DMEM supplemented with 1% fetal bovine serum, penicillin, streptomycin, 2 mM L-
glutamine. Media replacement was accomplished in waves corresponding to cell-stimulation. Following
media replacement, samples were removed as necessary for the duration of the time-course.
Inhibitor Experiments- Methods for inhibitor experiments are as described for Cell Stimulation, except
that cells were additionally stimulated with either 0 or 20 ptM PD98059 by spiking in 9 ptL of carrier
(DMSO) or of 1000x PD98059 stock (stock is 20 mM PD98059 in DMSO; Sigma). Stimulation was always
in the order 1) PD98059, 2) TNF-a and 3) Doxorubicin. At media replacement (4 hr following initial
stimulation), PD98059 is added to the replacement media prior to its application to the cells in the cases
where PD9059 was present in the media prior to media replacement.
Synchronization Experiments - U20S cells were seeded at 5 x 105 on 10 cm2 tissue-culture dishes in
10 mL DMEM supplemented with 10% fetal bovine serum, penicillin, streptomycin, 2 mM L-glutamine
and incubated 20-24 hr. Cells were exposed to 2.5 IpM thymidine by spiking in 90 ptL of 100x thymidine
stock (stock is 250 iM thymidine in PBS, filtered; Sigma), and incubated for 18 hr. Media was aspirated,
plates were washed 3x with PBS, and replaced with 10 mL DMEM supplemented with 10% fetal bovine
serum, penicillin, streptomycin, 2 mM L-glutamine. Cells were incubated for 12 hr. Cells were again
exposed to 2.5 IpM thymidine by spiking in 90 ptL of 100x thymidine stock, and incubated for 18 hr.
Media was aspirated, plates were washed 3x with PBS, and replaced with 10 mL DMEM supplemented
with 10% fetal bovine serum, penicillin, streptomycin, 2 mM L-glutamine, plus 10 pM aphidicolin
(Sigma). Cells were incubated for 1 hr. Methods from this point are as described in CellStimulation and
Inhibitor Experiments, except that at media replacement (4 hr following initial stimulation), PD98059 is
added to the replacement media prior to its application to the cells in the cases where PD9059 was
present in the media prior to media replacement AND aphidicolin is added to the replacement media
prior to its application to the cells in ALL cases. In the case that aphidicolin is "washed off," media was
aspirated, cells were washed 3x with PBS and media was replaced with DMEM supplemented with 1%
fetal bovine serum, penicillin, streptomycin, 2 mM L-glutamine. Again, PD98059 is added to the
replacement media prior to its application to the cells in the cases where PD9059 was present in the
media prior to media replacement.
Sample Collection for Cell Extracts - Cells were removed from the incubator 30 seconds prior to the
collection time-point and placed on ice. Media was removed and placed in corresponding 15 mL Falcon
tube on ice. 4 mL of ice-cold PBS was added to each plate, moved over plate to rinse cells, then
removed and placed in corresponding 15 mL Falcon tube with media. Cells were scraped in residual PBS
(usually about 1.5 mL) with non-lysing rubber scrapers. Cells in residual PBS were removed and placed
in corresponding 15 mL Falcon tube with media and PBS. Cells/media were centrifuged for 5 min at
1000g, 4C. Supernatant was aspirated. Pellet was brought up in 1 mL ice-cold PBS and transferred to
1.5 mL Eppendorf tube on ice, then micro-centrifuged for 5 min at 4000 rpm, 4C. Supernatant was
aspirated and cell-pellets were snap-frozen with liquid nitrogen and transferred to -80C for storage.
Lysis of Cell-pelletsfor Cell Extracts - Cell pellets were removed from -80C and placed on ice. 350 ptL
of fresh, ice-cold lysis buffer (1% Triton-X, phosphatase and protease inhibitor tablets (Roche)) was
added. Cell-pellets were sonicated for 20-25 duty cycles at 10-20% power. Samples were replaced on
ice immediately following sonication. Two aliquots of 12 piL each were removed for use in protein
quantification assays; these aliquots were stored at 4C not longer than over-night. One 50 ptL aliquot
was removed for use in ELISA assays; these aliquots were snap-frozen in liquid nitrogen and stored at
- 80C. An aliquot of 55 pL of 6X SDS Sample buffer was added to the remaining lysate and vortexed to
mix. Extracts plus sample buffer were snap frozen in liquid nitrogen and stored at - 80C.
Protein Quantification for Cell Extracts - Protein quantification was done using a micro-BCA assay
(Pierce) according to the manufacturer's instructions. Standard curves were generated at least in
duplicate for every assay plate. Two biological replicates (two aliquots from the original cell-extract) and
two assay replicates (two aliquots from the dilution mixture of each original aliquot) were performed for
each measurement. Final dilutions of 1:50 and/or 1:100 were used for protein concentration
measurements.
Quantitative Westerns - Gels: Gels were always 1.5 mM, 15 lane, 10% acrylamide mini SDS-PAGE
gels, except for measurement of p-H2AX/H2AX (12% acrylamide) and p-ATM (6% acrylamide). In
general, gels were loaded in the order: 1) ladder, 2) negative control, 3) positive control, 4) empty, 5)
0.25 hr, 6) 0.5 hr, 7) 1 hr, 8) 1.5 hr, 9) 2 hr, 10) 4 hr, 11) 8 hr, 12) 12 hr, 13) 16 hr, 14) 24 hr. The amount
of cell-extract loaded in each lane was adjusted according to the data from protein quantification assays
in order to load equal amounts of total protein in all lanes. Optimal amount of total protein to load was
determined in validation of each of the signaling measurement assays (See Appendix 1). In general,
total protein loaded was 10 p'g, except for measurement of p-ATM (15 ptg). Gels were run out at 180V
for 50 min, or until the dye front neared the gel-bottom. For measurement of p-ATM, gels were run out
at 180V for 3 hr. Transfer: Protein was transferred to nitrocellulose membranes in a wet transfer in
10% Methanol (20% Methanol for transfer of p-ATM). Transfer was at 120V for 105 min or at 20V over-
night (p-ATM). Block/Ab incubation: Membranes were blocked for 1 hr with Odyssey Blocking Buffer
(OBB; Odyssey) then incubated over-night with the primary antibody in OBB + 0.05% Tween.
Membranes were washed 3x, 10min in PBS + 0.1% Tween then incubated for 1 hr with the secondary
antibody in OBB + 0.05% Tween. Membranes were again washed 3x, 10min in PBS + 0.1% Tween.
Visualisation/Quantitation: Membranes were visualized on a Licor Odyssey IR-dye scanner. Signal was
quantitated using the Odyssey v2.1 software program. Boxes were drawn around the largest signal
band on the blot and duplicated to place around all other signal bands. For each signal band, a duplicate
box was created and placed at a point in each lane that did not contain a "background band." The signal
reported from this box served as the background signal; this value was subtracted from the signal
reported from the corresponding box containing the signal band in that lane. Whenever possible, all
background bands were placed at the same point in each lane. Quantitative signal and background data
was imported into Excel for further processing. Signaling data is reported as the mean of 2-3 replicates
(where error bars are shown, they represent +/- the standard error).
Sample Collection for Response Measurements (for subsequent FACS analysis) - Cells were
removed from the incubator 30 seconds prior to the collection time-point and placed in a tissue-culture
hood. Media was removed and placed in corresponding 15 mL Falcon tube. 2 mL of PBS was added to
each plate, moved over plate to rinse cells, then removed and placed in corresponding 15 mL Falcon
tube with media. 1 mL of trypsin was added and cells were replaced in the incubator for 2 min (If many
samples are to be collected at one time-point, collection is accomplished in waves. Trypsin incubation in
this case is the length of time necessary to accomplish this first step in any other waves). Cells were
removed from the incubator again and media from the corresponding 15 mL Falcon was used to quench
the trypsin reaction and to resuspend all cell from the plate. Media and cells were then removed and
replaced in corresponding 15 mL Falcon tube, and centrifuged for 5 min at 1000g, 4C. From this point,
cells were either fixed according to an Ethanol- or Formaldehyde-fixation protocol depending on
whether subsequent staining was to be for cell-cycle (Ethanol) or for cell-death outcomes
(Formaldehyde).
Measurement of Cell -cycle Cellular Response (Ethanol-fixation, staining and FACS analysis) -
Fixation: Supernatant was aspirated and 200 ptL of ice-cold PBS was added. Cell-pellet was re-
suspended to a single-cell suspension. 2 mL of ice-cold 70% Ethanol was added drop-by-drop, while
vortexing gently. Samples were placed at 4C for storage for at least two hours and not longer than one
week. Staining: Cells were centrifuged for 5 min at 1000g, 4C. Supernatant was aspirated, cells were
re-suspended in 200 ptL ice-cold PBS and transferred to wells of a V-bottom 96-well plate. Plates were
centrifuged for 4 min at 1800 rpm, 4C. Supernatant was flicked off and washed once more with PBS.
Cells were re-suspended in 200 pL of ice-cold PBS + 0.25% Triton-X and incubated on ice for 15 min.
Cells were centrifuged for 4 min at 1800 rpm, 4C. Supernatant was flicked off and cells were rinsed once
with PBS + 1% BSA (200 ptL). Cells were re-suspended in 50ptL PBS + 1% BSA plus primary antibody (anti
phospho-Histone H3, Upstate; 1:100), and incubated overnight at 4C. Cells were washed 2x with PBS +
1% BSA (200 L) and then re-suspended in 50 pL PBS + 1% BSA plus secondary antibody (488-conjugated
anti-Rabbit, Invitrogen Molecular Probes; 1:100), and incubated for one hour at room temperature,
protected from light. Cells were washed once with PBS + 1% BSA and once with PBS. Cells were then re-
suspended in PBS + 0.1 M boiled RNase + 0.1 mg/mL Propidium iodide. Samples were stored at 4C,
protected from light, for at least one hour and not more than overnight. Data collection/Analysis: Data
was collected on a FACScalibur flow-cytometer with Cell-Quest Pro software. Detector parameters were
optimized for detection in the FL-1 (for detection of the 488-conjugated secondary antibody) and FL-3
channels (for detection of propidium iodide). Data was analyzed with FlowJo v6.8 for Mac. Cell-cycle
data is reported as the mean of at least 4 replicates (where error bars are shown, they represent +/- the
standard error).
Measurement of Apoptosis Cellular Response (Formaldehyde-fixation, staining and FACS
analysis) - Fixation: Supernatant was aspirated and 400 ptL of 4% Formaldehyde (40% stock
Formaldehyde diluted 1:10 in PBS; Sigma) was added. Cell-pellet was re-suspended to a single-cell
suspension and incubated for 10-15 min. Cells were centrifuged for 5 min at 1000g, 4C. Supernatant
was aspirated and 800 ptL ice-cold PBS was added. Cells were re-suspended and centrifuged for 5 min at
1000g, 4C. Supernatant was aspirated and 175 ptL ice-cold 100% Methanol (Sigma) was added. Cells
were re-suspended and samples were placed at -20C for storage for at least two hours and not longer
than one week. Staining: Cells were transferred to wells of a V-bottom 96-well plate. Plates were
centrifuged for 4 min at 1800 rpm, 4C. Supernatant was flicked off and cells were re-suspended in 200
ptL PBS + 0.1% Tween (PBS-T). Plates were again centrifuged for 4 min at 1800 rpm, 4C. Supernatant
was flicked off, and cells were re-suspended in 50iL PBS + 1% BSA + 0.1% Tween (PBS-TB) plus primary
antibody (anti Cleaved Caspase-3, Becton Dickinson; 1:500), and incubated for one hour at room
temperature. 200 iL PBS-T was added and plates were centrifuged for 4 min at 1800 rpm, 4C.
Supernatant was flicked off, cells were washed once with PBS-T (200 pL), and then re-suspended in 50
pL PBS-TB plus primary-conjugated and secondary antibody (647-conjugated anti Cleaved PARP, and
488-conjugated anti-Rabbit, Invitrogen Molecular Probes; 1:250 for both), and incubated for one hour at
room temperature, protected from light. 200 il PBS-T was added and plates were centrifuged for 4 min
at 1800 rpm, 4C. Supernatant was flicked off, cells were washed once with PBS-T (200 ptL), and then re-
suspended in 200 lL PBS-TB. Samples were stored at 4C, protected from light, for at least one hour and
not more than overnight. Data collection/Analysis: Data was collected on a FACScalibur flow-
cytometer with Cell-Quest Pro software. Detector parameters were optimized for detection in the FL-i
(for detection of the 488-conjugated secondary antibody) and FL-4 channels (for detection of the 647-
conjugated primary antibody). Data was analyzed with FlowJo v6.8 for Mac. Apoptosis data is reported
as the mean of at least 4 replicates (where error bars are shown, they represent +/- the standard error).
Results
Compilation and Evaluation of a Quantitative Signal-Response Dataset: Molecular signaling
Following 6 distinct Dox/TNF-a cue combination treatment conditions, we observe large
quantitative and qualitative ranges of activation for the majority of signals measured, across conditions
(Figures 2-2 and 2-3). Signal measurements at each time-point were normalized to that observed in cell
populations prior to treatment (untreated cell populations), to yield a "Fold activation." Highest fold-
activations ranged from 3-fold in the case of Akt (p-Akt (S473)) to 60-fold in the case of p53 (p-
p53(S15)). We observe robust activation of MAPKs and other non-canonical DNA damage responsive
signals, such as p-p38, p- JNK, p- ERK1/2 and NFKB, across treatment conditions.
We also observe that much of the cue-activated signaling is resolved, or nearly resolved, by 24
hr, including p-JNK, p-p38, p-Akt and p-ERK1/2 signaling. Notably, cue-activated signaling that is not
resolved by 24 hr include signals that are core members of the chromatin-integrity signaling network,
and that are involved in the proximal response to DSB, including p-H2AX, p-ATM and p-Nbsl. p53
signaling, as measured by total p53 levels and p-p53 (S15) is also unresolved across several treatment
conditions at 24 hr following treatment.
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Figure 2-2. (A) Part 1; Represenative quantitative western blots for p-ERK1/2 (T202/Y204) shown for
each of the 6 cue-treatment conditions investigated. Negative control (nc) is untreated, asynchronous
cells; positive control (pc) is cells that have been serum-shocked for 5 minutes following over-night
serum starvation. Lanes 1-10 are cell extracts collected under each of the treatment conditions at 10
time-points following treatment (0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16 and 24 hr). Part 2; Quantitation of
western blot data for p-ERK1/2 (T202/Y204) for each of 6 treatment conditions investigated. Data is the
mean of replicates (n=2) and is normalized to the signal measured at 0 hr (prior to treatment) to yield a
measure of "Fold activation." (B) Part 1; Represenative quantitative western blots for p-H2AX (S139)
shown for each of the 6 cue-treatment conditions investigated. Negative control (nc) is untreated,
asynchronous cells; positive control (pc) is cells that have been exposed to Neocarzinostatin (45 nM) for
1 hr. Lanes 1-10 are cell extracts collected under each of the treatment conditions at 10 time-points
following treatment (0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16 and 24 hr). Part 2; Quantitation of western blot data
for p-H2AX (S139) for each of 6 treatment conditions investigated. Data is the mean of replicates (n=3)
and is normalized to the signal measured at 0 hr (prior to treatment) to yield a measure of "Fold
activation."
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Figure 2-3. Quantitation of western blot data for p-ATM (S1981), p-Nbsl (S343), p-H2AX (5139), p-p53
(S15), p-p38 (T180Y182), p-JNK (T183Y185), p-Akt (S473), p-ERK1/2 (T202/Y204) and total p53 and
quantitation of ELISA data for activation of NFkB, for each of 6 treatment conditions investigated. Data
is the mean of replicates (n=2 or 3) and is normalized to the signal measured at 0 hr (prior to treatment)
to yield a measure of "Fold activation."
Compilation and Evaluation of a Quantitative Signal-Response Dataset: Cellular response
The single cellular responses of apoptosis and cell-cycle arrest/regulation are both established
and essential cellular responses to DNA damage. These cellular responses are intimately and
dynamically related cellular responses to DNA damage, such that it is necessary to consider both of
0
0
(U
VU
L0
these single measures of cellular response in concert in order to understand the complex, holistic
cellular response to DNA damage, on either a single cell or cell population level.
Apoptosis
Following 6 distinct Dox/TNF-a cue combination treatment conditions, we see a wide
quantitative range of apoptosis across the conditions. For example, at 12 hr following treatment, almost
100% of cells stain negatively for both apoptotic markers in cell populations treated with carrier alone,
while nearly 80% or cells stain positively for at least one apoptotic marker in cell populations treated
with high Dox plus TNF-a. The percent of the cell population that is apoptotic increases with increasing
Dox dose. Also, for each Dox dose, the addition of TNF-a synergistically increases apoptosis from that
resulting from exposure to Dox alone (Figure 2-4B). The most dramatic changes in observed apoptosis
occur between 6 and 24 hr following treatment, and these are likely the most reliable measurements of
apoptosis across all six cue combination treatment conditions. At later times, populations treated with
high Dox exhibit advanced apoptotic processes including cellular disintegration. The result can be
inaccurate determination of the percent of the population that is apoptotic (as illustrated by the
apparent decrease in the percent of the population that is apoptotic between 24 and 48 hr in cell
populations exposed to either low Dox (2 pM) or high Dox (10 iM) plus TNF-a (Figure 2-5B).
We also observe a range in the qualitative nature of the apoptotic response across the six cue
combination treatment conditions. In untreated cell populations, measured apoptosis is minimal over
the whole time-course from 6-48 hr (<<5%). Addition of TNF-a to untreated cell populations does not
affect apoptosis, which remains minimal at <<5%.
In cell populations treated with low Dox (2 IM) or high Dox (10 pM) alone, the percent of the
population that is apoptotic by 6 hr following treatment is minimal (4% and 7% respectively). %
apoptosis quickly rises between 6-12 hr under both of these treatment conditions (in low Dox, from 4%
to 15%; in high Dox, from 7% to 30%). % apoptosis then remains nearly constant in cell populations
treated with low Dox (2 IM), for the remainder of the time-course, from 12-48 hr. In cell populations
treated with high Dox (10 IM), % apoptosis continues to rise through 24 hr, and then remains constant
through 48 hr following treatment.
In cell populations treated with low Dox (2 pM) or high Dox (10 pM) plus TNF-a, the percent of
the population that is apoptotic by 6 hr following treatment is already quite high (14% and 40%
respectively). % apoptosis quickly rises between 6-12 hr under both of these treatment conditions (in
low Dox plus TNF-a, from 14% to 32%; in high Dox plus TNF-a, from 40% to 56%). In cell populations
treated with low Dox plus TNF-a, % apoptosis remains stationary just above 30% through 24 hr, then
decreases between 24-48 hr from 34% to 22%. In cell populations treated with high Dox plus TNF-a,
the % of the cell population that is apoptotic continues to rise between 12-24 hr, from 56% to 72%,
before sharply decreasing between 24 -48 hr, from 72% to 38% (Figure 2-5B).
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Figure 2-4. (A) Representative FACS Pt (propidium iodide) histograms for DNA content for cells
exposed to 0 pM Dox +/- TNF-a (left, top and bottom respectively) and to 2 pM Dox +/- TNF-a (right, top
and bottom respectively) at 6, 12, 24 and 48 hr following treatment. (B) Representative FACS scatter
plots for cleaved caspase-3 and cleaved Parp, as measured simultaneously in single cells, for all 6
treatment conditions, at 12 hr following treatment.
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Figure2-5. (A) Quantitation of the % of the cell-population in the S (top), G1 (bottom left) and G2-M
(bottom right) phase of the cell-cycle, as measured from FACS PI histogram/DNA content data, for all 6
treatment conditions investigated, at 6, 12, 24 and 48 hr following treatment (Data from at least 4
replicates), (B) Quantitation of the % of apoptosis in the cell-population (% of the cell-population
staining positively for both apoptotic markers, cleaved caspase-3 and cleaved Parp, for all 6 treatment
conditions investigated at 6, 12, 24 and 48 hr following treatment.
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Cell-cycle
Following 6 distinct Dox/TNF-a cue combination treatment conditions, resulting cell-cycle
phenotypes track closely with Dox dose, with minimal affect from TNF-a addition. The most dramatic
cell cycle phenotypes are observed in cell populations treated with low Dox (2 pM) +/- TNF-a, and are
not observable until later times (after 12 hr) (Figure 2-4A and Figure 2-5A).
Untreated cell populations retain a largely similar cell-cycle profile over the full time-course,
exhibiting a slight increase in percent of the cell population in G1 (%G1) and parallel decrease in
percentage of the cell population in G2-M (%G2-M) by 24 hr. This is an effect that is commonly
observed in populations of adherent cells experiencing slowed cell-division due to contact inhibition. In
untreated cell-populations, percent of the cell population in S (%S) remains constant throughout the
time-course, from 6-48 hr. Cell populations treated with TNF-a alone exhibit cell-cycle profiles similar to
those observed in untreated cell-populations at all times (Figure 2-5A).
In cell populations treated with low levels of Dox (2 pM) minus TNF-a, the percent of cells in Gi
(%G1) decreases sharply (from 49% of the cell population to 15%) between 12-24 hr following
treatment. The %G1 then remains stationary for the rest of the time-course, from 24-48 hr. This sharp
decrease in % G1 between 12-24 hr is paralleled by a sharp increase in %S from 12-24 hr that is roughly
equal in magnitude and dynamics to the decrease in G1 population, suggesting the shift of a subset of
the population from Gl or G1/S to S over this time-period. %S, in this treatment condition, increases
sharply (from 22% of the cell population to 50% of the cell population) between 12-24 hr. %S then
decreases sharply (from 50% back to 20%)between 24- 48 hr following treatment. Again, this sharp
decrease in %S between 24-48 hr is paralleled by a sharp increase in %G2-M between 24-48 hr that is
roughly equal in magnitude to the decrease in S population, suggesting a further shift of this "subset"
population from S to G2-M over this time-period. %G2-M sharply increases from 35% of the cell
population to 70% of the cell population between 24- 48 hr following treatment.
Cell populations treated with low Dox (2 IM) plus TNF-a exhibit cell-cycle profiles similar to
those observed in populations treated with low Dox minus TNF-a at all times, with two significant
deviations. The sharp decrease in %G1 between 12-24 hr observed in populations treated with low Dox
alone (from 49% to 15%) is less pronounced in populations treated with low Dox plus TNF-a (from 45%
to 25%). Likewise, the parallel sharp increase observed in %S over this time period in populations
treated with low Dox alone (with a peak of 50% of the cell population in S, decreasing back to 20% by 48
hr) is also less pronounced in populations treated with Dox plus TNF-a (with a peak of 34% of the cell
population in S, decreasing back to 19% by 48 hr) (Figure 2-5A).
By 24 hr, cell-cycle profile data is not a reliable measure for cell populations exposed to high
dose Dox (10 pM) +/- TNF-a. In these populations, apoptotic processes are very advanced; much of the
cell population is fragmented and thus not counted in the measurement. G1, S and G2-M cell-
populations are counted as percentages of all cells. Thus, when all cells cannot be counted,
inconsistencies in determining % G1, % S and % G2-M may arise.
DNA damage-mediated cell cycle arrest in Gi or at the G1/S transition in cell populations
treated with low Dox (2 pM) +/- TNF-a
The observed build-up in S phase population between 12 and 24 hr in cell populations treated
with low Dox (2 pM) +/- TNF-a, and the apparent shifts in a subset of the population from G1 to S
between 12 and 24 hr and from S to G2-M between 24 and 48 hr is a strong cell-cycle phenotype (Figure
2-4A). Our observations could be the result of a DNA damage-mediated S-phase arrest in cell
populations treated with low Dox that we can observe by 24 hr, and that releases sometime after 24 hr
to allow a cohort of cells that have been synchronized by the arrest to enter G2-M by 48 hr.
Alternatively, our observations could be the result of a DNA damage-mediated arrest in GI or at the
G1/S transition in cell populations treated with low Dox that releases sometime before 24 hr to allow a
cohort of cells that have been synchronized by the arrest to enter S by 24 hr, and then to progress, still
synchronously into G2-M by 48 hr.
If these observations were the result of an S phase arrest between 12 and 24 hr, we would
expect that %G2-M during this time-period would be stationary, or decreasing (No cells should be
moving into G2-M from S if there is an active S phase check-point, and some cells should be moving
from G2-M back into G1, unless there is also a G2-M arrest). In fact, we observe the opposite: %G2-M
increases over this time-period (Figure 2-5A). These data support a hypothesis that our observed cell-
cycle phenotypes can be explained by the induction of a DNA damage-mediated cell cycle arrest in GI or
at the G1/S transition in cell populations treated with low Dox (2 pM) +/- TNF-a that is released before
24 hr to allow progression into S by 24 hr, and into G2-M by 48 hr.
Data-driven Mathematical modeling: PLSR and TI-SWR
We used a PLSR model and a TI-SWR analysis in complement to systematically discover detailed,
time-dependent signal-response relationships from the quantitative signal-response dataset described
above.
The overarching hypothesis that guides the data-driven mathematical modeling approach is that
cue-resultant cellular phenotype, across cue treatments, is a definable function of cue-initiated
molecular signaling. Measured molecular signaling can be cast as independent, or explanatory, variables
(X) and measured cellular responses can be cast as dependent, or response, variables (Y). Here, X is a
data matrix including the measurements of all signals at all time-points, across all cue combination
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treatment conditions, and Y is a data matrix including the measurements of all cellular-responses at all
time-points, across all cue combination treatment conditions. We would like to gain insight into the
nature of the function relating cellular response and molecular signaling (Y and X, respectively) using
data-driven computational approaches such as regression analysis. However, in order to do so, and to
find a unique solution for the function, traditional regression analysis requires that the number of
observations (or cue combination treatment conditions) be greater than the number of explanatory
variables (signal measurements) in the model. We are interested in understanding how a relatively
large number of signaling molecules contribute, in a dynamic fashion, to cellular response following DSB,
and our explanatory variable set is large. Additionally, the number of cue combination treatment
conditions we can obtain data for is significantly constrained by cost, in terms of both time and money,
and the number of observations we can include in our model is relatively small. These problems have
been addressed successfully in previous applications of regression analysis for the discovery of signal-
response relationships in biological networks by the use of a Partial Least Squares regression algorithm
(PSLR). We extend the utility of PLSR for the discovery of biological network signal-response
relationships by using PLSR in tandem with a novel analysis approach, introduced below, that we refer
to as hypothesis-based, Time-Interval Stepwise Regression (TI-SWR).
PLSR
In PLSR, we reduce our explanatory variable set substantially to an effective explanatory variable
set that is made up of orthogonal latent variables, or Principal components (PCs). PCs are linear
combinations of the original model independent variables that simultaneously maximally capture
variance in the independent variable space and covariance with the dependent variable space (Figure 2-
6A). The first principal component (PCI) maximally captures the variance in the independent variable
space (conditional on maximizing covariation with the dependent variable space). The second principal
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component (PC2) maximally captures the residual variance in the independent variable space (still
conditional on maximizing covariation with the dependent variable space), and so on for any additional
PCs, such that PCs are orthogonal and uncorrelated. The number of PCs necessary to capture the
majority of the variance in the explanatory (independent) variable set is much smaller than the number
of original explanatory variables, and should also be chosen to be smaller than the number of
observations (samples) available for analysis. These relatively few uncorrelated PCs serve as "super-
variables", standing in, as effective explanatory variables, for the large number of often-correlated
original explanatory variables. This effective reduction in the number of explanatory variables allows us
to use PLSR to find a unique solution for the signal-response functional relationship. We use this
approach to investigate the relationships between measured cellular responses of cell-cycle and cell-
survival and death that, together, yield a relatively complete picture of the holistic cellular phenotypic
response to DSB. We also use this approach to identify some high-level signal-response relationships
(Figure 2-6A).
PLSR
Signal space Pincipa cmompnent
space
PLS P1=
,.7 pERK1/2+ 0.3 pts1
z
pERK1/2 cell-cycle anest
1
NFkB pJNK * apoptosis
e pERK1/2 0 P1
p53 DOX + TM
stimLIus
pH2AX
SWR
pERK1/2
+ pJNK
pERK1/2
+ pJNK
SWR
p53
pH2AX
Figure 2-6. PLSR (A) and SWR (B) explanatory diagram
PLSR: Results
A PLSR model was constructed, including measures of apoptosis, survival and cell-cycle
arrest/regulation across the six treatment conditions investigated as response variables, Y, and time-
course signaling measurements across the six treatment conditions as explanatory variables, X. The two
principal components model captures 87% of the variation in the response variable space (R2= 0.87) and
has a cross-validated predictive capability of 58% overall (Q2 = 0.58). Cross-validated predictive
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capabilities for single cellular-responses in this model vary from high predictive capabilities of 80% for
the prediction of the percent of cells in G2-M at 24 hr, and 74% for the prediction of the percent of
surviving cells at 6 hr, to lower predictive capabilities of 50% for the prediction of the percent of
surviving cells at 12 hr, and 34% for the prediction of the percent of cells in s at 24 hr. Construction of a
PLSR model that includes just one measured cellular response as the response variable often results in a
model with a higher overall cross-validated predictive capability statistic (e.g. A two-component PSLR
model constructed with a single response variable - the measure of percent of cells surviving at 6 hr -has
an overall Q2 value of 0.80). However, PLSR gives us a powerful tool with which to visualize the
structure of a full data-set; correlations between responses, between signals, and between signals and
responses are indicated by proximity in the principal component space. By constructing a PLSR model
that includes multiple measures of cellular response as response variables, we can obtain an
understanding of the relationships between these cellular responses by examination of the relative
locations of the responses in the principal component space. We can also obtain an understanding of
the relationships between signaling measurements and multiple cellular responses by examination of
the relative locations of the signals and the responses in the principal component space. In the example
shown here, the model includes measures of apoptosis and survival at 6 and 12 hr, and measures of cell-
cycle status (%G1, %S and %G2-M) at 24 hr as responses (Table 2-2 and Table 2-3).
Principal components as Biological response Axes: PCI is a "Survial/Death" Axis
Measures of apoptosis at both 6 and 12 hr are highly and positively weighted in the first
principal component, and have low calculated weights in the second principal component. Measures of
cell-survival at 6 and 12 hr are highly and negatively weighted in the first principal component, and have
low calculated weights in the second principal component. A plot of these responses in the principal
component space (Figure 2-7A), reveals that the first principal component (PC1) is highly correlated with
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apoptosis and is highly anti-correlated with measures of survival, such that we may physically interpret
PCI as a "Survival-Death" Axis. Note that the PCs for the proteins (signals) and the PCs for the responses
are different, but are directly related when using PLSR. Under this interpretation, we expect that signals
that have strong, positive weight in PCI also correlate with cell-death outcomes and, conversely, that
signals that have strong, negative weight in PC1 correlate with cell-survival outcomes.
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Figure 2-7. (A) Plot of cellular-responses in the Principal component space (Principal component 1
(PC1) vs. Principal component 2 (PC2)) determined by a PLSR model. Cellular responses: The cellular
responses of apoptosis (CC3+CParp+) at 6 and 12 hr following treatment, survival (CC3-CParp-) at 6 and
12 hr following treatment and measures of the G1, S and G2-M cell-cycle populations at 24 hr following
treatment are plotted in the Principal component space based on the weights of each of the cellular
responses in PC1 and PC2. Apoptotic responses measured at 6 and 12 hr following treatment (red and
dark red diamonds respectively) are positively correlated with PC1 and survival responses measured at 6
and 12 hr following treatment (green and dark green diamonds respectively) are negatively correlated
with PCI; PC1 is a "Survival-Death" axis. Measurements of S and G2-M cell-cycle populations at 24 hr
following treatment (blue and dark blue circles respectively) are positively correlated with PC2 and
measurement of G1 cell-cycle population at 24 hr following treatment (light purple circle) is negatively
correlated with PC2; PC2 is a "Cell-cycle regulation" axis. (B) Plot of all time-point measurements of
total p53 ("total p53 signals") and cellular-responses in the Principal component space (Principal
component 1 (PC1) vs. Principal component 2 (PC2)) determined by a PLSR model. Total p53
measurements (including values of total p53 measured at each of 10 time-points following treatment)
are plotted in the principal component space based on their weights in PC1 and PC2 (light grey, small
circles). Some total p53 measurements are highly correlated with apoptotic responses only, some are
highly correlated with cell-cycle responses only and some are highly correlated with both; this PLSR
model allows us to capture the known dual role of p53 in mediating both apoptotic and cell-cycle
regulatory responses following DNA damage.
Principal components as Biological response Axes: PC2 is a "Cell cycle Arrest/Regulation" Axis
We also see that the cellular response read-outs of cell-cycle status/arrest spread out along the
second principal component (PC2) such that PC2 is highly correlated with a readout of cells in the S
phase of the cell-cycle (S populations) and a readout of cells in the G2-M phase of the cell-cycle (G2
population) and is highly anti-correlated with a readout of cells in the GI phase of the cell cycle (G1
population) (Figure 2-7A). From these observations, we may physically interpret PC2 as a "Cell-cycle
Arrest/Regulation" Axis. Under this interpretation, we expect that signals that have strong, positive
weight in PC2 also correlate with high S and G2 populations by 24 hr following treatment and,
conversely, that signals that have strong, negative weight in PC2 correlate with a high GI population by
24 hr (or low S and G2 populations by 24 hr). This organization of the responses (G1 is anti-correlated
with PC2, and separatedfrom S and G2-M populations, which lie close together and are correlated with
PC2) makes sense in light of our hypothesis that, following DNA damage under the experimental
conditions here, a DNA damage-mediated cell cycle arrest in Gl or at the G1/S transition is initiated, and
that this arrest releases such that cells can progress into S and G2-M by 24 hr.
Signals in the Principal component space: Signal-response relationships
Using PLSR, we can also obtain an understanding of the relationships between measured
molecular signals (explanatory variables, X) and measured cellular responses (response variables, Y) by
examining where the signals lie in the principal component space, relative to measured cellular
responses.
PLSR model confirms a role for p53 in promoting cell-death and cell cycle regulation following
DNA damage
For example, we know that p53 has roles in promoting both cell-death and cell-cycle regulation
and in coordinating these responses following DNA damage. Indeed, if we plot total p53 measurements
in the principal component space (Figure 2-7B), we can see that some time-point measurements are
highly and positively correlated with PC1, the "Survival-Death" Axis and with apoptotic outcomes at 6
and 12 hr. Some time-point measurements of total p53 are highly and positively correlated with PC2,
the "Cell-cycle Arrest/Regulation" Axis, and with S and G2 cell populations. And remaining time-point
measurements of total p53 are highly and positively correlated with both PCI and PC2. Total p53 seems
very "informative" in that all time-point measures of total p53 are weighted highly in either PCl or PC2,
or in both. Plotting total p53 signals in principal component space allows us to capture p53's known
dual role in both cell-death and cell-cycle regulation following DNA damage.
PLSR model suggest a role for ERK in promoting cell-death and in promoting population build-
up in S and G2-M following DNA damage
The MAPK ERKI/2 has an established role in promoting cell-cycle progression through the G1/S
transition in normal cell-cycles and in promoting survival following general types of stress. Roles for
ERK1/2 in mediating cellular responses of cell-cycle arrest/regulation and/or cell-death in the context of
DNA damage are not well-established or specified. If we plot p-ERK signals in the principal component
space (Figure 2-8), we can see that some time-point measurements are highly and positively correlated
with PC1, the "Survival-Death" Axis and with apoptotic outcomes at 6 and 12 hr. Some time-point
measurements of p-ERK are highly and positively correlated with PC2, the "Cell-cycle Arrest/Regulation"
Axis, and with S and G2 cell population measurements at 24 hr following treatment. And remaining
time-point measurements of p-ERK are highly and positively correlated with both PCi and PC2. This
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pattern is very similar to that observed for p53 signals. From this pattern we might hypothesize that,
despite ERK's established role in promoting cell-survival in some contexts, ERK has a role in both
promoting cell-death and in promoting cell-cycle arrest/regulation following DNA damage (p-ERK is
correlated with the build-up in S and G2-M populations at 24 hr).
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Figure 2-8. All p-ERK measurements (including values of p-ERK measured at each of 10 time-points
following treatment as well as the max, mean, and equilibrium value of total p53 over the whole time-
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course following treatment and the value for the area under the curve (AUC) of p-ERK measured over
the full time-course) are plotted in the principal component space based on their weights in PCI and
PC2 (light grey, small circles). Some p-ERK measurements are highly correlated with apoptotic
responses only, some are highly correlated with cell-cycle responses only and some are highly correlated
with both. These result are reminiscent of those obtained for total p53, and lead us to a hypothesis
that, though ERK has an established role in promoting cell-survival and cell-cycle progression under
normal or low stress conditions, under DNA damaging conditions, ERK may have a role in promoting
apoptosis and cell-cycle regulation.
TI-SWR
The goal of TI-SWR (Time-Interval Stepwise Regression) is to exploit the time dimension of the
dataset to find relatively detailed, time-dependent signal-response relationships, and to significantly
decrease the number of explanatory variables in the models we look at, to both allow for the
identification of unique functions relating signals and cellular response, and to increase model
interpretability.
In TI-SWR, we make our original hypothesis more restrictive in a few ways. Our original
hypothesis is that our measured cellular responses are a function of our measured molecular signaling
events (including all time-points at which these signals were measured). The hypothesis that a TI-SWR
analysis makes is that a subset of the molecular signaling events measured at one time-point work
together to mediate a measured cellular response (Supplementary Figure 2-2). This is a natural
hypothesis as a cell integrates information about previous physical/mechanical or signaling events via a
physical/chemical encoding of past events in the current status of its signaling components. At any given
time a cell uses only the current status of its signaling components and integrates these signals, which
occur temporally together, but which also encode past signaling events, in making the decisions which
determine future cell actions and eventually the cell fate. E.g., at 1 hr following DNA damage, a cell may
"remember" that ATM was activated at 30 min following damage, even if it is no longer activated at 1 hr
following damage, because the ATM activation at 30 min led to H2AX phosphorylation, and H2AX is still
phosphorylated at 1 hr.
We first choose just one cellular response of interest to investigate at a time. In order to make
this one cellular response variable as "information-rich" as possible, we choose the derivative of the
linearized change in a measured cellular response over some time-period as our response variable,
instead of the measured cellular response at one time-point. The choice of the derivative of the cellular
response as the dependent variable is explained in detail in Chapter 3: Computational Methods.
We next build a set of time-interval models, including one time-interval model for each time-
point at which signaling measurements were made. In each time-point specific time-interval model, the
response variable is the one that we have chosen to investigate. Explanatory variables include only the
measurements of all signals made at the time-point of the time-point specific model.
For the regression step in TI-SWR analysis, we make use of a Stepwise regression algorithm.
Stepwise regression is a well-established regression procedure that can be used to select a subset of
explanatory variables, from an original larger explanatory variable set, that maximally correlates with
the response variable. Explanatory variables that do not add to the model's ability to predict the
response variable are excluded from the model (Figure 2-6B). Time-interval models thus have few
explanatory (signal) variables and are very likely to have fewer explanatory variables than there are
observations in the dataset, thus allowing for the identification of a unique functional relationship
between the cellular response and signals at the time-point of the model.
The result of a TI-SWR analysis is a set of time-interval models that are used sequentially for the
time-points at which signals were measured to specifically investigate time-dependent signal-response
relationships between signals at each of the time-points and the cellular response being investigated.
These time-point specific time-interval models have few explanatory variables and are thus easily
interpretable. The sets of time-interval models yield insight into detailed, time-dependent signal-
response relationships and greatly facilitate the development of hypotheses regarding signal-response
causal relationships as well as the design and execution of hypothesis-motivated experiments to test
and validate these hypotheses.
TI-SWR: Results
We pursued the investigation of signal-response relationships related to the dramatic cell-cycle
phenotypes we observed for cell populations treated with low Dox +/- TNF-a using the TI-SWR
methodology. We chose the change in the percent of the cell population in S phase between 12 and 24
hr following treatment (A %S, 12-24 hr) as the response variable in a TI-SWR analysis.
When we choose this response variable (A %S, 12-24 hr) as the subject of a TI-SWR analysis, the
result is a set of 5 time-point specific time-interval models (Table 2-6). At five out of the 10 time-points
at which signals were measured, no signal-response relationships reach a level of significance (These
time-points include the 0.25, 0.5, 1, 1.5 and 12 hr time-points). That is, no signals at these time-points
are found to significantly correlate with the response variable. Therefore, the Stepwise regression
algorithm excludes all signals from these time-interval regression models and no model is reported at
these time-points.
Y : A % S phase, 12-24h
Time-point (hr) Signal correlates in decreasing order of R 2
0.25h ----
0.5h
1h ----
1.5h ----
2h + pH2AX, - total H2AX, + pERK1/2, - pNbsl
4h + pERK1/2, - total p53, - total JNK, - pp53
8h + pERK1/2
12h ----
16h + total p53
24h + total p53
Table 2-6. Table of results from a TI-SWR (Time-Interval Stepwise regression) analysis investigating the
change in S phase cell-cycle population between 12 and 24 hr following treatment (A %S, 12-24 hr) as
the cellular response variable. Rows present an overview of the results for each of the 10 time-point
specific Time-Interval models constructed (For each of the time-point specific Time-Interval models, the
response variable is A %S, 12-24 hr and the explanatory variable set is all signals measured at that time-
point). For each Time-interval model, signal names are listed in order of decreasing R2 (ability to explain
the variability in the response variable), within the single optimal model calculated. Where no signals
are listed, no signal-response relationships reached an acceptable level of significance (p < 0.05). p-ERK
(red) is positively correlated with A %S, 12-24 hr at 2, 4 and 8 hr following treatment. These data
strengthen our hypothesis that ERK has a role in mediating cell-cycle regulatory phenotypes following
DNA damage. For further details on individual Time-Interval models in this set, and on the full TI-SWR
analysis, reference Supplemental Figure 3-1 through 3-8.
......... ..  .... 
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TI-SWR analysis suggests that ERK promotes population build-up in S phase following DNA
damage
The five time-point specific models that do result from the TI-SWR analysis are for signaling at 2,
4, 8, 16 and 24 hr (Table 2-6). Interestingly, we find that H2AX and ERK1/2 are correlated with the
response variable (A %S, 12-24 hr) at relatively early times (2 hr). H2AX is excluded from the model by
the 4 hr time-point, but ERK1/2 remains in the 4 hr time-point model. In the 4 hr time-point model,
ERK1/2 has a much higher correlation with the response variable (A %S, 12-24 hr) than in the 2 hr time-
point model, and now works in concert with p53. ERK1/2 is also still retained in the 8 hr time-point
model. In the 8 hr time-point model, ERK1/2 is highly correlated with the response variable and is the
only signal at this time-point that is correlated with the response variable. By the 12 hr time-point,
ERK1/2 is excluded from the time-point model, and is not included in models for either of the later time-
point models (16 and 24 hr time-point models). Time-point specific models for the 16 and 24 hr time-
point exclude all signals except for total p53, indicating that only total p53 is significantly correlated with
the response variable at these late times.
Translating a Model-derived relationship into an experimentally testable Hypothesis
The results of a TI-SWR analysis with A %S, 12-24 hr as the response variable, indicate that p-
ERK1/2 activity at 2, 4 and 8 hr following treatment is correlated with the change in the percentage of
the population in S phase between 12 and 24 hr (A %S, 12-24 hr). This correlation is particularly strong
at the 4 and 8 hr time-points, with p-ERK1/2 showing up as the only signal correlate with the A %S from
12-24 hr at the 8 hr time-point (Supplementary Figures 3-1 through 3-5).
We can indeed see that there is robust activation of ERK1/2 over the time-period from 2-8 hr
following treatment under many of the treatment conditions examined (Figure 2-2A). In untreated cell
populations ERK1/2 activity is minimal over this time-period. In cell populations treated with TNF-a,
there is an early period of ERK1/2 activity, with pERK1/2 rising to 3 fold over untreated by 30 min
following treatment, up to nearly 5 fold by 2 hr following treatment, then rapidly decreasing to a low
activity level of about 2 fold over untreated by 4 hr and remaining at this low levels at least through the
8 hr time-point. Cell populations treated with low Dox (2 pM) alone exhibit low levels of ERK1/2 activity
early in the time-course following, but pERK1/2 begins to rise to 2 fold over untreated by 2 hr following
treatment and rapidly increases between 2-4 hr, exhibiting activity levels 6 fold over untreated by 4 hr
and 7 fold over untreated by 8 hr. Cell populations treated with low Dox (2 IpM) plus TNF-a exhibit an
early rise in ERK1/2 activity nearly identical in dynamics and magnitude to that observed in populations
treated with TNF- a alone. However, whereas in populations treated with TNF- a alone this ERK1/2
activity is not sustained beyond 2 hr following treatment, in cell populations treated with low Dox plus
TNF- a, early ERK1/2 activity is sustained beyond 2 hr, remaining at a consistently high 5-6 fold over
untreated activation level through 12 hr following treatment (these mid-time range kinetics are nearly
identical to those observed in populations treated with low Dox alone). Cell populations treated with
high Dox alone (10 IM) exhibit low early ERK1/2 activity levels, followed by a slow, continuous ascent
from 1.7 fold by 2 hr following treatment to 5.5 fold by 8 hr.
Because of these differential ERK1/2 activity dynamics over the time-period from 2-8 hr
following treatment, we posited that, in addition to the correlation between the activity of ERK1/2 at
each of the 2, 4 and 8 hr time-points and A %S from 12-24 hr, that there would also be a correlation
between the integrated ERK1/2 activity over the time-period from 2-8 hr and A %S from 12-24 hr. In
fact, the regression coefficient from a univariate linear regression analysis of these two variables was
0.8, revealing a high positive correlation between the integrated ERK1/2 activity over the time-period
from 2-8 hr following treatment and A %S from 12-24 hr (Supplementary Figure 2-3).
We posited that if this correlation represents a causal relationship between pERK1/2 from 2-8 hr
and A %S from 12-24 hr, then a lower pERK1/2 from 2-8 hr would result in a lower A %S from 12-24 hr.
Thus, we hypothesized that if we experimentally inhibit ERK1/2 over the time-period between 2-8 hr
following DNA damage, we would expect a lower A %S from 12-24 hr than if we do not inhibit ERK1/2
over this time-period.
Experimentally Testing a Model-derived Hypothesis
Cell populations treated with low Dox (2 ptm) exhibit the largest A %S from 12-24 hr (Figure 2-
5A) and the largest integrated ERK1/2 activity over the time-period from 2-8 hr following treatment
(Figure 2-2A). Therefore, we chose to pursue the validation of our hypothesis under this treatment
condition. We used PD98059, an ATP-competitive inhibitor of MKK2/MEK1, the only known activating
kinase of ERK1/2, to inhibit ERK1/2 activity over the time-period between 2-8 hr following treatment
with low Dox (2 pim).
We hypothesized that we would observe a lower A %S from 12 to 24 hr in cell populations
treated with PD98059 in the time period from 2-8 hr following treatment with low Dox (2 pim) than we
would observe in cell populations treated with low Dox alone. We reasoned that this decrease in the A
%S from 12 to 24 hr would manifest itself as either an observed decrease in the %S at 24 hr, an observed
increase in the %S at 12 hr, or as both of these effects. We considered that an observed decrease in the
%S at 24 hr would be an unsurprising result; ERK1/2 has an established role as a positive regulator of
proliferation and the G1/S transition, so that its inhibition could reasonably be expected to prevent cells
from entering S, thus decreasing the observed %S at some time following its inhibition. By the same
reasoning, an observed increase in %S at 12 hr would be an unexpected result. The combination of
these two results would be equally unexpected.
Inhibition of ERK results in a decrease in A %S between 12 and 24 hr
Cells were treated with Dox as before (Figure 2-1A), and PD98059 or carrier alone was added at
either the same time as Dox (0 hr) or at 2 hr following Dox treatment, to more specifically test the
hypothesis that ERK1/2 activity in the time period from 2-8 hr is crucial for this cellular response
phenotype. In cell populations treated with Dox plus PD98059 at 0 hr, or plus PD98059 at 2 hr, we
observed both a statistically significant decrease in %S at 24 hr and a statistically significant increase in
%S at 12 hr as compared to cells treated with Dox, plus carrier alone (Figure 2-9A). Thus, experimental
inhibition of ERK1/2 in the time period from 0-8 hr or in the time period from 2-8 hr following Dox
treatment results in lower A %S from 12 to 24 hr than is observed following Dox treatment without
inhibition of ERK1/2, confirming our model-derived hypothesis.
These results were surprising and suggested a novel role for ERK1/2 in cell-cycle regulation
following DNA damage. Therefore, we chose to pursue a more detailed study of cell-cycle dynamics in
cell populations treated with low Dox in the presence and absence of ERK1/2 inhibition.
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Figure 2-9. (A) A plot of the % of the total cell population that is observed to be in the S phase of the
cell-cycle at 12 and 24 hr following treatment with 2 lpIM Dox +/- PD98059 (20 jpM), added
simultaneously with Dox (0 h) or added 2 hr following Dox treatment (2 h). U20S cells were treated
with 2 pM Dox plus PD98059 (20 ptM) at 0 hr following Dox treatment or at 2 hr following Dox
treatment. Treatment protocol was as described in Figure 2-1. (A), except that PD98059 was either
never added, added simultaneously with Dox, or added 2 hr following Dox treatment. An additional
divergence from the previously described protocol is that, following media aspiration and replacement
with media containing 1% FBS, in this case media also contained PD98059 if it already contained
PD98059 prior to the media change. Whole cell samples were collected and fixed at 12 and 24 hr
following treatment and stained with PI (propidium iodide) for FACS measurement of DNA content.
FACS cell-cycle histograms were gated to distinguish fractions of the total cell population in G1, S or G2-
M cell-cycle phase, and these gates were subsequently quantified. (B) A plot of the % of the total cell
population that is observed to be in the S phase of the cell-cycle at 12, 15, 18, 24, 27 and 30 hr following
treatment with 2 iM Dox +/- PD98059 (20 ptM), added simultaneously with Dox (0 h) or added 2 hr
following Dox treatment (2 h). (C) A plot of the % of the total cell population that is observed to be
apoptotic at 12 hr following treatment with 2 pM Dox +/- PD98059 (20 pM), added simultaneously with
Dox. U20S cells were treated as described in (A). Whole cell samples were collected and fixed at 12 and
24 hr following treatment and stained for FACS measurement of cleaved caspase-3 and cleaved Parp.
FACS dot plots were gated to distinguish fractions of the total cell population staining positively for one,
none or both apoptotic markers, and these gates were subsequently quantified. Here, cells staining
positively for both apoptotic markers (CC3+CParp+) were considered to be apoptotic. (D) ERK1/2 has
an established role in promoting cell-survival and cell-cycle progression under normal or low stress
conditions. (E) Model 1: ERK1/2 has a role in promoting apoptosis and maintenance of a cell-cycle
check-point/arrest in G1 or at the G1/S transition following DNA damage; ERK1/2 switches between
promotion of the maintenance of a cell-cycle check-point and promotion of apoptosis based upon the
cell-cycle context at the time of damage. That is, if damage is induced prior to a cell-cycle check-point in
Gl or at the G1/S transition, ERK1/2 promotes maintenance of this check-point once it has been
engaged. If damage is induced post cell-cycle check-point, ERK1/2 promotes apoptosis. (F) Model 2:
ERK1/2 has a role in promoting apoptosis and maintenance of a cell-cycle check-point/arrest in Gl or at
the G1/S transition following DNA damage; ERK1/2 switches between promotion of the maintenance of
a cell-cycle check-point and promotion of apoptosis based upon the damage context of the cell. That is,
ERK1/2 promotes maintenance of a cell-cycle check-point in G1 or at the G1/S transition in the case that
damage is below some threshold in terms of amount and/or complexity and ERK1/2 promotes apoptosis
in the case that damage is above some threshold in terms of amount and/or complexity.
Inhibition of ERK results in early release from a DNA damage-mediated cell cycle arrest in GI
or at the G1/S transition
Cells were treated with Dox as before, and PD98059 or carrier alone was added at either the
same time as Dox (0 hr) or at 2 hr following Dox treatment. The cell-cycle status of these populations
was determined by FACS analysis at 6 time-points over 30 hr following treatment, including 3 "early"
time-points (12, 15 and 18 hr) and three "late" time-points (24, 27 and 30 hr). In untreated cell
populations, the percentage of the cell population in S phase (% S) remains nearly constant over the full
18 hr time course at about 25%. Adding PD98059 to untreated cell populations either at the same time
as mock treatment (0 hr) or 2 hr following mock treatment does not change the percentage of the cell
population in S phase (%S) or the constant dynamics of the %S over the full 18 hr time course. (In both
of these treatment conditions, the %S also remains nearly constant over the full 18 hr time course and
overlays almost exactly that of untreated cell populations that never see PD98059 with a constant %S of
approximately 25% over the full time course.) (Figure 2-9B)
In cell populations treated with low Dox (2 ptM), %S remains relatively constant at levels just
above those observed in untreated cell populations (28% at 12 hr; 29% at 15 hr) through 15 hr following
treatment. %S begins to increase to levels above those observed in untreated cell populations by 18 hr
following treatment (32%). The percent of the cell population in S rises dramatically between 18 hr
following treatment and 24 hr following treatment, such that 44% of the cell population is observed to
be in S phase at 24 hr following treatment. The %S peaks just above this value at 45% of the cell
population in S at 27 hr following treatment and may start to decrease by 30 hr following treatment,
with an observed %S of 43% at 30 hr following treatment.
As observed previously, in cell populations treated with low Dox plus PD98059 at the time of
Dox treatment (0 hr), %S was observed to be higher at 12 hr following treatment than that observed in
cell populations treated with Dox minus PD98059 (Figure 2-9A). %S at 12 hr following treatment in this
population was 41% (compared to 28% for the cell population treated with Dox minus PD98059, rose to
45% by 15 hr following treatment and remained at 45% through 18 hr following treatment before
beginning a steady descent over the remaining 12 hr in the time course back to levels just above those
seen in untreated cell populations, and equivalent to those seen in Dox treated cell populations minus
PD98059 at 12 hr following treatment (28%), by 30 hr following treatment. Results for cell populations
treated with low Dox plus PD98059 at 2 hr following treatment were nearly identical to those observed
for cell populations treated with Dox plus PD98059 at the time of Dox treatment (0 hr), with somewhat
lower values observed for %S at 12 and 15 hr following treatment than that observed in cell populations
treated with Dox plus PD98059 at 0 hr (36% vs. 41% and 40% vs. 45%, respectively), though still
significantly higher than values observed in untreated cell populations or populations treated with Dox
minus PD98059 (Figure 2-9B).
From examination of the cell-cycle profiles, we determined that the increase in S phase at 12 hr
following Dox treatment plus PD989059 that we quanitify in Figure 2-9B is due to a population moving
synchronously out of G1 into S. This population is a "shoulder" off of the G1 peak in a cell-cycle
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histogram staining for Pl at 12 hr, but by 15-18 hr this large cohort of the population has moved
synchronously into mid S phase (Supplementary Figure 2-4). By 24 hr, this cohort population is moving
from S into G2-M, and by 30 hr, this cohort has completed its transition into G2-M.
We previously noted, and again observed, this "cohort "effect of cells moving synchronously
through the cell cycle in cell populations treated with low Dox alone. Our data are consistent with the
hypothesis that this cohort effect is likely due to a population build-up at a DNA damage mediated cell
cycle checkpoint in G1 or at the G1/S transitions, followed by a release of the cell-cycle checkpoint that
allows the now synchronized population, or cohort, to continue through the cell cycle together. In cell
populations treated with low Dox alone (no PD) this "cohort" moves from G1 into S by 27 hr, and from S
into G2-M by 48 hr. In cell populations treated with low Dox plus PD, this "cohort" moves from GI into
S by 15-18 hr, and from S into G2-M by 24.
Addition of the PD drug then results in an early release of the "cohort" from a DNA damage
mediated cell cycle arrest in Gl or at the G1/S transition. From these observations we reasoned that
ERK1/2 may be involved in the maintenance of a DNA damage mediated cell-cycle checkpoint in Gl or at
the G1/S, transition, as its inhibition appears to result in an early release from a cell-cycle check-point.
Inhibition of ERK reduces apoptosis following DNA damage
We also examined the apoptotic phenotype of cell populations treated with low Dox plus or
minus PD. In untreated cell populations, apoptosis as measured by positivity for both apoptotic
markers, cleaved Caspase-3 and cleaved PARP, is minimal (<<5%). In untreated populations, addition of
PD98059 does not affect apoptosis; these populations also exhibit minimal apoptosis (<<5%) (Figure 2-
9C). In cell populations treated with Dox (2pM), nearly 20% of the population is apoptotic at 12 hr
following treatment. In cell populations treated with Dox (2piM) plus TNF-a, nearly 40% of the
population is apoptotic at 12 hr following treatment. Addition of PD98059 at the time of Dox treatment
to cell populations treated with Dox alone or Dox plus TNF-a significantly decreases apoptosis in these
populations at 12 hr following treatment, from nearly 19% to 11% and from 39% to 25% respectively
Figure 2-9C and data not shown). Similar results were found at 24 hr following treatment, with addition
of PD98059 decreasing apoptosis from 13% to 8% in populations treated with Dox alone, and from 28%
to 17% in populations treated with Dox plus TNF-a (Data not shown). These results indicated to us that
ERK1/2 might be involved in promoting apoptosis following DNA damage, as its inhibition results in
dramatically decreased apoptosis following DNA damage.
Inhibition of ERK reduces apoptosis in GI or at the G1/S transition following DNA damage
In cell populations treated with low Dox plus TNF-a, the % apoptosis is dramatically higher than
that observed in cell populations treated with low Dox alone at all time-points examined (Figure 2-5B).
The cell-cycle "cohort" effect observed in cell populations treated with Dox alone is likewise observed in
cell populations treated with low Dox plus TNF-a. However, the cohort that is released from G1 into S
by 24 hr and that leaves S to progresses into G2-M by 48 hr is a significantly smaller population in cell
populations treated with low Dox plus TNF-a than is observed in populations treated with low Dox alone
(Figure 2-5A and Supplementary Figure 2-6).
We reasoned that this cohort might be smaller in populations treated with low Dox plus TNF-a
than in populations treated with low Dox alone because the complement of this cohort is dying by
apoptosis prior to release of the cohort into S, either in GI or at the G1/S transition, and that this
apoptosis is ERK1/2 dependent. This is consistent with the observations that in cell populations treated
with low Dox plus TNF-a, 1) apoptosis is dramatically higher than that observed in populations treated
with low Dox alone, 2) the population cohort that makes its way from G1 into S by 24 hr following Dox
plus TNF- a is smaller than that observed in populations treated with low Dox alone, and 3) Inhibition of
ERK1/2 in populations treated with low Dox plus TNF-a results in both significant inhibition of apoptosis,
and in an increase in the size of the population cohort that is released from G1 into S by 12 hr
(Supplementary Figure 2-6).
Model
ERK1/2 has an established role in promoting cell-survival and progression through the cell-cycle
under normal and/or low stress conditions (Figure 2-9D). These data thus suggested that ERK1/2 is
involved in both 1) promotion of apoptosis, and 2) maintenance of a cell-cycle checkpoint in GI or at the
G1/S transition following DNA damage. We further hypothesized that 3) ERK1/2 activity switches
between promotion of apoptosis, or maintenance of a cell-cycle arrest in G1 or at the G1/S transition, in
a single cell based on the either the cell-cycle context in which the cell sustained DNA damage (e.g.
whether damage is sustained pre-Gi or G1/S checkpoint or post-checkpoint) (Figure 2-9E), or based on
the damage context of the cell following DNA damage (e.g. the extent/type of damage a cell has
sustained) (Figure 2-9F).
ERK promotes apoptosis in G1 or at the G1/S transition following DNA damage without
requiring progression through S phase
We proceeded to directly test the hypothesis that ERK1/2 is involved in promotion of apoptosis
in Gl or at the G1/S transition following DNA damage. We synchronized cells in G1 via a double
thymidine block, released into aphidicolin to prevent progression into S phase, then treated G1-
synchronized populations with Dox (2pM), or Dox plus TNF-a, plus or minus PD and measured apoptosis
at 8 hr following Dox treatment, without ever allowing cells to progress through S phase (Figure 2-10A).
In untreated, G1-synchronized cell populations, apoptosis as measured by positivity for both
apoptotic markers, cleaved Caspase-3 and cleaved PARP, is minimal (<<5%). In untreated G1-
synchronized populations, addition of PD98059 does not affect apoptosis; these populations also exhibit
minimal apoptosis (<<5%). In Gb-synchronized cell populations treated with Dox (2IM), 33% of the
population is apoptotic at 8 hr following Dox treatment when the population is blocked from
progression into S phase by the presence of aphidicolin. In G1-synchronized cell populations treated
with Dox (2pM) plus TNF-a, 55% of the population is apoptotic at 8 hr following Dox treatment when the
population is blocked from progression into S phase by the presence of aphidicolin. In both of these
populations, addition of PD98059 significantly reduces apoptosis in the population, from 33% to 17% (a
48% reduction) and from 55% to 35% (a 36% reduction) respectively (Figure 2-10B and data not shown).
These data support our hypothesis that ERK1/2 is involved in promotion of apoptosis in Gl or at
the G1/S transition following DNA damage. However, in order to rule out the "chattering" effect at the
G1/S boundary that has been observed to occur in cells blocked from entering S by incubation with
aphidicolin (minimal levels of origin firing may occur during incubation with aphidicolin) as a necessary
condition for this observed apoptosis, we repeated this experiment, this time allowing progression into
S phase by removing aphidicolin (Figure 2-10C). If origin firing and progression into S is a necessary
condition for ERK1/2 dependent promotion of apoptosis following DNA damage, we would expect that
G1-synchronized cell populations treated with Dox that are allowed to progress into S by removal of
aphidicolin will exhibit higher absolute levels of apoptosis than is observed in G1-synchronized cell
populations treated with Dox that are never allowed to progress into S phase. We also might expect a
greater margin of saving (reduction in apoptosis) by ERK1/2 inhibition in cell populations that are
allowed to progress into S.
In Gb-synchronized cell populations treated with Dox (2ptM), 17% of the population is apoptotic
at 7 hr following Dox treatment when the population is allowed to progress into S phase for 1 hr
following release from an aphidicolin block, accomplished at 6 hr following Dox treatment. In G1-
synchronized cell populations treated with Dox (2pM) plus TNF-a, 48% of the population is apoptotic at
7 hr following Dox treatment when the population is allowed to progress into S phase for 1 hr following
release from an aphidicolin block, accomplished at 6 hr following Dox treatment. In both of these
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populations, addition of PD98059 significantly reduces apoptosis in the population, from 17% to 11% (a
35% reduction) and from 48% to 31% (a 35% reduction) respectively (Figure 2-10D and data not shown).
These data thus support our hypothesis that ERK1/2 is involved in promotion of apoptosis in G1
or at the G1/S transition following DNA damage, and that this ERK1/2 dependent promotion of
apoptosis in Gl or at the G1/S transition does not require progression into S phase.
Apoptosis I PoxDD~ aOdox, PDA release into +/- Dox B .2dox
aphidicolin +/- PD + 40 -2dox. PD
synchronize C 30-1*(Thymidine) ~[ 1i
0 1 8h 20 -
FACS CC3/CParp measurement (apoptosi ' 0
FACS PI/BRDU measurement (cell-cycle)
C D Apoptosis
release into +/- Dox wash off + 20 -
aphidicolin +/- PD aphidicolin 0
e 15 -synch ro nizer C
(Thymidine)i 0 10 -
0 1 6 7h0 1 8 50 - C
Figure 2-10. (A) Time-line of experiment; data is in (B). U2OS cells were synchronized in late GI via a
double thymidine block and released into fresh media containing aphidicolin (10 ptM) to prevent
progression into the S phase of the cell cycle. One hour following release into aphidicolin, cells were
treated +/- Dox (0 or 2 p.M) and +/- PD98059 (20 jiM). At 4 hr following treatment, treatment media
was aspirated and replaced with media containing 1% FBS and +/- PD98059 according to whether
PD98059 was present or not prior to media exchange, and plus aphidicolin. Whole cell samples were
collected and fixed at 8 hr following treatment, then stained for FACS measurement of cleaved caspase-
3 and cleaved Parp. (B) A plot of the % of the total cell population that is observed to be apoptotic at 8
hr following treatment in cell populations that were treated in late G1, and never allowed to progress
into S phase, as described in (A). FACS dot plots of cleaved caspase-3 vs. cleaved Parp were gated to
distinguish fractions of the total cell population staining positively for one, none or both apoptotic
markers, and these gates were subsequently quantified. Here, cells staining positively for both
apoptotic markers (CC3+CParp+) were considered to be apoptotic. (C) Time-line of experiment; data is
in (D). U20S cells were synchronized in late G1 via a double thymidine block and released into fresh
media containing aphidicolin (10 pM) to prevent progression into the S phase of the cell cycle. One hour
following release into aphidicolin, cells were treated +/- Dox (0 or 2 p.M) and +/- PD98059 (20 pM). At 4
hr following treatment, treatment media was aspirated and replaced with media containing 1% FBS and
.... ....  .... ......
+/- PD98059 according to whether PD98059 was present or not prior to media exchange, and plus
aphidicolin. At 6 hr following treatment, media was aspirated and replaced with media containing 1%
FBS without aphidicolin, to allow progression into S phase. Whole cell samples were collected and fixed
at 7 hr following treatment, then stained for FACS measurement of cleaved caspase-3 and cleaved Parp.
(D) A plot of the % of the total cell population that is observed to be apoptotic at 7 hr following
treatment in cell populations that were treated in late G1, but subsequently allowed to progress into S
phase, as described in (C). FACS dot plots of cleaved caspase-3 vs. cleaved Parp were gated to
distinguish fractions of the total cell population staining positively for one, none or both apoptotic
markers, and these gates were subsequently quantified. Here, cells staining positively for both
apoptotic markers (CC3+CParp+) were considered to be apoptotic.
Future Experiments: ERK promotes maintenance of a DNA damage mediated cell cycle
checkpoint in GI or at the G1/S transition
In future experiments, we will provide further evidence of our hypothesis that ERK1/2 is
involved in maintenance of a cell cycle checkpoint in Gl or at the G1/S transition following DNA damage.
Similarly to previous experiments described, we will synchronize cells in G1 via a double thymidine
block, release into aphidicolin to prevent progression into S phase. We will then treat G1-synchronized
populations with Dox (2pM), or Dox plus TNF-a, plus or minus PD, remove aphidocolin at 6 hr following
Dox treatment to allow for progression into S phase, and make measurements of the cell-cycle profiles
of these populations at 3 hr intervals following release from aphidicolin (at 6, 9 and 12 hr following Dox
treatment). BRDU will be added 1 hr prior to sample collection for cell cycle profile measurement to
rigorously assess entry into S (Supplementary Figure 2-7). We expect that cell populations treated with
Dox or Dox plus TNF-a in the absence of PD will exhibit a cell-cycle arrest in G1 and will not progress into
S following release from aphidicolin within the time-period of this experiment (up to 12 hr following
Dox). On the other hand, we expect that cell populations treated with Dox or Dox plus TNF-a in the
presence of PD will not exhibit a cell-cycle arrest in G1 and will progress into S following release from
aphidicolin within the time-period of this experiment (up to 12 hr following Dox).
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Future Experiments: ERK switches between promoting maintenance of a DNA damage
mediated cell cycle checkpoint and promoting apoptosis in Gi or at the G1/S transition based
on either the cell-cycle context or the damage context
In future experiments, we will also attempt to distinguish between our two proposed models for
ERK1/2's role in mediating cellular responses following DNA damage. Our first model proposes that
ERK1/2 activity switches between a role in promotion of apoptosis or maintenance of a cell-cycle arrest
in GI or at the G1/S transition in a single cell following DNA damage based on the damage context of
that cell (the extent/type of damage sustained). A second model proposes that ERK1/2 activity switches
between a role in promotion of apoptosis or maintenance of a cell-cycle arrest in G1 or at the G1/S
transition in a single cell following DNA damage based on the cell-cycle context of that cell (pre- or post-
cell cycle checkpoint at the time of damage).
We will synchronize cell populations in metaphase via a nocodazol block, remove nocodazol to
release this metaphase-synchronized population to progress into G1. At 4 hr following release, greater
than 90% or the population is expected to have progressed into GO/G1 (early GI). Starting at 4 hr
following release, and at 2 hr intervals thereafter, through 10 hr following release (until progression
through G1 is complete - GI is approximately 6 hr in length), we will treat separate cell populations with
Dox, or Dox plus TNF-a, plus or minus PD, and measure apoptosis in, and cell-cycle profiles of, these
populations at 6 hr following treatment (Supplementary Figure 2-8A).
If the switch in ERK1/2 role is cell-cycle context dependent, such that in cells damaged pre- cell
cycle checkpoint ERK1/2 promotes maintenance of a cell cycle checkpoint and in cells damaged post-
cell cycle checkpoint ERK1/2 promotes apoptosis, then we expect that populations treated with Dox at
early times following release from nocodazol will exhibit a robust cell cycle arrest phenotype (a
population build-up in Gl or at the G1/S transition) and minimal apoptosis (Supplementary Figure 2-8B
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and Supplementary Figure 2-8C). Populations treated with Dox at later times following release from
nocodazol should exhibit an increasingly robust apoptotic phenotype (larger proportions of apoptotic
cells) as larger proportions of the cell population progress to a point in G1 that is post- cell cycle
checkpoint. Presumably, populations treated with Dox at 10 hr following release from nocodazol,
wherein the whole population should have progressed to a point in G1 that is post- cell cycle checkpoint
(late GI or G1/S), will exhibit a very robust apoptotic phenotype, and addition of PD will result in a
robust saving (reduction in apoptosis) (Supplementary Figure 2-8D and Supplementary Figure 2-8E).
If the switch in ERK1/2 role is damage context dependent, such that in cells that experience low-
level or simple damage ERK1/2 promotes maintenance of a cell cycle checkpoint and in cells that
experience high-level or complex damage ERK1/2 promotes apoptosis, then we expect that there will be
no change in the magnitude or proportion of cell-cycle arrest and apoptotic phenotypes exhibited by cell
populations treated with Dox at different points in G1.
One caveat to this projection is that if cells are more susceptible to damage at different points in
G1, then we would expect results similar to those projected in the case that our cell-cycle dependent
model is true. Therefore we might erroneously conclude that ERK1/2 switches its role in mediation of
cellular response following DNA damage in a cell-cycle context dependent manner, even if the true
model is that ERK1/2 switches its role in a damage-context dependent manner, IF extent/type of
damage is cell-cycle dependent.
In order to avoid such erroneous conclusions, we will additionally collect cell-extracts at 4 hr
following treatment with Dox in all cases and measure extent of damage by probing for yH2AX. If we
observe results consistent with a cell-cycle context dependent model and equal levels of yH2AX across
cell populations treated with Dox at different point in G1, then we will conclude that we have strong
evidence for a cell-cycle context dependent model. However, if we observe results consistent with a
cell-cycle context dependent model and levels of yH2AX across cell populations treated with Dox at
different point in G1 are not equal, then we will conclude that we have strong evidence for a damage
context dependent model.
Discussion
We have collected a large, quantitative signal-response dataset investigating network level
signaling and cellular responses following DNA damage, under inflammatory and non-inflammatory
treatment conditions. We used two distinct and complementary data-driven computational modeling
approaches to systematically investigate network level relationships between signals and cellular
phenotype in the data-set.
Data-driven computational modeling approaches are still in the early stages of development and
application in biology. Techniques such as PLSR and Bayesian network analysis have been used
successfully to gain insight into network level signal-response relationships, and as tools for prediction
of cellular response under novel treatment conditions. Janes et. al have used PLSR analyses of a large
quantitative signal-response dataset of population level, time-series signal and response measurements
to identify autocrine cascades involved in cytokine-induced apoptosis in HT-29 colon carcinoma cells
[165]. Kemp et. al have used PLSR analysis of a quantitative signal-response dataset of population level,
time-series signal and response measurements to predict the production of IL-2 in a T-cell hybridoma
cell line stimulated with altered peptide ligands of varying antigenicity [160]. More recently, Janes et. al
have developed a method they call "Model break-point analysis" that they use in conjunction with PLSR
analysis to further probe similar quantitative signal-response datasets to identify signaling that is
essential in a context (treatment)-specific manner (bounded by the treatments described in the dataset)
[166]. In this work, they show that break-point analysis allows for the identification of signals that are
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essential for cellular responses, such as apoptosis, under specific treatment conditions and not for
others, where the results from PLSR analysis alone does not identify the signal as essential for the
cellular response overall.
Sachs et. al have used Bayesian network analysis of a quantitative signaling dataset of single-cell
level signaling data measured at one time-point (including inhibitor-perturbed treatment conditions) to
reconstruct network level signaling relationships and to discover novel interpathway network causalities
following activation of human primary naive CD4* T-cells via CD3, CD28 and LFA-1 receptors [167]. A
major drawback to a Bayesian approach, as pointed out by the authors, was the inability of the analysis
to identify cyclic signaling relationships, such that several well-established feed-back relationships in the
signaling network were missed in the signaling network reconstruction. More recently, Sachs et. al have
developed a Generalized Bayesian network analysis approach to infer signaling network structure from a
quantitative signaling dataset of single-cell level, time-course signaling data; this generalized analysis
approach, applied to time-course data, aims to allow for inference of cyclic relationships in signaling
networks [168].
These examples demonstrate that 1) data-driven analysis methods can be successfully used to
discover network-level signaling relationships and signal-response relationships, 2) different data
analysis methods can be usefully applied depending on the type of data collected (conversely, the type
of data to be collected in an experimental investigation should be thoughtfully considered before-hand,
with an eye to what data-analysis methods will be applied), and 3) more than one data-driven analysis
method may be applied to a single dataset and the consideration of results from these analyses together
can greatly increase the depth of insight gained from the data (e.g. as in the consideration of break-
point analysis and PSLR analysis together).
In this work, we applied PLSR and TI-SWR methods to study DNA damage signaling. This work
represents the first application of data-driven computational modeling to the analysis of signaling events
90
following genotoxic stress. Results from the construction of a PLSR model suggested a role for ERK1/2 in
mediating both cell-cycle regulatory effects (increase in S phase and G2-M populations at 24 hr) and in
mediating apoptotic effects following DNA damage. A TI-SWR analysis identified a strong correlation
between ERK1/2 activity at 2, 4 and 8 hr following damage, and the change in percent of the cell
population in S phase between 12 and 24 hr (A %S, 12-24 hr). To our knowledge, this use of TI-SWR is
the first systematic application of SWR to investigate time-specific network-level relationships between
signals and cellular phenotypes.
ERK has a well-established role in promoting survival and progression into the cell-cycle under
normal and/or low-stress conditions [169-172]. A role for ERK1/2 following DNA damage has not been
well established, with some studies reporting a pro-survival role, and a few reporting a pro-apoptotic
role, for ERK1/2 following DNA damage. Tsakiridis et. al have shown that detection of active ERK in
samples of NSCLC tumors correlates with poor radiologic response [173], and Nishioka et. al have shown
that inhibition of ERK enhances apoptosis in acute myelogenous leukemia cells concurrently exposed to
the DNA damaging chemotherapeutic agent cytaribine [174]. Tang et. al have suggested that ERK
contributes to maintenance of a G2/M arrest following low dose etoposide treatment and to promotion
of apoptosis following high dose etoposide [175]. Yan et. al have suggested that ERK is necessary for the
induction of a G2/M checkpoint following irradiation in MCF-7 cells, and mediates the G2/M checkpoint
via activation of ATR [176]. We demonstrate that ERK1/2 plays a role in promoting apoptosis following
DNA damage, and also plays a role in maintaining a DNA damage-mediated cell-cycle arrest following
DNA damage. Thus our data point to a context specific role for ERK following DNA damage that is in
opposition to the role it plays under non-DNA-damaging conditions.
Two of the key steps in tumor development include acquisition of the ability to evade apoptosis
and the acquisition of the ability to proliferate in an uncontrolled manner. Consistent with ERK's role in
promoting survival and proliferation under non-DNA damaging conditions, upstream components of the
91
ERK cascade, including Ras, Raf and the EGFR are often mutated in cancer [177, 178], and the
dysregulation and hyper-activation of these pathways has been shown to be pathological in many
tumors, conferring resistance to therapy [179]. There has been a large effort to design rational
therapies to inhibit this pathway. Several MEK inhibitors are under development and EGFR inhibitors
have been some of the first targeted therapies to be approved and used in the clinic [178]. The success
of these agents had been surprisingly limited and has highlighted the complexity of this signaling
mechanism.
If the predominant role of ERK1/2 is to promote apoptosis under DNA damaging conditions,
inhibition of ERK1/2 (via, for example, application of a MEK inhibitor) should lead to inhibition of
apoptosis and could result in increased resistance to DNA damaging chemotherapy. If, on the other
hand, the predominant role of ERK1/2 is to promote cell-cycle checkpoint maintenance under DNA
damaging conditions, inhibition of ERK1/2 should lead to bypass of that checkpoint and result in
increased sensitization to DNA damaging chemotherapy [180]. We have demonstrated that ERK1/2
promotes apoptosis and maintenance of a checkpoint following DNA damage. It is crucial to determine
under what conditions the predominant effect of ERK1/2 is to promote apoptosis and under what
conditions the predominant effect of ERK1/2 is to promote maintenance of checkpoints, in order to
effectively implement chemotherapeutic regimens that combine DNA damaging chemotherapeutic
agents with MEK inhibitors.
Two hypotheses, consistent with our data, are that within a single cell ERK1/2 switches between
promotion of apoptosis and promotion of maintenance of a DNA damage-mediated cell-cycle
checkpoint based on either 1) the extent of damage sustained, or 2) the cell-cycle status at the time
damage was sustained. In the case where the predominant effect of ERK1/2 is determined by the extent
of damage sustained, ERK1/2 may promote checkpoint maintenance when low damage levels are
sustained, and ERK1/2 may promote apoptosis when high damage levels are sustained. If this is correct,
92
adjuvant therapy with MEK inhibitors may be effective in combination with doses of DNA damaging
chemotherapeutic agents that inflict only low levels of damage, but should be avoided in regimens that
include high doses of DNA damaging chemotherapeutics. In the case where the predominant effect of
ERK1/2 is determined by the cell-cycle status at the time damage was sustained, ERK1/2 may promote
checkpoint maintenance when damage was sustained prior to a DNA damage checkpoint in G1 or at the
G1/S transition, and ERK1/2 may promote apoptosis when damage was sustained after a DNA damage
checkpoint in Gl or at the G1/S transition. If this is correct, the timing of the administration of both the
DNA damaging agent and MEK inhibitors may be crucial for the effectiveness of the treatment. It may
be effective to attempt to synchronize tumor cells using cdk inhibitors, such as Roscovitin, prior to
administration of DNA damaging agents and MEK inhibitors.
Further elucidation of the context dependent activity of ERK following DNA damage will provide
clinicians with better guidelines in designing chemotherapeutic regimens that combine DNA damaging
chemotherapeutic agents and MEK inhibitors for the treatment of a wide range of tumors. Elucidation
of other such network signaling context dependencies through experimental and computational systems
level analysis of DNA damage responsive signaling networks will be crucial to the effective
implementation of treatment regimens that exploit the combination of traditional DNA damaging
chemotherapeutic agents and the broad range of targeted chemotherapeutics now under development.
Discussion of potential ERK mechanisms
ERK and Cyclin D1
Nuclear Cyclin D1 levels increase via Raf-Mek-Erk dependent transcriptional upregulation [181-
184], PI3K/Akt dependent translational upregulation and decreased degradation [62, 185, 186] during
GI in a mitogen dependent fashion [187]. In complex with ckd4 and cdk6, Cyclin D1 leads to the
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phosphorylation and inactivation of Rb, resulting in the activation of E2F transcription factors and
transcription of genes such as Cyclin E that are necessary for the transit from G1 to S [188-192].
Following G1/S transition, Cyclin D1 is phosphorylated on T286, exported from the nucleus and
degraded in the cytoplasm via the 26S proteosome. Nuclear export and degradation are both essential
for normal progression into S phase [186, 193, 194].
Inhibition of Cyclin D1 nuclear export results in re-replication of DNA and chromosomal
instability and uncontrolled proliferation and is highly transforming [195-199]. Inhibition of Cyclin D1
degradation in the cytoplasm results in delayed entry into S phase [194].
In a normal cell cycle, GSK3@ is implicated as the kinase that phosphorylates T286 on Cyclin D1.
Phosphorylation of T286 allows interaction of Cyclin D1 with a nuclear export factor, CRM1, and
subsequent nuclear export of Cyclin D1. T286-phosphorylated Cyclin D1 in the cytoplasm is recognized
by the F-box protein, Fbx4, and a co-factor, alphaB crystalline, resulting in its polyubiquitilation and
subsequent degradation by the 26S proteosome [193].
Okabe et al have also suggested that ERK serves as the primary kinase that phosphorylates T286
in normal S phase progression. They show that ERK interacts with Cyclin D via a D domain in Cyclin D
and phosphorylates it on T286 and that in cells expressing a mutant Cyclin D1 lacking a D domain, Cyclin
D1 is not efficiently phosphorylated. They also show that inhibition of ERK activity leads to increased
stability of Cyclin Dl in S phase cells. In this study, they suggest that the F-box protein required for
recognition, polyubiquitilation and proteosomal degradation of T286-phosphorylated Cyclin D1 is
FBXW8 [194].
In addition to occurring in the course of normal cell cycle progression, Cyclin D1 degradation is
also a well characterized stress response mechanism that is essential for proper cell-cycle checkpoint
induction or cell-cycle exit following various cellular stresses, including osmotic and genotoxic stress.
Human kidney cells induce a transient cell cycle arrest that is p38 dependent following exposure
to osmotic stress and oxidative stress [200-202]. Under these conditions, cells also degrade Cyclin D1.
GSK3@ is not required for Cyclin D1 degradation under these conditions. In fact, Casanovas et al showed
that, under these two stress conditions, p38 phosphorylates Cyclin D1 on T286, leading to its
ubiquitilation and proteosomal degradation [203].
Human melanoma cells degrade Cyclin D1 following exposure to irradiation and many other
types of genotoxic stress. Under these conditions, cells also induce a cell cycle arrest at the G1/S
transition that is dependent on Cyclin D1 phosphorylation on T286 and on its degradation. Santra et al
show that ATM phosphorylation and stabilization of the F-box protein FBXO31 is required for
ubiquitilation and proteosomal degradation of Cyclin D1. They also show that GSK3B kinase activity is
dispensable for the degradation of Cyclin D1 under these conditions, but that ERK kinase activity is
required for the degradation of Cyclin D1 under these conditions [204].
This study suggests that, in addition to promoting degradation of Cyclin D1 in the course of
normal S phase progression, ERK may also have a role in promoting degradation of Cyclin D1 in the
context of genotoxic-stress induced cell-cycle arrest. By blotting for Cyclin D1 levels in cells treated with
low Doxorubicin plus or minus PD98059, we can investigate whether this mechanism may be operating
in our system.
ERK and Myc
As discussed above, ERK activity is necessary for the transcriptional upregulation of Cyclin D1 in
the GI phase of the cell cycle, and therefore, for normal cell-cycle progression from G1 into S phase.
One mechanism by which ERK upregulates Cyclin D1 is via stabilization of the Myc transcription factor.
Myc protein participates directly in the transcriptional induction of Cyclin D1, promoting cell-cycle
progression [205].
The strict regulation of Myc protein levels is essential to normal cell cycle progression. Myc is
absent in quiescent cells, and is upregulated both transcriptionally and via Ras dependent increase in
stability following mitogenic stimulation, as cells enter G1 [206]. Homozygous deletion of myc genes
results in embryonic lethality [207, 208]. On the other hand, constitutive overexpression of myc protein
cultured cells or transgenic animals blocks differentiation and induces neoplastic transformation [209,
210].
Down-regulation of c-Myc is also associated with induction of cell-cycle arrest or cell-cycle exit
phenotypes in tumor cells. Benaud et al show that downregulation of c-Myc is required for a G1 cell
cycle arrest following loss of adhesion in mammary epithelial cell lines [211]. Janardhanan et al show
that treatment of human neuroblastoma cells with the combination of N-(4-hydroxyphenyl) retinamide
(4-HPR, 0.5muM) and genistein (GST, 25muM) resulted in cell-cycle exit to a neuronal differentiation
phenotype that required downregulation of n-Myc [212].
Myc is a highly unstable molecule with a half-life of about 30 minutes [213, 214], and is rapidly
degraded via the proteosomal pathway in a ubiquitin mediated fashion [215-217]. Myc's stability is
regulated in a post-transcriptional fashion, by two adjacent N-terminal phosphorylation sites, T58 and
S62. These sites have opposing roles in the control of Myc protein stability. Phosphorylation of Myc at
S62 by ERK stabilizes Myc protein. Subsequent phosphorylation of Myc at T58 requires the prior
phosphorylation on S62, is accomplished by GSK3@, and promotes degradation of Myc via a PP2A and
Pin1 dependent mechanism [206, 218-222].
Pin1 induces conformational changes in S62/T58-dually phosphorylated Myc that allow PP2A to
dephosphorylate the S62 site on Myc, resulting in T58-singly phosphorylated Myc. T58-singly
phosphorylated Myc is rapidly degraded via ubiquitilation and proteosomal degradation [219].
In normal cell cycle progression, Ras pathway activation by mitogens leads to the activation of
both ERK and Akt. ERK phosphorylates Myc at S62, and Akt likely phophorylates GSK30, preventing
phosphorylation of Myc at T58, overall increasing Myc protein stability [206, 223-225].
These studies suggests that, in addition to promoting stabilization of Myc in the course of
normal cell cycle progression, ERK may also have a role in promoting degradation of Myc and
subsequent cell cycle arrest or exit under some conditions. ERK phosphorylation of Myc at 62 is a
"stabilizing" phosphorylation, but it also primes Myc for degradation. Where Akt activity is not present
or strong enough to antagonize GSK30, and where PP2A activity is high, phosphorylation of Myc at S62
by ERK could have a net destabilizing effect. Additionally, Sears et al note that ERK may be capable of
phosphorylating both S62 and T58 on Myc [226, 227]. Therefore, in the presence of especially high ERK
activity, it is possible that ERK could be the perpetrator of both the "priming" phosphorylation on S62
and the degradation-promoting phosphorylation on T58. By blotting for Myc levels in cells treated
with low Doxorubicin plus or minus PD98059, we can investigate whether this mechanism may be
operating in our system.
ERK and Mcl-1
ERK pathway signaling plays a major role in promoting survival in many tumor cell types [170,
228-231]. One of the major mechanisms by which signaling in the ERK pathway regulates survival is via
regulation of Bcl-2 family members [232].
Bcl-2 family members consist of multi-domain members that are anti-apoptotic (Bcl-2, Bcl-xL,
and Mcl-1) and proapoptotic (Bax and Bak) and of BH3 domain-only pro-apoptotic members (BOPs).
In viable cells, pro-apoptotic multi-domain members, Bax and Bak, are bound to and
sequestered by anti-apoptotic multi-domain partners. In response to stress, BOPs are either expressed
or activated and bind to anti-apoptotic multi-domain members, promoting release of pro-apoptotic
multi-domain members, which can then oligomerize among themselves leading to mitochondrial outer
membrane permeabilization, release of cytochrome C and initiation of apoptosis [91, 233, 234].
BIM is a BOP that is negatively regulated by ERK on at least two levels. First, it is well
established that ERK activation leads to the repression of BIM mRNA levels [235]. Nuclear entry of the
transcription factor FOXO3A, for example, following cytokine withdrawal, leads to the transcriptional
upregulation of pro-apoptotic BIM [236]. Yang et al have recently shown that ERK can phosphorylate
FOXO3A, targeting it for proteosomal degradation, thereby preventing BIM accumulation [237]. A
second mechanism by which ERK regulates BIM is via direct phosphorylation of BIM on S69, which
targets BIM for proteosomal degradation [238-242]. The relevant E3 ligase necessary for BIM
degradation is unclear. Finally, ERK appears to inhibit the binding of BIMEL to anti-apoptotic multi-
domain Bcl-2 family members such as BCL-xL and Mcl-1, functionally inhibiting BIMEL, as BOPs must
interact with pro-survival family members to kill cells [240, 243].
ERK also directly participates in the regulation of the anti-apoptotic Mcl-1. Mcl-i has a short
half life and turnover is regulated by phosphorylation at two sites within an N-terminal PEST domain.
ERK directly phosphorylates Mcl-i on T163 within the PEST domain of Mcl-1, and this phosphorylation is
generally thought to result in increased Mcl-i stability [244]. However, Maurer et al show that this
"stabilizing" phosphorylation at T163 also acts as a "priming" phosphorylation for the second site in the
PEST domain, S159, to be phosphorylated by GSK3@. Phosphorylation of this second site promotes
polyubiquitilation and proteosomal degradation of Mcl-1 [245]. The relevant E3 ligase necessary for
Mcl-1 degradation is unclear. Thus, as in the case of ERK regulation of Myc stability, there is a fine
balance deciding when ERK promotes stabilization and when destabilization of Mcl-1, and there is room
for ERK to mediate a pro-apoptotic effect via destabilization of Mcl-1. By blotting for Mcl-1 levels in cells
treated with low Doxorubicin plus or minus PD98059, we can investigate whether this mechanism may
be operating in our system.
Chapter 3: Computational Methods
Introduction
Here we will review, and show example results for, two data-driven, computational methods,
Partial Least Squares regression (PLSR) and a hypothesis-based, iterative Time-Interval Stepwise
regression (TI-SWR), that can be used successfully in complement to systematically discover signal-
response relationships from quantitative signal-response datasets that address biological network
questions. In designing a system in which to collect such a signal-response dataset, we consider that
when cells are exposed to a cue of interest (treatment, or other environmental perturbation), molecular
signaling across signaling pathways is activated, and this molecular signaling is integrated in some
fashion by the cell to make and mediate cell-fate decisions regarding resultant phenotype. The
overarching hypothesis guiding this approach is that cue-resultant cellular phenotype is a function of
cue-initiated molecular signaling and that we can gain insight into the nature of this function using data-
driven computational approaches such as regression analysis.
There are several prerequisites for successfully using data-driven modeling of quantitative
signal-response datasets as a means to address biological network questions. One requirement is that
the biological network question is part of a relatively well defined system where a significant fraction of
the components involved in mediating cellular responses of interest in response to cues of interest are
known. A corollary to this is that participant molecules should be relatively well characterized in their
own right, at least in some contexts. A second requirement is the identification of an appropriate
system, with clear physiological relevance to the problem at hand, in which to compile a signal-response
dataset that includes observations, wherein the range of both signal and response measurements is
maximized in quantitative and qualitative variability. A final requirement is the ability to measure
network signaling, and cellular responses to the cues of interest that define the system, in a rigorously
quantitative fashion.
Our goal in this project was to systematically discover signal-response relationships in the DNA
damage signaling network response to DNA double-strand breaks, from a quantitative signal-response
dataset, using data-driven modeling approaches. The DNA damage signaling network response to DNA
double-strand breaks is a relatively well-studied response, such that most proteins involved in the
proximal signaling response have been identified. Additionally, many other signaling molecules with
established roles in mediating cell-death, cell-survival, cell-cycle checkpoints and general stress
responses following wide ranges of stimuli have been shown to be activated by DSB. These molecules
are also thought to be involved in mediating cellular responses to DSB, such as apoptosis and cell-cycle
arrest (Figure 1-1).
We treated U2OS human osteosarcoma cells with 6 distinct cue treatment combinations of
Doxorubicin and TNF-a (Table 2-1), that together expose cells to a range of DSB, in two different
physiologically relevant contexts. We did work to compile a quantitative signal-response dataset using
this system, consisting of 17 distinct and quantitative signal measures at 10 timepoints over 24 hr
following treatment (Table 2-4 and Figure 2-1A, Figure 2-1B) and 7 distinct and quantitative response
measures at 4 timepoints over 48 hr following treatment (Table 2-5 and Figure 2-1A, Figure 2-1B).
In this chapter we will review computational approaches we have used in the investigation of
this quantitative signal-response dataset with the goal of systematically discovering signal-response
relationships. The computational approaches used include Partial Least Squares regression (PLSR) and a
hypothesis-based, iterative, Time-Interval Stepwise regression (TI-SWR) for discovery of both signal-
response and signal-signal relationships. We will discuss challenges, and solutions that may easily
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generalize to other biological problems investigated in a like manner, illustrated by examples from our
specific study.
Challenges
There are several major technical challenges to using traditional data-driven modeling
approaches such as Multiple Linear regression (MLR) for the analysis of quantitative signal-response
datasets that address biological network questions. Some of these challenges include high
dimensionality in the independent variable set, small numbers of observations, potential high
collinearity in the dataset, and an inability to consider multiple response variables together.
High dimensionality and a low number of observations in the dataset pose two major problems.
First, each additional independent variable results in an additional degree of freedom in finding a
solution to the regression; there is no unique solution for a regression in which independent variables
outnumber observations. Especially in the context of low numbers of observations (in our example, 6
observations), this high dimensionality (in our example 170-dimensional; 17 signal measurements x 10
time-points) can be crippling if all signals measured are considered simultaneously in the analysis of any
given outcome. Second, high dimensionality introduces noisy independent variables into the regression
that result in degradation of solution quality. And finally, even in the best of circumstances, high
dimensionality will lead to a regression solution that is difficult to interpret. High dimensionality with
respect to number of observations will inherently be a problem that must be addressed in analysis of
signal-response datasets addressing biological network problems, at least for the foreseeable future.
Data for additional observations is time-consuming and costly to obtain, and we want to understand
how relatively large networks of proteins and other signaling elements work together, over a time-
course, to mediate cellular responses of interest to cues of interest, leading to large independent
variable sets.
101
High collinearity in the dataset is a problem if we want to use our regression solution to infer the
contributions that individual signals (independent variables) make to the response of interest
(dependent variable), as collinearity results in inaccurate and inconsistent estimation of independent
variable coefficients, and high confidence intervals on coefficients. If, for example, three of our
consecutive time-point ERK1/2 activity measurements contribute highly to cell-death outcomes, and the
ERK1/2 activity measurements are also highly correlated with each other, then removing any one of
these ERK1/2 measurements does not lead to a significant degradation of the model. The result is that
each of these ERK1/2 measurements is assigned a low coefficient in the resulting regression model.
There are two main ways to deal with the distorting effects of collinearity on coefficient determination
in regression models. One approach is to increase the observation size which will reduce coefficient
confidence intervals despite collinearity. Another way to deal with the effect of collinearity is to identify
the source of collinearity and to remove it by either removing or combining variables in some way that
makes sense in the context of the application. Multicollinearity will inherently be a problem that must
be addressed in analysis of quantitative signal-response datasets addressing biological network
problems. The largest source of collinearity in our signal-response dataset comes from measures of
single signals at each of 10 time-points. These measurements are clearly not independent of each other
and are likely highly correlated in many cases. Additionally, while the signals we chose to measure for
this dataset were chosen at least partly to minimize redundancy of information between measured
signals, we still expect that some of these signals will not be completely independent of each other.
Finally, classical regression approaches such as MLR do not allow multiple response variables to
be considered together in a single regression model. This poses a problem in the analysis of quantitative
signal-response datasets addressing biological network problems as cellular responses of interest are
often complex phenotypes that are best described by a combination of measurements of more than one
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single cellular response, considered together. In the case of our specific study, for example, the cellular
responses of apoptosis, survival, and cell-cycle arrest/regulation are intimately entwined in such a way
that it is difficult to describe the holistic cellular phenotypic response to DNA damage without
measuring and considering each of these individual measures of the phenotype together.
The data-driven modeling approaches for analysis of quantitative signal-response datasets
addressing biological network problems that we discuss here (PLSR and TI-SWR) each address these
challenges to varying extents and effects.
PLSR
Prinicipal Component regression (PCR) is a combined method using Principal Component
Analysis (PCA) and MLR. In PCR, PCA is used to compute Principal Components (PCs). PCs are linear
combinations of model independent variables that maximally capture variance in the independent
variable space. PC1 maximally captures the variance in the independent variable space. PC2 maximally
captures the residual variance, and so on for any additional PCs, such that PCs are orthogonal and
uncorrelated (Figure 2-6A top panels). The number of PCs necessary to capture the majority of the
variance in the explanatory (independent) variable set is smaller than the number of original
explanatory variables, and should also be chosen to be smaller than the number of observations
(samples) available for analysis. These relatively few uncorrelated PCs serve as "super-variables",
standing in for the large number of often-correlated original explanatory variables, and in a second step,
response variables are regressed against these "super-variables" using OLS (ordinary least squares).
PCR thus allows for a significant reduction in dimensionality and elimination of collinearity in the
effective independent variable set, from many, correlated explanatory (independent) variables to a few,
uncorrelated PCs. A major limitation of PCR is that PCs are calculated without consideration of the
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dependent variable set. This has no bearing on the ability to compute a regression model with high
predictive capability. However, in the context of a biological network problem, where explanatory
(independent) variables are measures of molecular signaling and response (dependent) variables are
measures of cellular responses, we care about understanding the contribution of individual signals to
individual cellular responses or to all measured cellular responses together. It is then often useful to be
able to assign some physical/biological meaning to PCs (which can be thought of as "directions in
signaling space") that is also relevant to cellular response (e.g. If we follow a particular "direction in
signaling space" we will get to a particular cellular response). When PCs are calculated without
consideration for response variables, the result is often PCs that are difficult to interpret in this manner
(e.g. they may be "directions in signaling space" that do not lead to any of the measured cellular
responses).
PLSR is a conceptually similar method that addresses this problem by calculating PCs that
simultaneously maximize the variation in the independent variable set, and the covariation with the
dependent variable set. The result is a method that significantly reduces dimensionality and collinearity
in the signal dataset and that also results in PCs in the response space to which we can often assign
some physical/biological meaning that is relevant to cellular response and that we can interpret as a
"direction in signaling space" that leads to a specific cellular response. The PCs in the independent
variable (signal) space and in the dependent variable (response) space are defined as linear
combinations of the original signals and responses, respectively, as shown in Equations 1 and 2.
Principal components for the signals (signals, 1 to j)
PCs =>j C, *S1  (1)
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Principal components for the responses (responses, 1 to m)
PC=R =Z Cm * R,, (2)
PLSR can provide a fast overview of the overall structure of the data, and insight into some
generalized relationships among the cellular responses measured in the dataset and between the signals
and the cellular responses measured in the dataset (Figure 2-6A bottom panels).
PLSR Results: Response-Response Relationships
Our example model includes measures of apoptosis (cell-death) and cell-cycle arrest/regulation
as cellular responses to DNA damage. These single cellular responses are both established and essential
cellular responses to DNA damage. Apoptosis and cell-cycle arrest are intimately and dynamically
related cellular responses to DNA damage, such that it is really necessary to consider both of these
single measures of cellular response in concert in order to understand the complex, holistic cellular
response to DNA damage, on either a single cell or cell population level. Using PLSR, we can get some
understanding of the relationship between these responses by examining where each of these
responses lie in the principal component space. In the example shown here, the model includes
measures of apoptosis and survival at 6 and 12 hr, and measures of cell-cycle status at 24 hr as
responses.
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When we plot these responses in the principal component space (Figure 3-1), we can see that
the first principal component (PC1) is highly correlated with apoptosis and is highly anti-correlated with
measures of survival, such that we may physically interpret PC1 as a "Survival-Death" Axis. Note that
the PCs, for the proteins (signals) and the PCRj for the responses are different, but are directly related
when using PLSR. Under this interpretation, we expect that signals that have strong, positive weight in
PC1 also correlate with cell-death outcomes and, conversely, that signals that have strong, negative
weight in PC1 correlate with cell-survival outcomes.
PLSR Model Loadings (w*c)
Responses
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*/* survival (6/12 hr)
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0
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Figure 3-1. Plot of selected cellular-responses in the Principal component space (Principal component
1 (PC1) vs. Principal component 2 (PC2)) determined by a PLSR model. Cellular responses: The cellular
responses of apoptosis (CC3+CParp+) at 6 and 12 hr following treatment, survival (CC3-CParp-) at 6 and
12 hr following treatment and measures of the G1, S and G2-M cell-cycle populations at 24 hr following
treatment are plotted in the Principal component space based on the weights of each of the cellular
responses in PC1 and PC2. Apoptotic responses measured at 6 and 12 hr following treatment (red and
dark red diamonds respectively) are positively correlated with PC1 and survival responses measured at 6
and 12 hr following treatment (green and dark green diamonds respectively) are negatively correlated
with PC1; PC1 is a "Survival-Death" axis. Measurements of S and G2-M cell-cycle populations at 24 hr
following treatment (blue and dark blue circles respectively) are positively correlated with PC2 and
measurement of G1 cell-cycle population at 24 hr following treatment (light purple circle) is negatively
correlated with PC2; PC2 is a "Cell-cycle regulation" axis.
We also see that the cellular response read-outs of cell-cycle status/arrest spread out along the
second principal component (PC2) such that PC2 is highly correlated with a read-out of cells in the S
phase of the cell-cycle (S populations) and with a read-out of cells in the G2-M phase of the cell-cycle
(G2 population), and is highly anti-correlated with a readout of cells in the G1 phase of the cell cycle (GI
population). From these observations, we may physically interpret PC2 as a "Cell-cycle
Arrest/Regulation" Axis. Under this interpretation, we expect that signals that have strong, positive
weight in PC2 also correlate with high S and G2 populations by 24 hr following treatment and,
conversely, that signals that have strong, negative weight in PC2 correlate with a high G1 population by
24 hr (or low S and G2 populations by 24 hr).
Another interesting feature we can observe is a reversal of timing in apoptosis and cell-survival
responses along PC2, our "Cell-cycle Arrest/Regulation" axis. From this observation (and some
knowledge of the system), we may hypothesize that in this system, cell-cycle arrest and regulation
modulate the timing of cell-death and survival responses.
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One final observation regarding response-response relationships is that cell-survival responses
and S and G2 populations are all positively correlated along PC1, while cell-death and G1 populations are
both negatively correlated along PC1, suggesting that cell-survival may be associated with S and G2 cell
populations and that cell-death may be associated with G1 cell populations.
PLSR Results: Signals-Response Relationships
Our quantitative signal-response dataset includes measures of signals in the chromatin integrity
network that are involved in the proximal response to DNA Double-strand breaks (DSB), as well as
measures of signals involved in distinct signaling networks governing cell-cycle arrest, cell-death and
cell-survival and general stress responses that have been shown to be activated by DSB. Signals in the
example model include: p-Nbs1, p-H2AX, p-Nbsl, p-p53, total p53, p-p38, p-JNK, active NFkB, p-ERK1, p-
ERK2, and p-Akt. The measured value for each of these signals at each of the 10 time-points over a
period of 24 hrs following treatment was included in the dataset, and a measure of the mean,
maximum, and total area under the curve for each signal was also included, resulting in a model with
greater than 100 explanatory variables.
These signals are known to respond to DSB, and some have established roles in mediating the
cellular responses of cell-cycle arrest/regulation and/or apoptosis, at least in some contexts. For
example, NFkB has an established role in modulating cell-survival following many types of stressors and
p38 and JNK have established roles in mediating apoptosis following many types of stressors. p53 has
an established role in mediating both cell-cycle arrest (at both Gi and G2/M DNA damage check-points),
specifically in the context of DNA damage, and in mediating cell-death outcomes in many physiological
contexts, including DNA damage. However, the majority of these signaling molecules do not have
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established or well-specified roles in mediating the cellular responses of cell-cycle arrest/regulation
and/or apoptosis specifically in the context of DNA damage.
Using PLSR, we can gain an understanding of the relationships between these signals and
measured cellular responses by examining where the signals lie in the principal component space,
relative to measured cellular responses when both signals and responses are plotted in the principal
component space based on their respective weights in each of the principal components. Loadings for
all signals and responses included in this example model, in each of the two Principal components
included in the final model, are listed in Supplementary tables 3-1, 3-2 and 3-3. Supplementary Table 3-
1 is unsorted, while Supplementary Table 3-2 lists loadings sorted by positive weight in the first Principal
component and Supplementary Table 3-3 lists loadings sorted by positive weight in the second Principal
component.
For example, we know that p53 has roles in promoting both cell-death and cell-cycle regulation
and in coordinating these responses following DNA damage. Indeed, if we plot total and p-p53
measurements in the principal component space (Figure 3-2), we can see that, for total p53
measurements, some time-point measurements are highly and positively correlated with PC1, the
"Survival-Death" Axis and with apoptotic outcomes at 6 and 12 hr. Some time-point measurements of
total p53 are highly and positively correlated with PC2, the "Cell-cycle Arrest/Regulation" Axis, and with
S and G2 cell populations. And remaining time-point measurements of total p53 are highly and
positively correlated with both PC1 and PC2. Total p53 seems very "informative" in that all time-point
measures of total p53 are weighted highly in either PCl or PC2, or in both. We can see that p-p53
follows the same pattern as total p53, with some time-point measures correlated mostly with PC1, some
correlated mostly with PC2, and some time-point measures correlated with both. p-p53 signals are
weighted less highly than total p53 signals and p-p53 signal measurements may be somewhat less
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informative in general than total p53 measurements in determining the holistic cellular phenotypic
response to DNA damage. Plotting total and p-p53 signals in principal component space allows us to
capture p53's known dual role in both cell-death and cell-cycle regulations following DNA damage.
PLSR Model Loadings (w*c)
U
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* p-p53 signals
* total p53 signals
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*/* survival (6/12 hr)
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Figure 3-2. Plot of selected signals and cellular-responses in the Principal component space (Principal
component 1 (PC1) vs. Principal component 2 (PC2)) determined by a PLSR model. Cellular responses:
Refer to Figure 3-1 for further explanation. Signals: All total p53 measurements (including values of
total p53 measured at each of 10 time-points following treatment as well as the max, mean, and
equilibrium value of total p53 over the whole time-course following treatment and the value for the
area under the curve (AUC) of total p53 measured over the full time-course) are plotted in the principal
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component space based on their weights in PCI and PC2 (light grey, small circles). Some total p53
measurements are highly correlated with apoptotic responses only, some are highly correlated with cell-
cycle responses only and some are highly correlated with both; this PLSR model allows us to capture the
known dual role of p53 in mediating both apoptotic and cell-cycle regulatory responses following DNA
damage. All p-p53 measurements (including values of p-p53 measured at each of 10 time-points
following treatment as well as the max, mean, and equilibrium value of p-p53 over the whole time-
course following treatment and the value for the area under the curve (AUC) of p-p53 measured over
the full time-course) are plotted in the principal component space based on their weights in PC1 and
PC2 (dark grey, small circles). Measurements of p-p53 show patterns similar to those observed for total
p53 measurements, but are less informative. That is, some measurements of p-p53 are correlated with
apoptosis alone, some are correlated with cell-cycle regulatory responses alone, and some are
correlated with both. However, measurements of p-p53 are, overall, not as highly correlated with these
cellular responses as measurements of total p53.
The MAPK p38 has an established role in mediating apoptotic outcomes following general types
of stress to the cell, such as osmotic stress. However, a role for p38 in mediating cellular responses
following DNA damage (e.g. promoting apoptosis or cell-cycle arrest/regulation) is not well-established
or specified. If we plot p-p38 signals in our principal component space (Figure 3-3), we can see that, in
opposition to the pattern displayed by signal measurements of total p53, p38 signals all cluster close to
apoptotic response outcomes, being highly and positively correlated with PCI (the "Survival-Death"
Axis) almost exclusively. We might hypothesize from this pattern that p38 likely (and unsurprisingly) has
a role in promoting cell-death in the context of DNA damage.
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PLSR Model Loadings (w*c)
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Figure 3-3. Plot of selected signals and cellular-responses in the Principal component space (Principal
component 1 (PCI) vs. Principal component 2 (PC2)) determined by a PLSR model. Cellular responses:
Refer to Figure 3-1 for further explanation. Signals: All total p53 measurements (including values of
total p53 measured at each of 10 time-points following treatment as well as the max, mean, and
equilibrium value of total p53 over the whole time-course following treatment and the value for the
area under the curve (AUC) of total p53 measured over the full time-course) are plotted in the principal
component space based on their weights in PCI and PC2 (light grey, small circles). Some total p53
measurements are highly correlated with apoptotic responses only, some are highly correlated with cell-
cycle responses only and some are highly correlated with both; this PLSR model allows us to capture the
known dual role of p53 in mediating both apoptotic and cell-cycle regulatory responses following DNA
damage. All p-p38 measurements (including values of total p-p38 measured at each of 10 time-points
following treatment as well as the max, mean, and equilibrium value of total p-p38 over the whole time-
course following treatment and the value for the area under the curve (AUC) of p-p38 measured over
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the full time-course) are plotted in the principal component space based on their weights in PCI and
PC2 (dark grey, small circles). All p-p38 measurements are highly correlated with apoptotic responses;
this PLSR model allows us to capture the known role of p-p38 in mediating apoptotic responses in
general, although the role of p-p38 in mediating apoptosis specifically following DNA damage has not
been well characterized.
The MAPK JNK also has an established role in mediating apoptotic outcomes following general
types of stress and the MAPK ERK1/2 has an established role in promoting cell-cycle progression through
the G1/S transition in normal cell-cycles and in promoting survival following general types of stress.
Roles for these MAPKs in mediating cellular responses of cell-cycle arrest/regulation and/or cell-death in
the context of DNA damage are not well-established or specified. If we plot p-JNK signals in our
principal component space (Figure 3-4), we can see that p-JNK signals for the most part cluster closely
with apoptotic response outcomes, being highly and positively correlated with PC1 (the "Survival-Death"
Axis) almost exclusively. We might hypothesize from this pattern that JNK, like p38, likely (and
unsurprisingly) has a role in promoting cell-death in the context of DNA damage. If we plot p-ERK signals
in the principal component space (Figure 3-4), we can see that some time-point measurements are
highly and positively correlated with PC1, the "Survival-Death" Axis and with apoptotic outcomes at 6
and 12 hr. Some time-point measurements of p-ERK are highly and positively correlated with PC2, the
"Cell-cycle Arrest/Regulation" Axis, and with S and G2 cell populations. And remaining time-point
measurements of p-ERK are highly and positively correlated with both PCI and PC2. This pattern is very
similar to that observed for p53 signals. From this pattern, we might hypothesize, despite ERK's
established role in promoting survival in some contexts, that ERK has a role in both promoting cell-death
and in promoting cell-cycle arrest/regulation following DNA damage.
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Figure 3-4. Plot of selected signals and cellular-responses in the Principal component space (Principal
component 1 (PCI) vs. Principal component 2 (PC2)) determined by a PLSR model. Cellular responses:
Refer to Figure 3-1 for further explanation. Signals: All p-ERK measurements (including values of p-ERK
measured at each of 10 time-points following treatment as well as the max, mean, and equilibrium value
of total p53 over the whole time-course following treatment and the value for the area under the curve
(AUC) of p-ERK measured over the full time-course) are plotted in the principal component space based
on their weights in PC1 and PC2 (light grey, small circles). Some p-ERK measurements are highly
correlated with apoptotic responses only, some are highly correlated with cell-cycle responses only and
some are highly correlated with both. These result are reminiscent of those obtained for total p53, and
lead us to a hypothesis that, though ERK has an established role in promoting cell-survival and cell-cycle
progression under normal or low stress conditions, under DNA damaging conditions, ERK may have a
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role in promoting apoptosis and cell-cycle regulation. All p-JNK measurements (including values of p-
JNK measured at each of 10 time-points following treatment as well as the max, mean, and equilibrium
value of p-JNK over the whole time-course following treatment and the value for the area under the
curve (AUC) of p-JNK measured over the full time-course) are plotted in the principal component space
based on their weights in PCl and PC2 (dark grey, small circles). Nearly all p-JNK measurements are
highly correlated with apoptotic responses and is very similar to the pattern observed for p-p38
measurements (See Figure 3-3); this PLSR model allows us to capture a known role for p-JNK in
mediating apoptotic responses in general, although the role of p-JNK in mediating apoptosis specifically
following DNA damage has not been well characterized.
Members of the chromatin-integrity network and proximal responders to DNA double-strand
break (DSB) damage, H2AX and Nbs1, have established roles in initiating and sustaining the signaling
response to DSB, including recruiting repair factors and activating downstream signaling components
such as p53. However, there is no established role for these molecules in mediating the cellular
responses of cell-cycle arrest/regulation and/or cell-death following damage. If we plot p-H2AX signals
in our principal component space (Figure 3-5), we can see that p-H2AX signals for the most part cluster
closely with apoptotic response outcomes, being highly and positively correlated with PC1 (the
"Survival-Death" Axis) almost exclusively. On the other hand, If we plot p-Nbsl signals in our principal
component space (Figure 3-5), we can see that p-Nbsl signals are highly and positively correlated with
PC2 (the "Cell-cycle Arrest/Regulation" Axis) almost exclusively, for the most part clustering closely with
measures of S and G2 cell populations. From these patterns, we might hypothesize that, despite their
overlapping and complementary roles as proximal responders to DSB, H2AX and Nbsl influence the
cellular response to DNA damage in distinct ways, with H2AX primarily having a role in mediating cell-
death outcomes following damage, and with Nbsl primarily having a role in mediating cell-cycle
arrest/regulation following damage.
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Figure 3-5. Plot of selected signals and cellular-responses in the Principal component space (Principal
component 1 (PC1) vs. Principal component 2 (PC2)) determined by a PLSR model. Cellular responses:
Refer to Figure 3-1 for further explanation. Signals: All p-Nbsl measurements (including values of p-
Nbsl measured at each of 10 time-points following treatment as well as the max, mean, and equilibrium
value of p-Nbsl over the whole time-course following treatment and the value for the area under the
curve (AUC) of p-Nbsl measured over the full time-course) are plotted in the principal component space
based on their weights in PCl and PC2 (light grey, small circles). Nearly all p-Nbsl measurements are
highly correlated with cell-cycle regulatory responses (measurements of S and G2-M population at 24 hr
following treatment). There is no known/well-characterized role for p-Nbsl in mediating cell-cycle
regulatory and/or apoptotic responses following DNA damage. However, these data suggest that Nbs1
may have a role in mediating cell-cycle regulation following DNA damage. All p-H2AX measurements
116
_-)2
(including values of p-H2AX measured at each of 10 time-points following treatment as well as the max,
mean, and equilibrium value of p-H2AX over the whole time-course following treatment and the value
for the area under the curve (AUC) of p-H2AX measured over the full time-course) are plotted in the
principal component space based on their weights in PCl and PC2 (dark grey, small circles). Nearly all p-
H2AX measurements are highly correlated with apoptotic responses and this pattern is similar to the
pattern observed for p-p38 and p-JNK measurements (See Figure 3-3 and 3-7). There is no known/well-
characterized role for p-H2AX in mediating cell-cycle regulatory and/or apoptotic responses following
DNA damage. However, these data suggest that p-H2AX may have a role in mediating apoptotic
responses following DNA damage.
PLSR: Strengths and Weaknesses
PLSR is a fast method to get an understanding of the overall structure of a signal-response
dataset. We can use our full signal-response dataset, including explanatory variables consisting of all
signals measured at all times and including response variables consisting of all cellular responses
measured at all times. It does not require any manual "weeding" of the data or further hypothesis
formulation. It allows us to look at multiple measured cellular responses in a single analysis and
therefore can give us some insight into complex cellular response phenotypes that are combinations of
single measured cellular responses. Using PLSR, we can often calculate PCs to which we can assign
biological/physical meaning that is relevant to cellular response. In this case, we can also use
explanatory variable (signal) coefficients in each of the PCs to which we have assigned a
physical/biological meaning that is relevant to cellular response to gain an understanding of
relationships between signals and cellular responses, or between signals and complex phenotypes that
are combinations of measured cellular responses.
However, the ability to encompass and integrate a large amount of wide-ranging data, which is
the main strength of PLSR, is also a weakness. Large numbers of original explanatory (signal) variables
can result in PCs with difficult to interpret explanatory variable (signal) coefficients due to an overload of
simultaneous information. The coefficient for a given signal may give an accurate idea of how well that
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signal is correlated to a specific cellular response relative to other signals in the model. However, the
coefficient for a given signal does not necessarily give an accurate idea of how well that signal is
correlated to a specific cellular response in an absolute fashion. A relatively high absolute correlation
can be hidden by inclusion of highly collinear signals in the independent variable set. For example, if
signal A measured at time-point #2 is very highly correlated with cell-death, and signal B measured at
time-point #2 is also quite highly correlated with cell-death, but measures of signal A at 6 of the other
time-points are highly correlated with signal A measured at time-point #2, then these other measures of
signal A may be assigned higher coefficients than signal B at time-point #2. This coefficient assignment
may or may not be reflective of the true value of these signals in the model. That is, it is possible that
several measurements of signal A together powerfully influence cell-death and so the inclusion of all is
necessary to the model. It is also possible that any one of the measures of signal A is powerfully
predictive of cell-death. In this case, the inclusion of more than one measure of signal A is redundant
and artificially lowers coefficients on explanatory variables that are somewhat less highly correlated
with cell-death. This quality can lead to difficulties in using PLSR model results to identify precise signal-
response relationships and to formulate hypotheses to drive specific experiments to test these
identified signal-response relationship.
We can address this problem to some extent by building smaller models using PLSR with subsets
of our signal-response dataset to get a better idea of what signals have important relationships with
measured cellular responses, as we will briefly illustrate here, and by using other analysis methods such
as TI-SWR in conjunction with PLSR to get a better idea of when a particular signal is important and what
other signals might also be important at that time, which we will discuss later.
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PLSR Results: Signals-Response Relationships from small models
We can build small models where all explanatory variables (signals) are excluded, except for all
of the measurements of one single signal, and ask how well all of the measurements of this one signal
together predict a cellular response or group of responses. Here we have built small models for each of
the signals in our large example model for both cell-cycle arrest/regulation cellular outcomes and for
cell-death/cell-survival outcomes. The results of the small models built with the cellular response of
cell-cycle arrest/regulation as the response variable are quite informative. We can see that more than
half of our original signal explanatory variable sets are not predictive of cell-cycle arrest/regulation
outcomes at all (Figure 3-6A). In fact, p-ERK1/2, p-Nbsl and total p53 clearly have the highest predictive
capabilities for cell-cycle arrest/regulation, such that only three of the original nine signal explanatory
variable sets contain the majority of the information about this cellular response. The results of the
small models built with the cellular response of cell-survival/cell-death as the response variable are less
informative. Only one of our original nine signal explanatory variable sets is not predictive at all of cell-
death. We can perhaps say something about the relative strength of the relationship between the
remaining signal explanatory variable sets based on their relative predictive capabilities; p-p38 and p-
JNK may be very important in mediating the cell-death response, whereas p-H2AX, total p53, NFkB, pAkt
and pERK1/2 play secondary, but still important roles in this process (Figure 3-6B). The main conclusion
though from these small models is that relatively few of our measured signaling molecules (p-ERK1/2, p-
Nbsl and total p53) play a role in mediating cell-cycle arrest/regulation following DNA damage, whereas
nearly the full complement of measured signaling molecules plays a role in mediating cell-death
following DNA damage.
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Figure 3-6. PLSR "small-model" results for PLSR small models built with a response variable set
including measurements of G1, S and G2-M populations at 24 hr following treatment (A) or including
measurements of apoptosis (CC3+CParp+) and survival (CC3-CParp-) at 6, 12 and 24 hr following
treatment (B). PLSR small models were built with these respective response variable sets and with
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explanatory variable sets that include all measurements (including values measured at each of 10 time-
points following treatment as well as the max, mean, and equilibrium value over the whole time-course
following treatment and the value for the area under the curve (AUC) measured over the full time-
course) of one single signaling molecule (e.g. all measurements of p-ERK). Small models were built for
each signaling molecule and the resulting PLSR model were forced to include only one single Principal
component. The predictive capability (Q2) of each model was determined via an automated "leave one
out" cross-validation process, and this predictive capability is reported. (A) Only four out of 9 single-
signaling molecule PLSR "small models" have any ability to predict this response set that includes
measures of G1, S and G2-M populations at 24 hr following treatment. These data support a substantial
individual contribution to cell-cycle regulatory responses following DNA damage from p-ERK, p-Nbsl and
total p53. (B) Eight out of 9 single- signaling molecule PLSR "small models" have at least some ability to
predict this response set that includes measures of apoptosis (CC3+CParp+) and survival (CC3-CParp-) at
6, 12, and 24 hr following treatment. The single-signaling molecule models that have the highest
predictive capability are those built on explanatory variable sets including p-p38 and p-JNK
measurement. These data imply that many more signaling molecules have a role in determining
apoptotic responses following DNA damage than have a role in determining cell-cycle regulatory
responses, and that apoptotic response regulation may be dominated by the activity of (and information
integrated by) general stress kinases in the cell. Together, these data support a potential dual role for p-
ERK, total p53 and p-H2AX, in mediating both cell-cycle regulatory responses and apoptotic responses
following DNA damage.
We can also try to look for more detailed signal-response relationships, such as time-
dependence of signal-response relationships, by plotting the time-point measurements of all the signals
and responses in the principal component space and looking by eye at what falls close together. This is
a tedious and tenuous process; it is hard, and likely to yield hard to interpret results. An easier and
more systematic approach to this problem is afforded by a second analysis approach, TI-SWR.
TI-SWR
In this section we introduce Time-Interval Stepwise regression (TI-SWR), a novel approach that
was used in this work to investigate the relationships between the measured cell responses and signals
and the dynamic interactions between various signals. The goal of TI-SWR (Time Interval Stepwise
Regression) is to use the established Stepwise Regression method in a manner designed to exploit the
time dimension of the dataset in order to find relatively detailed, time-dependent signal-response and
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signal-signal relationships, and to dramatically decrease the number of explanatory variables in the
models we look at, and thus increase model interpretability. In this approach, the time domain is
discretized in a series of time intervals, corresponding to the time intervals between successive
measurements.
The basic steps of the approach are to 1) choose a single measured cellular response to
investigate, 2) make the hypothesis that the measured signals at one time-point work in concert to
mediate the selected cellular response at some later time, and 3) regress the single cellular response
against all of the signal measurements at that time-point (Figure 2-6B and Figure 3-7A).
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0.25h ---
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24h N/A
Figure 3-7. (A) Illustration of the hypothesis that each time-point specific, Time-Interval model in a TI-
SWR (Time-interval Stepwise regression) analysis set makes. In a TI-SWR analysis set, there is one
cellular response of interest under investigation and there are as many time- point specific, Time-
Interval models in the set as there are time-points at which signaling is measured that precede the
cellular response of interest. For each of these time-point specific, Time-Interval models, the response
variable is the cellular response under investigation and the possible explanatory variable set includes all
of the signaling measurements made at that time point. Here is illustrated a time-point specific, Time-
Interval model for which the response variable is the change in the cellular response R2 between 12 and
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24 hr and for which the possible explanatory variable set includes all signaling measurements taken at
the 8 hr time-point (S1, 8hrthrough Sj, 8hr). (B) Table of results from a TI-SWR (Time-Interval Stepwise
regression) analysis investigating the change in S phase cell-cycle population between 12 and 24 hr
following treatment (A %S, 12-24 hr) as the cellular response variable. Rows present an overview of the
results for each of the 10 time-point specific Time-Interval models constructed (For each of the time-
point specific Time-Interval models, the response variable is A %S, 12-24 hr and the explanatory variable
set is all signals measured at that time-point). For each Time-interval model, signal names are listed in
order of decreasing R2 (ability to explain the variability in the response variable). Where no signals are
listed, no signal-response relationships reached an acceptable level of significance (p < 0.05). p-ERK
(red) is positively correlated with A %S, 12-24 hr at 2, 4 and 8 hr following treatment. These data
strengthen our hypothesis that ERK has a role in mediating cell-cycle regulatory phenotypes following
DNA damage. For further details on individual Time-Interval models in this set, and on the full TI-SWR
analysis, reference Supplementary Figures 3-1 through 3-8. (C) Table of results from a TI-SWR (Time-
Interval Stepwise regression) analysis investigating the change in apoptosis between 6 and 12 hr
following treatment (A % apoptosis (CC3+CParp+), 6-12 hr) as the cellular response variable. Here cells
staining positively for both apoptotic markers (CC3+CParp+) are considered apoptotic. Rows present an
overview of the results for each of the 10 time-point specific Time-Interval models constructed (For each
of the time-point specific Time-Interval models, the response variable is A %apoptosis, 6-12 hr and the
explanatory variable set is all signals measured at that time-point). For each Time-interval model, signal
names are listed in order of decreasing R2 (ability to explain the variability in the response variable).
Where no signals are listed, no signal-response relationships reached an acceptable level of significance
(p < 0.05). Where N/A is listed, the time-point is later than the cellular response under investigation. p-
ERK1/2 at 12 hr is positively correlated with A %apoptosis between 6-12 hr following treatment. In a TI-
SWR analysis investigating apoptosis at later times (between 12 and 24 hr following treatment) p-
ERK1/2 at 12 hr is also positively correlated with this apoptotic response. These data suggest that
ERK1/2 activity between 8 and 12 hr following treatment may have a role in promoting apoptosis
following DNA damage, and further supports a dual role for p-ERK1/2 in mediating both cell-cycle
regulatory and apoptotic responses following DNA damage. For further details on individual Time-
Interval models in this set, and on the full TI-SWR analysis, reference Supplementary Figures 3-9 through
3-15. For details on a TI-SWR analysis investigating apoptosis at later times (between 12 and 24 hr
following treatment), reference Supplementary Figures 3-16 through 3-25 and Supplementary Table 3-4.
Cellular response: maximizing information
The first step in TI-SWR is to choose a single measured cellular response to investigate. Using
this method, we investigate one cellular response at a time. We choose the cellular response that we
investigate strategically, to be as informative as possible. Specifically, we choose a specific cellular
response measure that is particularly interesting, and we also choose to investigate the change in a
measured cellular response over some time-period of interest, rather than choosing the actual
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measured cellular response. The reason for selecting the change in the cellular response over a period of
time - i.e. the derivative of the linearized response during the selected time interval - as the dependent
variable in the regression analysis is explained below.
Assume that, for a given time interval At" = t"*' - t" we define Cij as the change in response i due
to S"; - the protein j at time n - per unit time and per unit of protein j at the beginning of the time
interval. Then, the response i at the end of the time interval can be written as;
R"* =. R* S * (t"*l -t" ):
We can re-arrange eq. 3, moving Rni, on the LHS, and dividing by Atnto obtain:
DR[ ZC 1 . * Sn
IR l
Where DR", is the derivative of response i over the time interval n, defined as:
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DR," = (R,"*l -_R," )l(t"** - t" )
We note that equation 4 is now in the exact form of the multiple linear regression equation,
where the independent variables are the measured values of the protein i at time n, and the dependent
variable is DR i the derivative of response i over the time interval n, which can be calculated from the
measured data using equation 5. This means that the coefficients Cni, calculated by the multiple linear
regression have a clearly defined meaning, i.e. they represent the change in response i over the
selected time interval due to S"j - the protein j at time n - per unit time and per unit of protein j at the
beginning of the time interval.
A notable advantage of this formulation of the multiple linear regression equation is that the
coefficients C>j represent changes in response i per unit time, during the time interval n. This means
that although our measurements - and corresponding regressions - have been performed for intervals
of time of different length, the regression coefficients, which represent change per unit time, can be
compared across multiple time intervals to provide a measure of the change in specific response-protein
dependence over time. This approach results in response variables that are as densely informative as
possible.
For the example TI-SWR model we show here, we chose to investigate a cell-cycle regulation
phenotype that we had identified as being of interest. In two of our treatment instances (cell-
populations exposed to low levels of DNA damage, in the presence or absence of TNF-a), we observed a
dramatic build-up in S-phase populations by 24 hr following treatment, and hypothesized that this was
due to a DNA-damage mediated cell-cycle arrest in Gl or at the G1/S transition, followed by a release
from that arrest that allows a cohort population of cells to enter S phase synchronously by 24 hr
following treatment. In order to capture this phenotype as fully as possible, we chose to use the change
in S population between 12 hr (when S population is approximately equal across cue treatment
conditions) and 24 hr (when S population is dramatically higher in cell-populations exposed to low levels
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of DNA damage) following treatment as the response variable in a TI-SWR model. We will refer to this
response variable as A S, 12-24 hr.
Hypothesis: Selecting the explanatory variable sets
The second step in TI-SWR is to make the hypothesis that the measured signals at one time-
point work in concert to mediate this cellular response (Figure 3-7A). In general, we expect that the
closer in time the selected set of measured signal are to the time interval of interest, the more likely it is
that the assumption of linear dependence between the dependent variable and the set of independent
variables applies. We can, for example, make the hypothesis that all of the signals we measure (pH2AX,
p-Nbsl, total p53, p-p53, p-p38, p-Akt, p-ERK1/2, p-JNK and NFkB) work together at 12 hr following
treatment to mediate the cell-cycle regulation phenotype that we have captured with our response
variable, A S, 12-24 hr.
A cell integrates information about previous physical/mechanical or signaling events via a
physical/chemical encoding of past events in the current status of its signaling components. At any given
time a cell uses only the current status of its signaling components and integrates these signals, which
occur temporally together, but which also encode past signaling events, in making the decisions which
determine future cell actions and eventually the cell fate. E.g., at 1 hr following DNA damage, a cell may
"remember" that ATM was activated at 30 min following damage, even if it is no longer activated at 1 hr
following damage, because the ATM activation at 30 min led to H2AX phosphorylation, and H2AX is still
phosphorylated at 1 hr. Then the hypothesis that the measured states of all signaling molecules at one
time-point are integrated by the cell to make decisions that eventually mediate the cellular response is a
logical and natural hypothesis.
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Making this hypothesis significantly reduces the size of the model. In our example model, we
have a regression model with one response variable (A S, 12-24 hr) and 9 potential explanatory (signal)
variables (the measurement of each of 9 signals at the 12 hr time-point), as compared to our PLSR
model, with 7 response variables and over 100 explanatory (signal) variables. The reduction in
dimensionality (size) results in a far more tractable and interpretable model. Also along with this
reduction in size comes a very desirable significant reduction in multicollinearity and associated
problems in the determination of model coefficients.
The hypothesis that the measured states of all signaling molecules at one time-point are
integrated such that, together, they mediate a cellular response is a logical and natural hypothesis.
However, we do not have to limit our investigation to only the relationship between the signaling at one
time-point and the cellular response of interest. We will exclude the time-points that are after the time
interval of the selected cellular response, but we can build multiple small time-interval regression
models to investigate the relationship between the selected time interval cellular response and the
signal sets at each of the time-points that precede, or overlap with, the selected cellular response time
interval, in an iterative fashion.
We build one model for every time-point at which signals were measured and at which we may
reasonably hypothesize that a causal relationship between the signaling at that time-point and the
cellular response of interest exists. It is worth noting that the closer in time the small-model time-point
is to the cellular response of interest, the more likely it is that identified relationships between signals
and cellular response are direct, and linear in nature. This iterative approach allows us to systematically
discover specific, time-dependent signal-response relationships from our signal-response dataset using
sets of small, interpretable, time-interval models.
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Regression: Filtering the explanatory variables
The third step in TI-SWR is to run the regressions for all of these time-point specific models,
regressing the single cellular response against all of the signal measurements at a previous time-point,
iteratively, for each of the time-points at which signals were measured. In the example TI-SWR model
we present here, our response variable is the change in S population between 12 and 24 hr (A S, 12-24
hr), and signals were measured at 10 time-points over 24 hr following treatment. None of these time-
points are at times after the cellular response of interest, and we have no other reason to believe that
signaling at any of the time-points is uninformative to the cellular response decision. Therefore our TI-
SWR model is a set of 10 small models; one for each measured signal time-point, each having 9 potential
explanatory (signal) variables (Figure 3-7B).
However, we can further reduce the number of explanatory variables in each of our models if
we make another very natural hypothesis; that only a subset of the signals at a time-point are working in
concert to mediate a later cellular response. That is, not all signals contribute to the cell-fate decision at
all times. For example, perhaps the activity of hypothetical signals A, B, and C at 2 hr following
treatment are important for the cell-fate decision and the cellular response that we measure between
12 and 24 hr. At 4 hr following treatment (the next measured time-point), the activity of hypothetical
signals A and B are no longer "important", but the activity of hypothetical protein C is still important,
and the activity of hypothetical protein D and E are also important now. This situation might arise if, for
example, the activities of hypothetical signals A and B at 2 hr cooperate to activate hypothetical protein
D by 4 hr, and this is their only important function in the cell-fate decision process. This hypothesis
implies that in each of our small, time-interval models, not all explanatory (signal) variables should be
represented in the final regression model; signals that are important at the time-interval model time-
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point for the cell-fate decision and the later cellular response should be represented and signals that are
not important should be dropped from the model.
In order to incorporate this hypothesis, we make use of a Stepwise regression algorithm in the
regression step for each of our time-interval models. Stepwise regression is a well-established
regression procedure that can be used to select a subset of explanatory variables, from an original larger
explanatory variable set, that maximally correlates with the response variable. Explanatory variables
that do not add to the model's ability to predict the response variable are excluded from the model.
The combination of these three steps defines the approach we call hypothesis-based, Time
Interval Stepwise regression (TI-SWR). TI-SWR exploits the time-dimension of the signal-response
dataset by systematically exploring time-dependent signal-response relationships for each chosen
cellular response. The result is a set of time-interval models that are low dimensional and thus easily
interpretable. These sets of time-interval models yield insight into detailed, time-dependent signal-
response relationship and greatly facilitate the development of hypotheses about signal-response causal
relationships as well as the design and execution of hypothesis-motivated experiments to test and
validate these hypotheses.
TI-SWR: signal-response correlations
In this example, we have used TI-SWR to investigate signal-response relationships for the cell-
cycle regulation phenotype previously described, which we capture with a response variable that is a
readout of the change in S population between 12 and 24 hr (A S, 12-24 hr). For every time-point at
which signals were measured (0.25, 0.5, 1, 1.5, 2, 4, 8, 12,16, and 24 hr), we iteratively regressed the
response variable, A S, 12-24 hr, against all of the signal measured at that time-point, using a Stepwise
regression algorithm in each case to build each of our time-point specific, time-interval regression
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models. The result is a set of 10 time-point specific time-interval models that reveal detailed, time-
dependent relationships between the signals we have measured (p-H2AX, p-Nbs1, p-p53, total p53, p-
p38, p-JNK, p-ERK1/2, p-Akt, and NFkB) and the response variable we have investigated here.
In fact, in this example, the result is a set of 5 time-point specific small models (Figure 3-7B). At
five out of the 10 time-points at which signals were measured, no signal-response relationships reach a
required level of significance (These time-points include the 0.25, 0.5, 1, 1.5 and 12 hr time-points).
That is, no signals at these time-points are found to significantly correlate with the response variable.
Therefore, the Stepwise regression algorithm excludes all signals from these time-interval regression
models and no model is reported at these time-points. The signaling at these time-points is perhaps
"uninformative" to the cell in determining cell-fate and cellular response. A possible explanation is that
at these times other proteins, not included in the measured set, play a dominant role in the dynamic
signaling, while the measured proteins are temporarily not important.
The five time-point specific models that do result from the hi-SWR analysis are for signaling at 2,
4, 8, 16 and 24 hr. Interestingly, we find that H2AX, in concert with ERK1/2, appears to be important at
relatively early times (2 hr). H2AX is excluded from the model by the 4 hr time-point, but ERK1/2
remains in the 4 hr time-point model. In the 4 hr time-point model, ERK1/2 has a much higher
correlation with the response variable and now works in concert with p53. ERK1/2 is also still present in
the 8 hr time-point model. In the 8 hr time-point model, ERK1/2 is highly correlated with the response
variable and is the only signal at this time-point that is correlated with the response variable. By the 12
hr time-point, ERK1/2 is excluded from the time-point model, and is not included in models for either of
the even later time-point models (16 and 24 hr time-point models). Time-point specific models for the
16 and 24 hr time-point exclude all signals except for total p53, indicating that only total p53 is
significantly correlated with the response variable at these late times. Why do we find a relationship
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between H2AX at one early time, but not at any later times? It is possible that H2AX activity at the 2 hr
time-point is critical for regulating the activation of ERK1/2 at that time. Once ERK1/2 has been
activated, the critical role of H2AX activity in the cell-fate decision is passed. H2AX activity at later time-
points is no longer important or necessarily related to cellular response. The critical information has
been "passed" from H2AX to ERK1/2 and it is between ERK1/2 activity and the cellular response that we
find significant relationships at a later time. A similar reasoning can be used to hypothesize that ERK1/2
activity may be critical in regulating the activation of p53 under these damaging conditions, as we
identify significant relationships between ERK1/2 and cellular response in 2, 4 and 8 hr time-point
specific models, but lose this significant relationship in later time-point specific models, as we gain
significant relationships between total p53 and cellular response. It is at least possible then, to
hypothesize that we are identifying direst "transfer of critical information" relationships between these
signals. However, another explanation for "losing" significant relationships between a given signal and
cellular response in later time-point specific models, after having observed a significant signal-response
relationship in earlier time-point specific models, is that, for example, H2AX activity at the 2 hr time-
point is critical for regulating the activation of some signal that we have not measured. This is perhaps
more likely than the hypothesis that H2AX directly acts to regulate activation of ERK1/2, as these two
molecules have not been reported in the literature to directly interact. If our hi-SWR model results do
not indicate that H2AX directly regulates the activation of ERK1/2 (direct critical information transfer),
then there are two additional things that the model results could indicate. One is that H2AX indirectly
regulates the activation of ERK1/2, via some molecule that we have not measured (indirect critical
information transfer). A second possibility is that H2AX has no role in regulating activation of ERK1/2,
and that H2AX is critically involved in regulating some other signaling in parallel to ERK1/2 signaling that
is critical for cellular response (parallel critical information transfer).
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In another example of TI-SWR analysis, we chose the change in cell-death between 6 and 12 hr
following treatments (A % apoptosis, 6-12 hr) as the cellular response of interest (Figure 3-7C). In this
analysis, the final model set resulting from the analysis consists of only 4 time-point specific small
models. Two of the time-points at which we have measured signals fall after our cellular response (the
16 and 24 hr time-points). It is not possible for signaling at these later time-points to have a causal
relationship with the cellular response that came before, so we exclude these time-points from the
analysis. At four of the eight remaining time-points, there are no significant relationships found
between signals and our response variable (A % apoptosis, 6-12 hr). The time-points specific small
models which do result from this analysis are for the time-points of 0.25, 4, 8 and 12 hr.
It is worth noting here that p53 is included in the time-point specific small model at 8 hr and p-
ERK1/2 is included, to the exclusion of all other signals, in the 12 hr time-point specific small model.
Both of these signals were included in time-point specific small models for the previously discussed cell-
cycle phenotype cellular response TI-SWR analysis. Thus these TI-SWR analyses suggest that both p53
and ERK1/2 are involved in making and mediating cell-fate decisions governing cell-cycle
arrest/regulatory phenotypes and cell-death phenotypes. Our PLSR analysis also suggested that both
p53 and p-ERK1/2 have roles in mediating both of these cell-fate decisions. This is just one example to
illustrate that results from TI-SWR and PLSR analysis are often mutually confirming methods. This dual
confirmation raises our confidence level in the specific case of overlapping results, but also raises our
confidence in the case of results that can only be produced by either PLSR or TI-SWR analysis, such as
response-response relationship inferences in the case of PLSR, or systematic, time-dependent
relationships between signals and cellular response in the case of TI-SWR.
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TI-SWR: signal-signal correlations
TI-SWR can also be used to investigate dynamic signal-signal relationships. The methodology for
investigating the signal-signal relationships is similar to that described above for the study of signal-
response relationships, with the proteins (signals) being viewed as "responses" to the previous sets of
signals. We choose a dependent variable of interest as before, which is now the change in a particular
cell signal (protein) divided by the time interval (t"*l - tn), i.e. the derivative of the linearized signal over
the selected time interval. The explanation for this choice is presented below, and follows the same
approach presented above for the cell responses.
For a given time interval At" = t"*1 - t" we define Cni as the change in protein i due to S", - the
protein j at time n - per unit time and per unit of protein j at the beginning of the time interval. Then,
the protein i at the end of the time interval can be written as;
S,"*n+ S," + C," * Sn * (t"*l -t"3) : (6
We can re-arrange eq. 6, moving Sni, on the LHS, and dividing by Atnto obtain:
DS,=ZC," -* Sn (7)
Where DSni is the derivative of protein i over the time interval n, defined as:
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DS,"n = (S,"* - S," )/(t"*l - t" ) (8)
We note that equation 7 is now in the exact form of the multiple linear regression equation,
where the independent variables are the measured values of the proteins j at time n, and the
dependent variable is DS": the derivative of protein i over the time interval n, which can be calculated
from the measured data using equation 8. This means again that the coefficients Cni; calculated by the
multiple linear regression have a clearly defined meaning, i.e. they represent the change in protein i
over the selected time interval due to S"j - the protein j at time n - per unit time and per unit of protein j
at the beginning of the time interval.
As noted previously for the responses, a significant advantage of this formulation of the multiple
linear regression equation is that the coefficients Cn ; represent changes in protein i per unit time, during
the time interval n. This means that although our measurements - and corresponding regressions -
have been performed for intervals of time of different length, the regression coefficients, which
represent change per unit time, can be compared across multiple time intervals to provide a measure of
the change in specific protein-protein dependence over time.
The dynamic signal-signal relationships can be investigated in either a "walk-back" fashion or in
a systematic fashion, as described below.
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A "Walk-Back" approach for linking cell responses with dynamic signal (protein) changes and
for the investigation of signal-signal relationships
The "walk-back" approach provides an approach to studying the dynamic signal (protein)
changes associated with a selected cellular response. In this case, we choose a cellular response of
interest as before, which is the derivative of the linearized selected cellular response over a time interval
n, between the times t" and t"'. Then we make the hypothesis that the signals at the time-point t" (the
starting time-point for the time interval of the cellular response of interest) are integrated by the cell to
make and mediate the cell-fate decision and cellular response of interest. Measured signal sets at other
time points that precede the selected time interval can also be selected as independent variables, but as
we noted before, the closer in time the independent variables (protein signal set) are to the cellular
response of interest, the more likely any identified relationships between signals and cellular responses
are to be direct, and linear in nature.
We regress the cellular response of interest against the signal measurements at t" using the
Stepwise regression algorithm, as before, to identify signal-response relationships between signals at t"
and the cellular response. The cellular response at the end of the interval n, time tn+, is given by:
R"** = Ri" + DJ" * (t"* -" (1
where the response derivative DR i is obtained from the TI-SWR as a function of the explanatory
proteins at time n:
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DR"=ZC,"*Sj (12)
The explanatory proteins in Equation 12 can now be expressed as a function of the signals at time t"':
S =S - +DS n-' *(t" -t" )I (13)
Next we choose DS" as our response variable. Here the dependent variable is no longer the
derivative of a cellular response over a time-period, but the derivative of a linearized measured signal
over the time interval n-1. We can continue "walking back" in time to investigate what signals are
related to the signals that have been identified as being related to the change in the selected cell
response. This method has the advantage that all models are constructed in a manner that maximizes
the probability of finding signal-response and signal-signal relationships that are direct, and linear in
nature (Figure 3-8A).
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Responses*
Y: A CC3+, 12-24 hr 1 p-p38, 16 hr 0.03 0.69
Y: A p-p38, 12-16hr p-p38, 12 hr/p-Akt, 12 hr 8e-6/0.01 0.99/0.004
Y: A p-p38, 8-12 hr NFkB, 8 hr 0.03 0.70
Y: A NFkB, 4-8 hr p-JNK, 4hr/NFkB, 4 hr 0.008/0.02 0.8510.12
Figure 3-8. (A) Illustration of the "walk back" approach to TI-SWR (Time-Interval Stepwise regression)
analysis. In a "walk back" approach, start with a cellular response of interest and construct just one
time-point specific, Time-Interval model for a time-point that is close in time to the cellular response of
interest. This model has the cellular response of interest as a response variable and all of the signaling
measurements made at one time-point as the potential explanatory variable set (In the illustration, the
response variable for this first model is the change in the cellular response, R2, between 12 and 24 hr
following treatment and the potential explanatory variable set includes all signaling measurements
made at 8 hr following treatment). The top signal correlate/s from this model now specifies the
response variable in a new time-point specific, Time-Interval model that we can construct. In this
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model, the response variable no longer refers to a change in a cellular response over a time-interval, but
to a change in a signal over a time-period. Specifically, the response variable for this next model is the
change in the top-correlate signal between the time-point immediately preceding the first time-point
specific model, to the time-point of the first time-point specific model (In the illustration, the response
variable for this second model is the change in Sj between 4 and 8 hr following treatment and the
potential explanatory variable set includes all signaling measurements made at 4 hr following
treatment). Again, the top signal correlate/s from this model specifies the response variable in a new
time-point specific, Time-Interval model that steps us back one more time-point. This "walk back" in the
time-space, following first the chain of signal-response relationship, then signal-signal relationships, can
be continued as long as the signal-signal relationship chain is unbroken (until we reach a time-point
specific, Time-Interval model for which no signal-signal relationships reach a required level of
significance; p<0.05). In the illustration, we stop after the 2 hr time-point specific model (for which the
response variable is the change in the signal Sj-2between 2 and 4 hr following treatment and for which
the potential explanatory variable set includes all signaling measurements at 2 hr following treatment),
because this model yields no significant signal-signal relationships to follow further back in time.
(B) Table of results from a "walk back" TI-SWR (Time-Interval Stepwise regression) analysis investigating
the change in apoptosis between 12 and 24 hr following treatment (A %apoptosi (CC3+), 12-24 hr) as the
cellular response variable. Cells staining positively for one of the apoptotic markers (CC3+) regardless of
whether they stained positively for another apoptotic marker (+/- CParp) were considered apoptotic in
this analysis. Rows present an overview of the results for each of the time-point specific Time-Interval
models constructed. For each of the time-point specific Time-Interval models, the response variable is
listed first and models are listed in time-space "walk back" order. The potential explanatory variable set
is all signaling measurements made at the time-point that defines the beginning of the response variable
time-interval, except in the case of the first model that begins with the cellular response of interest. For
this first model in the "walk back" analysis, the potential explanatory variable set includes all
signaling measurements made at the 16 hr time-point, which is a time-point that falls within the time-
interval of the cellular response of interest (12-24 hr following treatment). For each Time-interval
model, the top signal correlate/s are listed in order of decreasing R2 (ability to explain the variability in
the response variable). The significance levels of top signal correlate/s are listed, as are R2 values. For
further details on individual Time-Interval models in this set, reference Supplemental Figure 3-26
through 3-29.
As an example, we chose to investigate the change in apoptosis between 12 and 24 hr following
treatment (A %apoptosis (CC3+), 12-24 hr) using a "walk back" TI-SWR approach (Figure 3-8B and
Supplementary Figures 3-26 through 3-29). In the "first step" model, this cellular response is the
response variable, and the potential set of explanatory variables are all signal measurements at 16 hr
following treatment (a time-point that falls within the cellular response time-interval). The top signal
correlate identified from the first step model is p-p38, 16 hr. In the second step model, the change in p-
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p38 between 12 and 16 hr following treatment (A p-p38, 12-16hr) serves as the response variable, and
the potential set of explanatory variables are all signal measurements at 12 hr following treatment. The
top signal correlates identified from the second step model are p-p38, 12 hr and p-Akt, 12 hr. However,
p-Akt, 12 hr contributes almost no additional ability to explain the variability in the response variable
(Supplementary Figure 3-27) and so we do not pursue that path, but continue with a third step model in
which the response variable is the change in p-p38 between 8 and 12 hr following treatment, and the
potential set of explanatory variables are all the signal measurements at 8 hr following treatment. The
top signal correlate identified from the third step model is NFkB, 8 hr. In a fourth step model then, the
change in NFkB between 4 and 8 hr serves as the response variable, and the potential set of explanatory
variables are all signal measurements at 4 hr following treatment. The top signal correlates identified
from the fourth step model are p-JNK, 4 hr and NFkB, 4 hr. Both significantly contribute ability to
explain variability in the response variable (Supplementary Figure 3-29). Therefore, either/both may be
followed back (e.g. fifth step models with either the change in p-JNK between 2 and 4 hr following
treatment as the response variable or the change in NFkB between 2 and 4 hr following treatment as
the response variable, with a potential explanatory variable set of all signal measurements at 2 hr in
both cases). However, in neither case do we identify any further significant signal-signal relationships.
This is then the end of a "walk back" TI-SWR analysis, where this analysis has yielded insight into some
dynamic, time-dependent signal-signal relationships, and has yielded further insight into potential
mechanisms of signal-signal-cellular response trajectories.
A systematic approach to studying signal-signal relationships
We can also take a "systematic" approach to finding signal-signal relationships. In this case we
do not start with a cellular response of interest. Instead, we start with the first signal time-point
measurements. For each of the signals we have measured we say that the change in that signal
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between the first and second time-point is a function of all of the signals measured at the first time-
point, build a time-interval regression model with the linearizied signal derivative as the response
variable and signal measurements at the first time-points as explanatory variables to find which signals
are related to the change in our response variable signal. For each signal measured, we can "step
forward" and build time-interval regression models to identify which signals are identified as related to
the change in any measured signal over any of the time-periods for which we have measured data
(Figure 3-9). If we execute this for all measured signals over all measured time-periods, then the result
is a systematic identification of time-dependent signal-signal relationships that can be discovered in the
dataset. Models to identify signal-response relationships can also be included in this systematic "step
forward" approach over appropriate time intervals. The ability to identify signal-signal relationships can
help to clarify identified signal-response relationships and may yield clues to the mechanism of
identified signal-response relationships.
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Figure 3-9. Illustration of the systematic, forward approach to TI-SWR (Time-Interval Stepwise
regression) analysis. In a systematic, forward approach, do NOT start with a cellular response of
interest. Instead start at the earliest time-points at which signaling measurements were made. The
response variable for the first time-point specific, Time-Interval model constructed will be the change in
one of the signals measured over this first time interval; the potential explanatory variable set will be all
of the signaling measurements made at the beginning of this time-interval. This model construction in
repeated for all signals measured. The result is a set of time-point specific, Time-Interval models that
specifies the relationship between all of the signals measured at the first time-point and the change in
each of the signals over the first time-interval. The next step is to move to the next time-interval over
which signals were measured and repeat the process for all time intervals over which signals were
measured. The result is a systematic investigation of all time-dependent signal-signal relationships
captured in the dataset. Cellular responses can be included as either response variables or potential
explanatory variables as appropriate.
Discussion
Computational modeling approaches are necessary tools to facilitate our progress towards a
deeper and more complete understanding of how specific biological networks function, and of how
biological networks function in general.
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This type of biological network study is part experimental study, part computational
modeling/analysis. It is a highly iterative process. The modeling gives us insight into the biology we
have measured and points us in the direction of where we should be looking - what parts of our data
are important. However, the other direction is at least as important. And oftentimes, close examination
of the original data, or subsequently obtained data, can illuminate features of the model that were
previously unclear.
Quantitative measurement of signaling data is becoming more accessible, high (or higher)
throughput data is also becoming more accessible. It is clear that network level biology that addresses
how signaling molecules within and across canonical signaling pathways work in concert to mediate
complex cellular and cell-population phenotypes is an area of study that is critically important for the
understanding of complex human pathologies and for the development of targeted therapies to treat
these pathologies.
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Chapter 4: Future Directions
In this work we have developed a quantitative signal-response data set that allows the study of
the dynamic response of the cell signaling network following DSB. We have also developed a promising
analytical methodology, TI-SWR, which could open the way to a better understanding of the functioning
of the cell signaling networks. The efficacy of the TI-SWR techniques is expected to improve significantly
as the signal and response measurements are spaced closer in time, discretizing the cellular response
and making the linear approximation of the network dependencies an increasingly accurate
approximation. Thus, a future direction for continuing this work is to expand the quantitative signal
response data base by making additional measurements at shorter time intervals for the selected
treatments. We also recommend a better discretization of the treatments, in order to understand better
the importance of the DSB level on the cellular response. As demonstrated in this work, the application
of TI-SWR to such a dataset can generate interesting hypothesis about the cellular response that can
suggest specific time-dependent treatment interventions. Experiments involving such time-dependent
treatments can be planned in the future to allow the systematic study of treatments where both the
dose of the treatments and the time-dependent treatment interventions are varied systematically;
signaling and response measurements collected under these treatment conditions may be added to a
continuously expanding quantitative, DNA damage signal-response data base.
It would be interesting to much more fully explore the interaction between the cellular
responses of cell-cycle arrest and cell-death following DNA damage. The relationship between these
responses is complex and has been under-explored, especially in light of the relevance of this interaction
to cancer therapy. Many studies focus on measuring either cell-death or cell-cycle arrest outcomes, and
even then only measure at a single time-point. Additionally, often studies investigate one or two levels
of DNA damage based on the phenotype they are more interested in. DNA damage is either very high in
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studies that primarily investigate apoptosis or relatively low in studies that primarily investigate cell-
cycle checkpoints.
However, it is clear that these are continuously evolving and interacting processes. Cell-
populations that have been subjected to DNA damage may arrest at more than one DNA damage-
mediated cell-cycle checkpoint at different times following DNA damage, and cell-death is often not a
linear function with respect to time, but may occur in a burst or bursts. DNA damage mediated cell
cycle checkpoints are initiated and/or maintained in a cell in order to stop DNA synthesis (prevent a cell
from replicating its DNA while damaged and thus passing on mutations) and to allow for DNA repair.
The accepted view is that when DNA has been repaired, checkpoints are released and the cell re-enters
the cell-cycle. On the other hand, when DNA cannot be repaired, in a normally functioning cell,
apoptotic processes are initiated. It seems clear that there must be feedback between the cell-cycle
checkpoints and apoptotic processes, but the interactions between these two processes, even on the
cell-biologic level of cellular phenotype has not been explored in any depth.
A first step might be to find a set of conditions that covered a spectrum of the balance between
cell-cycle arrest and apoptotic phenotypes (ranging from mild cell-cycle arrest and high apoptosis to
very robust cell-cycle arrest phenotypes and very low apoptosis, concentrating more on the lower end
of apoptosis). Under these conditions, it would be interesting to carry out detailed dynamic studies of
cell-cycle and apoptotic phenotypes. It would also be interesting to explore other parameters in a
dynamic fashion, including 1) the dynamics and spectrum of DNA damage being induced, 2) dynamics
and mode of DNA repair, 3) dynamics of autophagy and 4) dynamics of other modes of cell-death such
as necrosis.
The measurement of cell-cycle phenotypes could be expanded to more precisely understand the
cell-cycle and checkpoint status at the time of measurement; phase-specific cyclin levels and
localizations and cdk activities may be measured, BRDU incorporation levels may be measured to
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determine S phase fraction, and cki levels may also be measured. The spectrum of DNA damage (and
perhaps DNA repair) could be monitored by pulsed gel electrophoresis (for single and double strand
DNA breaks), measurement of various DNA adducts via mass spectrometry, and measurement of H2AX
localization and phosphorylation via live-cell imaging or IF. The dynamics of DNA repair may be
captured by these same measurements. The mode of DNA repair could be monitored by measurement
of recruitment of repair mode-specific factors (e.g. recruitment of XRCC4, DNA ligase IV and Artemis
would indicate repair via non-homologous end joining). Autophagy could be monitored by cleavage of
the marker protein LC3B or by IF staining for LC3B foci, in the case that the cell type under investigation
natively expresses adequate levels of LC3B. Necrosis may be monitored by concurrent measurement of
Annexin V staining of phospatidyl-serine on the cell-surface and of membrane permeability to propidium
iodide. Such a dataset could be explored extensively and in a detailed time-dependent fashion using the
TI-SWR methods outlined in Chapter 3 of this thesis, where each of these measured cellular phenotypes,
at almost any time-point at which it was measured, can move freely between consideration as an
explanatory and as a response variable. This study would give us a much stronger understanding of the
interaction between these dynamic and interacting processes on a phenomenological level, and could
serve as a strong basis for more detailed signaling studies to investigate the molecular signaling
governing these outcomes.
Another interesting avenue would be to explore the autocrine/paracrine networks stimulated by
DNA damage, and also to further explore how the effect of DNA damage on cells changes based on the
extra-cellular milieu.
We did not investigate autocrine/paracrine factors in this thesis. However, tumor cells are
noted for their production of both inflammatory and anti-inflammatory cytokines and these factors have
been associated with tumor grade and implicated in aiding tumor cells to evade immune recognition
and attack. Some interesting questions include: 1) what factors are released; are they
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inflammatory/anti-inflammatory/mitogenic?, 2) do the factors that are released change with treatment
condition? with any of the cellular responses discussed above?, 3) if the factors (or combinations of
factors) that are released change, how do these various factor-combinations affect the ability of
adaptive immune cells to be activated by cognate antigen or to avoid anergy or tolerization? How do
they affect the ability of endothelial cells to vascularize?, 4) do released factors (or combinations of
factors) promote genomic instability and/or increased proliferation in tumor cells? (factors released by
tumor cells could be associated with tumor grade because they directly affect tumor cells and allow
tumor cells to accumulate additional advantageous mutations via increased genomic instability, or
because they allow tumor cells to proliferate in an unregulated manner via increased stimulation to
proliferate, or because they indirectly affect tumor cells and prevent adaptive immune cells from
recognizing and attacking them or stimulate endothelial cells to promote vascularization...) and 5) can
the addition of an additional factor or neutralization of a factor moderate or reverse these outcomes?
We did investigate how the effect of DNA damage on cells changes based on the extracellular
milieu (by adding the inflammatory cytokine TNF-a). However, it would be interesting to deeply
investigate this effect by testing the effect of a panel of single inflammatory and/or mitogenic factors as
well as combinations of these factors. An additional dimension to add might be seeding tumor cells to
be treated on various extracellular matrix component combinations to vary the nature of the
mechanical contacts the cell makes with the surface it rests on. Tumor cells could be seeded in a 3-D
matrix system and even co-seeded with non-tumor stromal cells to investigate the effect of the 3D
nature of a true tumor environment and the interaction of tumor cells with non-tumor cells in its
surroundings.
Another interesting avenue would be to extend the work done in this thesis by replicating the
dataset in a panel of U20S cell-lines with defined mutations or stably transfected with shRNA against
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key signaling molecules or stably transfected with constitutively active versions of key signaling
molecules.
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Appendix 1: Signaling Assay Validation
The most informative data for the purposes of analysis via data-driven mathematical modeling
approaches, such as linear regression, are quantitative data. Therefore, we validated all signaling assays
used in this work to collect molecular signaling data, for their ability to provide a quantitative, linear
signal with increasing activity or level of the relevant signaling molecule present.
We validated quantitative Western assays for over 17 measurements of either phosphorylated
signaling proteins or total protein levels and one quantitative ELISA assay for measurement of the
activation of the NFkB transcription factor. Quantitative western assays validated include those for: p-
ATM (S1981), p-Nbsl (S343), total Nbs1, p-H2AX (S139), total H2AX, p-p53 (S15), p-p53 (S20), total p53,
p-p38 (T180/Y182), p-JNK (T183/Y185), total JNK, p-ERK1/2 (T202/Y204), total ERK1 and p-Akt (S473).
Below are data from the validation of these assays, including the full blots and the quantification
of the identified relevant signal.
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Figure A1-1. Quantitative western blots for p-ATM (S1981) (A) and for total ATM (B). For both (A) and
(B) blue circles on the plots are signal obtained from positive control lysates; red circles on the plots are
signal obtained from negative control lysates. Positive control lysates are extracts from asynchronous
U20S cells treated with Neocarzinostatin (45 nM) for 1 hr. Negative control lysates are extracts from
asynchronous U2OS cells that are untreated and sub-confluent. For both (A) and (B) Lanes 1-6 on
membrane images are increasing amounts of total protein loaded from positive control lysates for p-
ATM (S1981). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pg of total protein loaded in that order. Lane 7 is
15 pg of total protein loaded from negative control lysates for p-ATM (S1981). (A) Signal for p-ATM
(S1981) increases in a linear fashion with increasing amounts of total protein loaded (from 2.5-30 pg of
total protein loaded) from positive control extracts (blue circles on plot; regression coefficient of 0.95).
Signal to background is high (compare blue circle and red circle on plot at 15 ug of total protein loaded)
and signal is easy to distinguish by eye at 15 pg of total protein loaded (lane 4 on membrane image). All
subsequent measurements of p-ATM were carried out using 15 pg of total protein from the sample
lysate and include positive and negative controls on the blot (also 15 pg of total protein loaded) as
described here, for comparison and normalization. (B) Signal for total ATM increases in a linear fashion
with increasing amounts of total protein loaded (from 2.5-30 pg of total protein loaded) from positive
control extracts (blue circles on plot; regression coefficient of 0.96). 15 ug of total protein loaded from
negative control extracts (lane 7 on membrane image) gives the same signal as that obtained from
positive control extracts (compare to lane 3 on membrane image), implying that there is no regulation of
total levels of protein under these conditions. All subsequent measurements of total ATM were carried
out using 15 pg of total protein from the sample lysate and include positive and negative controls on the
blot (also 15 pg of total protein loaded) as described here, for comparison and normalization.
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Figure A1-2. Quantitative western blots for p-H2AX (S139) (A) and for total H2AX (B). For both (A) and
(B) blue circles on the plots are signal obtained from positive control lysates; red circles on the plots are
signal obtained from negative control lysates. Positive control lysates are extracts from asynchronous
U20S cells treated with Neocarzinostatin (45 nM) for 1 hr. Negative control lysates are extracts from
asynchronous U20S cells that are untreated and sub-confluent. For both (A) and (B) Lanes 1-6 on
membrane images are increasing amounts of total protein loaded from positive control lysates for p-
H2AX (S139). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 ig of total protein loaded in that order. Lane 7 is
152
A
pH2AX S139
CST #2577
Cin
C
a)
46-0
'
B
C
C_0
4-4
c)
...........
10 pg of total protein loaded from negative control lysates for p-H2AX (S139). (A) Signal for p-H2AX
(S139) increases in a linear fashion with increasing amounts of total protein loaded (from 2.5-30 ig of
total protein loaded) from positive control extracts (blue circles on plot; regression coefficient of 0.96).
Signal to background is high (compare blue circle and red circle on plot at 10 ug of total protein loaded)
and signal is easy to distinguish by eye at 10 ig of total protein loaded (lane 3 on membrane image). All
subsequent measurements of p-H2AX were carried out using 10 Ig of total protein from the sample
lysate and include positive and negative controls on the blot (also 10 ptg of total protein loaded) as
described here, for comparison and normalization. (B) Signal for total H2AX increases in a linear fashion
with increasing amounts of total protein loaded (from 2.5-30 pg of total protein loaded) from positive
control extracts (blue circles on plot; regression coefficient of 0.99). 10 ug of total protein loaded from
negative control extracts (lane 7 on membrane image) gives a lower signal than that obtained from
positive control extracts (compare to lane 3 on membrane image), implying that there may be
regulation of total levels of protein under these conditions (up-regulation of total H2AX under DNA
damaging conditions). All subsequent measurements of total H2AX were carried out using 10 pg of total
protein from the sample lysate and include positive and negative controls on the blot (also 10 pg of total
protein loaded) as described here, for comparison and normalization.
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Figure A1-3. Quantitative western blots for p-Nbsl (S343) (A) and for total Nbsl (B). For both (A) and
(B) blue circles on the plots are signal obtained from positive control lysates; red circles on the plots are
signal obtained from negative control lysates. Positive control lysates are extracts from asynchronous
U20S cells treated with Neocarzinostatin (45 nM) for 1 hr. Negative control lysates are extracts from
asynchronous U20S cells that are untreated and sub-confluent. For both (A) and (B) Lanes 1-6 on
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membrane images are increasing amounts of total protein loaded from positive control lysates for p-
Nbs1 (S343). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pg of total protein loaded in that order. Lane 7 is 10
ig of total protein loaded from negative control lysates for p-Nbs1 (S343). (A) Signal for p-Nbsl (S343)
increases in a linear fashion with increasing amounts of total protein loaded (from 2.5-30 pig of total
protein loaded) from positive control extracts (blue circles on plot; regression coefficient of 0.97). Signal
to background is high (compare blue circle and red circle on plot at 10 ug of total protein loaded) and
signal is easy to distinguish by eye at 10 pg of total protein loaded (lane 3 on membrane image). All
subsequent measurements of p-Nbs1 were carried out using 10 Ig of total protein from the sample
lysate and include positive and negative controls on the blot (also 10 pg of total protein loaded) as
described here, for comparison and normalization. (B) Signal for total Nbsl increases in a linear fashion
with increasing amounts of total protein loaded (from 2.5-30 pg of total protein loaded) from positive
control extracts (blue circles on plot; regression coefficient of 0.99). 10 ug of total protein loaded from
negative control extracts (lane 7 on membrane image) gives the same signal as that obtained from
positive control extracts (compare to lane 3 on membrane image), implying that is no regulation of total
levels of protein under these conditions. All subsequent measurements of total Nbsl were carried out
using 10 pg of total protein from the sample lysate and include positive and negative controls on the
blot (also 10 ig of total protein loaded) as described here, for comparison and normalization.
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Figure A1-4. Quantitative western blots for p-p38 (T180/Y182) (A) and for total p38 (B). For both (A)
and (B) blue circles on the plots are signal obtained from positive control lysates; red circles on the plots
are signal obtained from negative control lysates. Positive control lysates are extracts from
asynchronous U20S cells treated with UV (50 J/m2) and collected 1 hr later. Negative control lysates are
extracts from asynchronous U20S cells that are untreated and sub-confluent. For both (A) and (B) Lanes
1-6 on membrane images are increasing amounts of total protein loaded from positive control lysates
for p-p38 (T180/Y182). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pig of total protein loaded in that order.
Lane 7 is 10 pig of total protein loaded from negative control lysates for p-p38 (T180/Y182). (A) Signal
for p-p38 (T180/Y182) increases in a linear fashion with increasing amounts of total protein loaded
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(from 2.5-30 ig of total protein loaded) from positive control extracts (blue circles on plot; regression
coefficient of 0.99). Signal to background is high (compare blue circle and red circle on plot at 10 ug of
total protein loaded) and signal is easy to distinguish by eye at 10 ptg of total protein loaded (lane 3 on
membrane image). All subsequent measurements of p-p38 were carried out using 10 pg of total protein
from the sample lysate and include positive and negative controls on the blot (also 10 pg of total protein
loaded) as described here, for comparison and normalization. (B) Signal for total p38 increases in a
linear fashion with increasing amounts of total protein loaded (from 2.5-20 ig of total protein loaded)
from positive control extracts (blue circles on plot; regression coefficient of 0.98). 10 ug of total protein
loaded from negative control extracts (lane 7 on membrane image) gives a higher signal than that
obtained from positive control extracts (compare to lane 3 on membrane image), implying that there
may be regulation of total levels of protein under these conditions (down-regulation of total p38 levels
under UV treatment conditions). All subsequent measurements of total p38 were carried out using 10
pg of total protein from the sample lysate and include positive and negative controls on the blot (also 10
ig of total protein loaded) as described here, for comparison and normalization.
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Figure A1-5. Quantitative western blots for p-p53 (S15) (A), p-p53 (S20) (B) and for total p53 (C). For
(A), (B) and (C) blue circles on the plots are signal obtained from positive control lysates; red circles on
the plots are signal obtained from negative control lysates. Positive control lysates are extracts from
asynchronous U20S cells treated with Doxorubicin (10 ptM) for 8 hr. Negative control lysates are
extracts from asynchronous U20S cells that are untreated and sub-confluent. For both (A) and (B) Lanes
1-6 on membrane images are increasing amounts of total protein loaded from positive control lysates
for p-p53 (S15 and/or S20). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pg of total protein loaded in that
order. Lane 7 is 10 ig of total protein loaded from negative control lysates for p-p53 (S15 and/or S20).
(A) Signal for p-p53 (S15) increases in a linear fashion with increasing amounts of total protein loaded
(from 2.5-30 ig of total protein loaded) from positive control extracts (blue circles on plot; regression
coefficient of 0.98). Signal to background is high (compare blue circle and red circle on plot at 10 ug of
total protein loaded) and signal is easy to distinguish by eye at 10 p'g of total protein loaded (lane 3 on
membrane image). All subsequent measurements of p-p53 were carried out using 10 ig of total protein
from the sample lysate and include positive and negative controls on the blot (also 10 ptg of total protein
loaded) as described here, for comparison and normalization. (B) Signal for p-p53 (S20) increases in a
linear fashion with increasing amounts of total protein loaded (from 2.5-30 pig of total protein loaded)
from positive control extracts (blue circles on plot; regression coefficient of 0.99). Signal to background
is high (compare blue circle and red circle on plot at 10 ug of total protein loaded) and signal is easy to
distinguish by eye at 10 ptg of total protein loaded (lane 3 on membrane image). All subsequent
measurements of p-p53 were carried out using 10 pg of total protein from the sample lysate and include
positive and negative controls on the blot (also 10 pg of total protein loaded) as described here, for
comparison and normalization. (C) Signal for total p53 increases in a linear fashion with increasing
amounts of total protein loaded (from 2.5-30 ptg of total protein loaded) from positive control extracts
(blue circles on plot; regression coefficient of 0.99). 10 ug of total protein loaded from negative control
extracts (lane 7 on membrane image) gives a much lower signal than that obtained from positive control
extracts (compare to lane 3 on membrane image), implying that there is regulation of total levels of
protein under these conditions (up-regulation of total p53 levels under DNA damaging conditions). All
subsequent measurements of total p53 were carried out using 10 pg of total protein from the sample
lysate and include positive and negative controls on the blot (also 10 ptg of total protein loaded) as
described here, for comparison and normalization.
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Figure A1-6. Quantitative western blots for p-JNK (T183/Y185) (A) and for total JNK (B). For both (A)
and (B) blue circles on the plots are signal obtained from positive control lysates; red circles on the plots
are signal obtained from negative control lysates. Positive control lysates are extracts from
asynchronous U20S cells treated with UV (50 J/m2) and collected 1 hr later. Negative control lysates are
extracts from asynchronous U20S cells that are untreated and sub-confluent. For both (A) and (B) Lanes
1-6 on membrane images are increasing amounts of total protein loaded from positive control lysates
for p-JNK (T183/Y185). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pg of total protein loaded in that order.
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Lane 7 is 10 ptg of total protein loaded from negative control lysates for p-JNK (T183/Y185). (A) Signal
for p-JNK (T183/Y185) increases in a linear fashion with increasing amounts of total protein loaded (from
2.5-30 pg of total protein loaded) from positive control extracts (blue circles on plot; regression
coefficient of 0.99). Signal to background is high (compare blue circle and red circle on plot at 10 ug of
total protein loaded) and signal is easy to distinguish by eye at 10 ig of total protein loaded (lane 3 on
membrane image). All subsequent measurements of p-JNK were carried out using 10 pg of total protein
from the sample lysate and include positive and negative controls on the blot (also 10 ig of total protein
loaded) as described here, for comparison and normalization. (B) Signal for total JNK increases in a
linear fashion with increasing amounts of total protein loaded (from 2.5-30 ig of total protein loaded)
from positive control extracts (blue circles on plot; regression coefficient of 0.99). 10 ug of total protein
loaded from negative control extracts (lane 7 on membrane image) gives the same signal as that
obtained from positive control extracts (compare to lane 3 on membrane image), implying that there is
no regulation of total levels of protein under these conditions. All subsequent measurements of total
JNK were carried out using 10 pg of total protein from the sample lysate and include positive and
negative controls on the blot (also 10 pg of total protein loaded) as described here, for comparison and
normalization.
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Figure A1-7. Quantitative western blots for p-ERK1/2 (T202/Y204) (A) and for total ERK1 (B). For both
(A) and (B) blue circles on the plots are signal obtained from positive control lysates; red circles on the
plots are signal obtained from negative control lysates. Positive control lysates are extracts from
asynchronous U2OS cells serum starved overnight and then placed in 100% FBS for 5 min. Negative
control lysates are extracts from asynchronous U20S cells that are untreated and sub-confluent. For
both (A) and (B) Lanes 1-6 on membrane images are increasing amounts of total protein loaded from
positive control lysates for p-ERK1/2 (T202/Y204). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pg of total
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protein loaded in that order. Lane 7 is 10 ptg of total protein loaded from negative control lysates for p-
ERK1/2 (T202/Y204). (A) Signal for p-ERK1/2 (T202/Y204) increases in a linear fashion with increasing
amounts of total protein loaded (from 2.5-30 pg of total protein loaded) from positive control extracts
(blue circles on plot; regression coefficient of 0.99). Signal to background is high (compare blue circle
and red circle on plot at 10 ug of total protein loaded) and signal is easy to distinguish by eye at 10 ig of
total protein loaded (lane 3 on membrane image). All subsequent measurements of p-ERK1/2 were
carried out using 10 pig of total protein from the sample lysate and include positive and negative
controls on the blot (also 10 ptg of total protein loaded) as described here, for comparison and
normalization. (B) Signal for total ERKl increases in a linear fashion with increasing amounts of total
protein loaded (from 2.5-30 ig of total protein loaded) from positive control extracts (blue circles on
plot; regression coefficient of 0.98). 10 ug of total protein loaded from negative control extracts (lane 7
on membrane image) gives the same signal as that obtained from positive control extracts (compare to
lane 3 on membrane image), implying that there is no regulation of total levels of protein under these
conditions. All subsequent measurements of total ERK1 were carried out using 10 ig of total protein
from the sample lysate and include positive and negative controls on the blot (also 10 ptg of total protein
loaded) as described here, for comparison and normalization.
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Figure A1-8. Quantitative western blots for p-Akt (S473) (A) and for total Akt (B). For both (A) and (B)
blue circles on the plots are signal obtained from positive control lysates; red circles on the plots are
signal obtained from negative control lysates. Positive control lysates are extracts from asynchronous
U20S cells serum starved overnight and then placed in 100% FBS for 5 min. Negative control lysates are
extracts from asynchronous U20S cells that are untreated and sub-confluent. For both (A) and (B) Lanes
1-6 on membrane images are increasing amounts of total protein loaded from positive control lysates
for p-Akt (S473). Lanes 1-6 are 2.5, 5, 10, 15, 20 and 30 pg of total protein loaded in that order. Lane 7
is 10 pg of total protein loaded from negative control lysates for p-Akt (S473). (A) Signal for p-Akt
(S473) increases in a linear fashion with increasing amounts of total protein loaded (from 2.5-20 ig of
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total protein loaded) from positive control extracts (blue circles on plot; regression coefficient of 0.99).
Signal to background is high (compare blue circle and red circle on plot at 10 ug of total protein loaded)
and signal is easy to distinguish by eye at 10 ig of total protein loaded (lane 3 on membrane image). All
subsequent measurements of p-Akt were carried out using 10 ptg of total protein from the sample lysate
and include positive and negative controls on the blot (also 10 pg of total protein loaded) as described
here, for comparison and normalization. (B) Signal for total Akt increases in a linear fashion with
increasing amounts of total protein loaded (from 2.5-20 ig of total protein loaded) from positive control
extracts (blue circles on plot; regression coefficient of 0.99). 10 ug of total protein loaded from negative
control extracts (lane 7 on membrane image) gives a lower signal than that obtained from positive
control extracts (compare to lane 3 on membrane image), implying that there may be regulation of total
levels of protein under these conditions (up-regulation of total Akt under serum shock conditions). All
subsequent measurements of total Akt were carried out using 10 pg of total protein from the sample
lysate and include positive and negative controls on the blot (also 10 pg of total protein loaded) as
described here, for comparison and normalization.
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Figure A1-9. Plot of ELISA assay validation results for quantification of NFkB activation. Blue circles on
the plots are signal obtained from positive control lysates; red circles on the plots are signal obtained
from negative control lysates. Positive control lysates are extracts from asynchronous U2OS treated
with TNF-a (100 ng/ml) for 30 min. Signal for active NFkB increases in a linear fashion with increasing
amounts of total protein loaded (from 3-13.5 pig of total protein loaded) from positive control extracts
(blue circles on plot; regression coefficient of 0.92). Signal to background is high (compare blue circle
and red circle on plot at 11 ug of total protein loaded) and signal is easy to distinguish by eye at 11 pig of
total protein loaded (Data not shown). All subsequent measurements of NFkB activity were carried out
using 15 ptg of total protein from the sample lysate and include positive and negative controls in the
ELISA plate (also 15 ptg of total protein loaded) as described here, for comparison and normalization.
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Appendix 2: Chapter 2 Supplementary Figures
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Supplementary Figure 2-1. Plot of % of total cell population that is apoptotic at 24 hr following Dox
treatment (10 pM) +/- TNF-a (100ng/ml). U2OS cells were treated as described in Figure 2-1 (A). Whole
cell samples were collected and fixed at 24 hr following treatment and stained for FACS measurement of
cleaved caspase-3 and cleaved Parp. FACS dot plots of cleaved caspase-3 vs. cleaved Parp were gated to
distinguish fractions of the total cell population staining positively for one, none or both apoptotic
markers, and these gates were subsequently quantified. Here, cells staining positively for the apoptotic
marker, CC3+, were considered to be apoptotic.
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Supplementary Figure 2-2. Illustration of the hypothesis that each time-point specific, Time-Interval
model in a TI-SWR (Time-Interval Stepwise regression) analysis set makes. In a TI-SWR analysis set,
there is one cellular response of interest under investigation and there are as many time- point specific,
Time-Interval models in the set as there are time-points at which signaling is measured that precede the
cellular response of interest. For each of these time-point specific, Time-Interval models, the response
variable is the cellular response under investigation and the possible explanatory variable set includes all
of the signaling measurements made at that time point. Here is illustrated a time-point specific, Time-
Interval model for which the response variable is the change in the cellular response R2 between 12 and
24 hr and for which the possible explanatory variable set includes all signaling measurements taken at
the 8 hr time-point.
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Supplementary Figure 2-3. (A) Regression plot showing the change in the % of the cell-population
observed to be in the S phase of the cell-cycle between 12 and 24 hr following treatment (A %S, 12-24 hr
- the cellular response investigated in the previous TI-SWR analysis) vs. the integrated area under the
curve for the measurement of p-ERK1/2 between 2 and 8 hr following treatment (p-ERK1/2, AUC 2-8 hr).
The regression coefficient (R2 = 0.789) and the positive slope of the regression line indicates a strong and
positive relationship between p-ERK1/2 (2-8 hr following treatment) and the cell-cycle phenotype
captured by the change in the percentage of the cell-population in S phase between 12 and 24 hr (A %S,
12-24 hr). (B) Regression plot showing the change in the % of the cell-population observed to be in the
S phase of the cell-cycle between 12 and 24 hr following treatment (A %S, 12-24 hr - the cellular
response investigated in the previous TI-SWR analysis) vs. the integrated area under the curve for the
measurement of p-p38 between 2 and 8 hr following treatment (p-p38, AUC 2-8 hr). The regression
coefficient (R2 = 0.06) indicates that there is no discernible relationship between p-p38 (2-8 hr following
treatment) and the cell-cycle phenotype captured by the change in the percentage of the cell-
population in S phase between 12 and 24 hr (A %S, 12-24 hr).
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Supplementary Figure 2-4. (A) Cell-cycle profiles of U20S cell-populations treated with Dox (2 pM)
alone (upper boxes) or with Dox (2 pM) plus PD98059 (20 pM) (lower boxes) at 12 and 24 hr following
treatment. Populations treated with Dox alone show a clear build-up in early/mid-S phase population
by 24 hr following treatment. Populations treated with Dox plus PD show a clear build-up in early-S
phase population by 12 hr following treatment, but by 24 hr following treatment, this built-up
population has progressed through S phase and is observed to be in mid/late-S phase. (B) Overlay of a
cell-cycle profile of U20S cell-populations treated with Dox (2 pM) alone (red trace) or with Dox (2 pM)
plus PD98059 (20 pM) (blue trace) at 12 hr following treatment. There is a clear build-up in early-S
phase population in populations treated with Dox plus PD as compared to populations treated with Dox
alone. This build-up is a "shoulder" off of the G1 peak of the cell-cycle profile.
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Supplemenary Figure 2-5. (A) Cell-cycle profiles of U20S cell-populations treated with carrier alone
(upper boxes) or treated with carrier plus PD98059 (20 p.M) (lower boxes) at 12 and 24 hr following
treatment. Populations treated with carrier plus PD show no discernible differences in cell-cycle profile
as compared to populations treated with carrier alone, at 12 or 24 hr following treatment. (B) Overlay
of a cell-cycle profile of U20S cell-populations treated with carrier alone (red trace) or with carrier plus
PD98059 (20 pM) (blue trace) at 12 hr following treatment. Cell-cycle profiles for populations treated
with carrier alone or with carrier plus PD almost exactly overlay.
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Supplementary Figure 2-6. (A) A plot of the % of the total cell population that is observed to be in
the S phase of the cell-cycle at 12, 15, 18, 24, 27 and 30 hr following treatment with 2 pM Dox +/-
PD98059 (dark green dash and solid lines respectively), 2 pIM Dox + TNF-a (100ng/ml) +/- PD98059 (light
green dash and solid lines respectively) or carrier (0 piM Dox) +/- PD98059 (blue dash and solid lines
respectively). PD98059 added simultaneously with Dox treatment. There is a build-up in the S phase of
the cell-cycle by 24 hr following treatment with Dox or Dox plus TNF-a. The build-up in S phase is
smaller in magnitude in populations treated with Dox plus TNF-a as compared to populations treated
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with Dox alone. When PD98059 is added simultaneously with Dox to populations treated with Dox
alone, the population that builds up in S phase does so earlier than in the absence of PD98059 (by 12-15
hr following treatment), and the population build-up is of roughly equal magnitude. When PD98059 is
added simultaneously with Dox to populations treated with Dox plus TNF-a, the population that builds
up in S phase also does so earlier than in the absence of PD98059 (by 12-15 hr following treatment), but
the population build-up is greater in magnitude than it is in the absence of PD98059, and is roughly
equal in magnitude to that observed in populations treated with Dox alone. (B) A plot of the % of the
total cell population that is observed to be apoptotic at 12 hr following treatment with 2 pM Dox +/-
TNF-a and +/- PD98059 (20 tM), added simultaneously with Dox. U2OS cells were treated as described
in Figure 2-9A. Whole cell samples were collected and fixed at 12 hr following treatment and stained for
FACS measurement of cleaved caspase-3 and cleaved Parp. FACS dot plots were gated to distinguish
fractions of the total cell population staining positively for one, none or both apoptotic markers, and
these gates were subsequently quantified. Here, cells staining positively for both apoptotic markers
(CC3+CParp+) were considered to be apoptotic.
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Supplementary Figure 2-7. Experimental time-line for Future Experiment #1 which aims to provide
further evidence that ERK1/2 acts in GI or at the G1/S transition to promote maintenance of a cell-cycle
check-point following DNA damage. U2OS cells will be synchronized in late G1 via a double thymidine
block and released directly into fresh media containing aphidicolin to prevent progression into S phase.
One hour following release into aphidicolin, cells will be treated +/- Dox (2 pM) and +/- PD98059 (20
pM). At 4 hr following treatment, media will be aspirated and replaced with media containing 1% FBS,
+/- PD98059 according to whether PD98059 was present prior to media replacement, and aphidicolin.
At 6 hr following treatment, media will be aspirated and replaced with media containing 1% FBS without
aphidicolin, to allow progression into S phase. Whole cell samples will be collected and fixed at 9 and 12
hr following treatment and stained for FACS measurement of cell-cycle profile and apoptosis. We
expect that, over the course of this experiment, we will not see substantial progression of the cell
population that was treated with Dox in late G1, from late G1 into S phase. We also expect that, over
the course of this experiment, we will see substantial progression of the cell population that was treated
with Dox plus PD98059 in late G1, from late G1 into S phase.
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Supplementary Figure 2-8. (A) Experimental time-line for Future Experiment #2, which aims to
provide evidence either for or against the cell-cycle context dependent model for ERK1/2 role-switching
between promotion of maintenance of a cell-cycle check-point and promotion of apoptosis following
DNA damage presented in Figure 2-9 (E). U20S cells will be synchronized in metaphase via a nocodazol
arrest and mitotic shake-off, replated in fresh media and incubated for 4 hr to allow progression into
early G1. Cells will be treated +/- Dox and +/- PD98059 at 4, 6, 8 or 10 hr following re-plating, and whole
cell sample will be collected, fixed and stained for measurement of cell-cycle profile and apoptosis 6 hr
following treatment. (B)-(C) Hypothetical data for cell populations treated in early G1 (pre- cell cycle
check-point), if the cell-cycle context dependent model is true. Plots of % of the cell population in S
phase (B) and % of the cell population that is apoptotic (C). We expect a robust cell-cycle phenotype
(cell-cycle checkpoint in Gl or at the G1/S transition) in populations treated with Dox, and that this
check-point can be overcome by addition of PD98059. We also expect minimal apoptosis in populations
treated with Dox. (D)-(E) Hypothetical data for cell populations treated in late G1 (post- cell cycle check-
point), if the cell-cycle context dependent model is true. Plots of % of the cell population in S phase (D)
and % of the cell population that is apoptotic (E). We expect a minimal cell-cycle phenotype (cell-cycle
checkpoint in Gl or at the G1/S transition) in populations treated with Dox. We also expect signigicant
apoptosis in populations treated with Dox, and that this apoptotic phenotype can be largely overcome
by addition of PD98059.
175
...........................    ... ::   ..... 
Appendix 3: Chapter 3 Supplementary Figures
A
Y: A % S, 12-24 hr
X: X, 2 hr
y = 0.79 + 0.81 ph2ax, 2hr- 2.8 th2ax, 2hr+ 0.11 perkil/2, 2hr- 0.02 pnbs1, 2hr
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Supplementary Figure 3-1. (A) Full model equation and regression plots for the 2 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
the cell-population in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr) as the
response variable. The full model as determined by a Stepwise regression algorithm includes 4 signals
and these signals are listed in decreasing order of R2 (ability to explain variability in the response
variable) in thefull model equation. The regression plot for the full model, the model minus one
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variable ("model - 1 var"), the model minus two variables ("model - 2 var"), and the model minus
three variables ("model - 3 var") is shown where variables are subtracted in order, starting with the
signal with the lowest R2. (B) Residuals plot for the 2 hr time-point specific, Time-Interval model.
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Supplementary Figure 3-2. (A) Full model equation and regression plots for the 4 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
the cell-population in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr) as the
response variable. The full model as determined by a Stepwise regression algorithm includes 4 signals
and these signals are listed in decreasing order of R2 (ability to explain variability in the response
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variable) in thefull model equation. The regression plot for the full model, the model minus one
variable ("model - 1 var"), the model minus two variables ("model - 2 var"), and the model minus
three variables ("model - 3 var") is shown where variables are subtracted in order, starting with the
signal with the lowest R2. (B) Residuals plot for the 4 hr time-point specific, Time-Interval model.
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Supplementary Figure 3-3. (A) Full model equation and regression plots for the 8 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
the cell-population in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr) as the
response variable. The full model as determined by a Stepwise regression algorithm includes only one
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signal. The regression plot for the full model is shown. (B) Residuals plot for the 8 hr time-point
specific, Time-Interval model.
Y: A % S, 12-24 hr
X: X, 16 hr
y -0.46 + 0.19 tp53,16hr
Etyp-value
tpJ310.02 Regression plot
Residuals plot
Supplementary Figure 3-4. (A) Full model equation and regression plots for the 16 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
the cell-population in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr) as the
response variable. The full model as determined by a Stepwise regression algorithm includes only one
signal. The regression plot for the full model is shown. (B) Residuals plot for the 16 hr time-point
specific, Time-Interval model.
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Supplementary Figure 3-5. (A) Full model equation and regression plots for the 24 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
the cell-population in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr) as the
response variable. The full model as determined by a Stepwise regression algorithm includes only one
signal. The regression plot for the full model is shown. (B) Residuals plot for the 24 hr time-point
specific, Time-Interval model.
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Supplementary Figure 3-6. (A) Full model equation and regression plots for a combined time-point
model using top signal correlates from the TI-SWR analysis set investigating the change in the
percentage of the cell-population in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr)
as the response variable, as the potential explanatory variable set. The full potential explanatory
variable set is listed (top table) along with the R2 of each within the time-point specific model in which
they were determined to be top signal correlates with the cellular response of interest. The response
variable for this model is A %S, 12-24 hr. The full model as determined by a Stepwise regression
algorithm includes only one signal. The regression plot for the full model is shown. (B) Residuals plot
for the "combined time-point" model.
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Supplementary Figure 3-7. (A) Full model equation for a combined time-point model using top signal
correlates from the TI-SWR analysis set investigating the change in the percentage of the cell-population
in S phase between 12 and 24 hr following treatment (A %S, 12-24 hr) as the response variable, as the
explanatory variable set. A subset has been chosen to decrease the number of potential explanatory
variables to be less that the number of observations in the dataset (6 observations). The full
explanatory variable set is listed (top table) along with the R2 of each within the time-point specific
model in which they were determined to be top signal correlates with the cellular response of interest.
The response variable for this model is A %S, 12-24 hr. The full model as determined by OLS (Ordinary
Least squares) regression does not reach a required level of significance (p<0.05). (B) Model equation
and regression plot for a regression model relating two of the potential explanatory signal
measurements in the "combined time-point" model investigating A %S, 12-24 hr (Response variable is
total p53 at 16 hr; explanatory variable is p-ERK1/2 at 8 hr). A high degree of collinearity is
demonstrated between the two signal measurements.
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Supplementary Figure 3-8. (A) Model equation and regression plot for a regression model relating
two of the potential explanatory signal measurements in the "combined time-point" model investigating
A %S, 12-24 hr. (Response variable is total p53 at 16 hr; explanatory variable is p-ERK1/2 at 4 hr). A high
degree of collinearity is demonstrated between the two signal measurements. (B) Model equation and
regression plot for a regression model relating two of the potential explanatory signal measurements in
the "combined time-point" model investigating A %S, 12-24 hr (Response variable is total p53 at 16 hr,
explanatory variable is p-H2AX at 2 hr). A high degree of collinearity is demonstrated between the two
signal measurements.
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Y: A % CC3+CParp+, 6-12 hr
X: X, 0.25 hr
y = -2.3 + 5.2 pakt, 0.25hr
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Supplementary Figure 3-9. (A) Full model equation and regression plots for the 0.25 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 6 and 12 hr following treatment (A %apoptosis (CC3+CParp+),
6-12 hr) as the response variable. The full model as determined by a Stepwise regression algorithm
includes only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 0.25
hr time-point specific, Time-Interval model.
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Supplementary Figure 3-10. (A) Full model equation and regression plots for the 4 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 6 and 12 hr following treatment (A %apoptosis (CC3+CParp+),
6-12 hr) as the response variable. The full model as determined by a Stepwise regression algorithm
includes only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 4 hr
time-point specific, Time-Interval model.
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Supplementary Figure 3-11. (A) Full model equation and regression plots for the 8 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 6 and 12 hr following treatment (A %apoptosis (CC3+CParp+),
6-12 hr) as the response variable. The full model as determined by a Stepwise regression algorithm
includes 2 signals and these signals are listed in decreasing order of R2 (ability to explain variability in
the response variable) in thefull model equation. The regression plot for the full model and the model
minus one variable ("model - 1 var") is shown where variables are subtracted starting with the signal
with the lowest R2. (B) Residuals plot for the 8 hr time-point specific, Time-Interval model.
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Supplementary Figure 3-12. (A) Full model equation and regression plots for the 12 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 6 and 12 hr following treatment (A %apoptosis (CC3+CParp+),
6-12 hr) as the response variable. The full model as determined by a Stepwise regression algorithm
includes only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 12 hr
time-point specific, Time-Interval model.
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Supplementary Figure 3-13. (A) Full model equation and regression plots for a combined time-point
model using top signal correlates from the TI-SWR analysis set investigating the change in the
percentage of apoptosis between 6 and 12 hr following treatment (A %apoptosis (CC3+CParp+), 6-12 hr)
as the response variable, as the potential explanatory variable set. The full potential explanatory
variable set is listed (top table) along with the R2 of each within the time-point specific model in which
they were determined to be top signal correlates with the cellular response of interest. The response
variable for this model is A %apoptosis (CC3+CParp+), 6-12 hr. The full model as determined by a
Stepwise regression algorithm includes only one signal. The regression plot for the full model is shown.
(B) Residuals plot for the "combined time-point" model.
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Supplementary Figure 3-14. (A) Full model equation for a combined time-point model using top
signal correlates from the TI-SWR analysis set investigating the change in the percentage of apoptosis
between 6 and 12 hr following treatment (A %apoptosis (CC3+CParp+), 6-12 hr) as the response
variable, as the explanatory variable set. A subset has been chosen to decrease the number of potential
explanatory variables to be less that the number of observations in the dataset (6 observations). The
full explanatory variable set is listed (top table) along with the R2 of each within the time-point specific
model in which they were determined to be top signal correlates with the cellular response of interest.
The response variable for this model is A %apoptosis (CC3+CParp+), 6-12 hr. The full model as
determined by OLS (Ordinary Least squares) regression does not reach a required level of significance
(p<0.05). (B) Model equation and regression plot for a regression model relating two of the potential
explanatory signal measurements in the "combined time-point" model investigating A %apoptosis
(CC3+CParp+), 6-12 hr (Response variable is p-p53 at 8 hr; explanatory variable is p-Akt at 4 hr). A high
degree of collinearity is demonstrated between the two signal measurements.
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Supplementary Figure 3-15. (A) Model equation and regression plot for a regression model relating
two of the potential explanatory signal measurements in the "combined time-point" model investigating
A %apoptosis (CC3+CParp+), 6-12 hr. (Response variable is p-p53 at 8 hr; explanatory variable is p-Akt at
0.25 hr). A high degree of collinearity is demonstrated between the two signal measurements. (B)
Model equation and regression plot for a regression model relating two of the potential explanatory
signal measurements in the "combined time-point" model investigating A %apoptosis (CC3+CParp+), 6-
12 hr (Response variable is p-Akt at 4 hr, explanatory variable is p-Akt at 0.25 hr). A high degree of
collinearity is demonstrated between the two signal measurements.
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Supplementary Figure 3-16. (A) Full model equation and regression plots for the 0.25 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 0.25 hr time-
point specific, Time-Interval model.
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Supplementary Figure 3-17. (A) Full model equation and regression plots for the 0.5 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 0. 5 hr time-
point specific, Time-Interval model.
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Supplementary Figure 3-18. (A) Full model equation and regression plots for the 4 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 4 hr time-
point specific, Time-Interval model.
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Supplementary Figure 3-19. (A) Full model equation and regression plots for the 8 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
2 sig nals and these signals are listed in decreasing order of R2 (ability to explain variability in the
response variable) in thefull model equation. The regression plot for the full model and the model
minus one variable ("model - 1 var") is shown where variables are subtracted starting with the signal
with the lowest R2 . (B) Residuals plot for the 8 hr time-point specific, Time-Interval model.
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Supplementary Figure 3-20. (A) Full model equation and regression plots for the 12 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 12 hr time-
point specific, Time-Interval model.
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Supplementary Figure 3-21. (A) Full model equation and regression plots for the 16 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
only one signal. The regression plot for the full model is shown. (B) Residuals plot for the 16 hr time-
point specific, Time-Interval model.
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Supplementary Figure 3-22. (A) Full model equation and regression plots for the 24 hr time-point
specific, Time-Interval model from the TI-SWR analysis set investigating the change in the percentage of
apoptosis in the cell-population between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24
hr) as the response variable. The full model as determined by a Stepwise regression algorithm includes
2 signals and these signals are listed in decreasing order of R2 (ability to explain variability in the
response variable) in thefull model equation. The regression plot for the full model and the model
minus one variable ("model - 1 var") is shown where variables are subtracted starting with the signal
with the lowest R2. (B) Residuals plot for the 24 hr time-point specific, Time-Interval model.
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Supplementary Figure 3-23. (A) Full model equation and regression plots for a combined time-point
model using top signal correlates from the TI-SWR analysis set investigating the change in the
percentage of apoptosis between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24 hr) as
the response variable, as the potential explanatory variable set. The full potential explanatory variable
set is listed (top table) along with the R2 of each within the time-point specific model in which they were
determined to be top signal correlates with the cellular response of interest. The response variable for
this model is A %apoptosis (CC3+), 12-24 hr. The full model as determined by a Stepwise regression
algorithm includes only one signal. The regression plot for the full model is shown. (B) Residuals plot
for the "combined time-point" model.
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Supplementary Figure 3-24. (A) Full model equation for a combined time-point model using top
signal correlates from the TI-SWR analysis set investigating the change in the percentage of apoptosis
between 12 and 24 hr following treatment (A %apoptosis (CC3+), 12-24 hr) as the response variable, as
the explanatory variable set. A subset has been chosen to decrease the number of potential
explanatory variables to be less that the number of observations in the dataset (6 observations). The
full explanatory variable set is listed (top table) along with the R2 of each within the time-point specific
model in which they were determined to be top signal correlates with the cellular response of interest.
The response variable for this model is A %apoptosis (CC3+), 12-24 hr. The full model as determined by
OLS (Ordinary Least squares) regression does not reach a required level of significance (p<0.05). (B)
Model equation and regression plot for a regression model relating two of the potential explanatory
signal measurements in the "combined time-point" model investigating A %apoptosis (CC3+), 12-24 hr
(Response variable is p-ERK1/2 at 12 hr; explanatory variable is p-p53 at 8 hr). A high degree of
collinearity is demonstrated between the two signal measurements.
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Supplementary Figure 3-25. (A) Model equation and regression plot for a regression model relating
two of the potential explanatory signal measurements in the "combined time-point" model investigating
A %apoptosis (CC3+), 12-24 hr. (Response variable is p-ERK1/2 at 12 hr; explanatory variable is p-Akt at
4 hr). A high degree of collinearity is demonstrated between the two signal measurements. (B) Model
equation and regression plot for a regression model relating two of the potential explanatory signal
measurements in the "combined time-point" model investigating A %apoptosis (CC3+), 12-24 hr
(Response variable is p-ERK1/2 at 12 hr, explanatory variable is p-Akt at 0.25 hr). A high degree of
collinearity is demonstrated between the two signal measurements.
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Supplementary Figure 3-26. (A) Full model equation and regression plots for the first time-point
specific, Time-Interval model from the "walk back" TI-SWR analysis that starts by investigating the
change in the percentage of apoptosis in the cell-population between 12 and 24 hr following treatment
(A %apoptosis (CC3+), 12-24 hr) as the response variable. The potential explanatory variable set for this
first step model is all of the signaling measurements taken at 16 hr following treatment. The full model
as determined by a Stepwise regression algorithm includes only one signal. The regression plot for the
full model is shown. (B) Residuals plot for the first step "walk back" model.
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Supplementary Figure 3-27. (A) Full model equation and regression plots for the second time-point
specific, Time-Interval model from the "walk back" TI-SWR analysis that starts by investigating the
change in the percentage of apoptosis in the cell-population between 12 and 24 hr following treatment
(A %apoptosis (CC3+), 12-24 hr) as the response variable. The response variable for this second step
model is the change in the signal, p-p38, between 12 and 16 hr following treatment. The potential
explanatory variable set for the second step model is all of the signaling measurements taken at 12 hr
following treatment. The full model as determined by a Stepwise regression algorithm includes 2 signals
and these signals are listed in decreasing order of R2 (ability to explain variability in the response
variable) in thefull model equation. The regression plot for the full model and the model minus one
variable ("model - 1 var") is shown where variables are subtracted starting with the signal with the
lowest R2. (B) Residuals plot for the second step "walk back" model.
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Supplementary Figure 3-28. (A) Full model equation and regression plots for the third time-point
specific, Time-Interval model from the "walk back" TI-SWR analysis that starts by investigating the
change in the percentage of apoptosis in the cell-population between 12 and 24 hr following treatment
(A %apoptosis (CC3+), 12-24 hr) as the response variable. The response variable for this third step
model is the change in the signal, p-p38, between 8 and 12 hr following treatment. The potential
explanatory variable set for the third step model is all of the signaling measurements taken at 8 hr
following treatment. The full model as determined by a Stepwise regression algorithm includes only one
signal. The regression plot for the full model is shown. (B) Residuals plot for the third step "walk back"
model.
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Supplementary Figure 3-29. (A) Full model equation and regression plots for the fourth and last
time-point specific, Time-Interval model from the "walk back" TI-SWR analysis that starts by
investigating the change in the percentage of apoptosis in the cell-population between 12 and 24 hr
following treatment (A %apoptosis (CC3+), 12-24 hr) as the response variable. The response variable for
this last step model is the change in the signal, NFkB, between 4 and 8 hr following treatment. The
potential explanatory variable set for the second step model is all of the signaling measurements taken
at 4 hr following treatment. The full model as determined by a Stepwise regression algorithm includes 2
signals and these signals are listed in decreasing order of R2 (ability to explain variability in the
response variable) in thefull model equation. The regression plot for the full model and the model
minus one variable ("model - 1 var") is shown where variables are subtracted starting with the signal
with the lowest R2. (B) Residuals plot for the last step "walk back" model.
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Supplementary Table 3-1. Table of PLSR model Principal component loadings in Principal component
1 (PCI) and Principal component 2 (PC2), unsorted. (t=1,2,3,4,5,6,7,8,9,10 translates to time-points:
0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16 and 24 hr following treatment)
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Supplementary Table 3-2. Table of PLSR model Principal component loadings in Principal component
1 (PCi) and Principal component 2 (PC2), sorted on PCI, descending order of weight. (t = 1,2 ,3 14,5,6,
..,7,8 ,9,10 translates to time-points: 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16 and 24 hr following treatment)
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0.115234 -0.0423155
0.0954801 -0.0435324
0.0595703 -0.0446348
0.119636 -0.0473851
0.0894899 -0.0498191
0.113139 -0.0513266
0.055974 -0.0518483
0.0970943 -0.0558031
0.0525114 -0.05682
0.111903 -0.0570618
0.0969654 0.0587174
0.0773869 -0.0593712
0.11726 -0.0611587
0.0736769 -0.063662
0.110141 -0.0658864
0.111449 -0.0683459
0.0328073 -0.0698916
0.119745 -0.070052
0.0873464 -0.0706922
0.0904217 -0.0708525
0.0936551 -0.0763857
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0.114264 -0.0770403
0.114872 -0.07726
0.0232599 -0.0776807
0.115669 -0.0780101
0.0814595 -0.0788701
70.0657994 -0.0796637
0.102993 -0.0832459
0.108375 -0.0833421
0. 114913 -0.0840816
0.114669 -0.0866432
0.0871647 -0.0869112
0.0666345 -0.0882125,
0.015101 -0.0919611
0.0613373 -0.0945423
0.043174 -0.0998411
0.0928178 -0.100231
0.0939553 -0. 100494
0.092967 -0.10299
0.0757371 -0.106417
0.0981512 -0.114956
0.0982903 -0.121443
0.0969752 -0.123551
0.0799011 -0.125725
0.0662563 -0.127869
-0.0686022 -0.135821
0.08647 -0.138719
0.0513974 -0.143972
Supplementary Table 3-3. Table of PLSR model Principal component loadings in Principal component
1 (PCi) and Principal component 2 (PC2), sorted on PC2, descending order of weight. (t = 1 ,2 ,3,4,5 ,6,
..17 ,8,9,110 translates to time-points: 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 16 and 24 hr following treatment)
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Y : A % apoptosis (CC3+), 12-24h
Time-point (hr) Signal correlates in decreasing order of R 2
0.25h + pAkt
0.5h + total Nbsl
1h --
1.5h
2h --
4h + pAkt
8h + pp53,+ pp38
12h + pERK1/2
16h + pp38
24h + pH2AX, + total Nbs1
Supplementary Table 3-4. Table of results from a TI-SWR (Time-Interval Stepwise regression) analysis
investigating the change in apoptosis between 12 and 24 hr following treatment (A % apoptosis (CC3+),
12-24 hr) as the cellular response variable. Here cells staining positively for one apoptotic marker
(CC3+) regardless of whether they stain positively for another apoptotic marker (+/- CParp) are
considered apoptotic. Rows present an overview of the results for each of the 10 time-point specific
Time-Interval models constructed (For each of the time-point specific Time-Interval models, the
response variable is A %apoptosis, 12-24 hr and the explanatory variable set is all signals measured at
that time-point). For each Time-interval model, signal names are listed in order of decreasing R2 (ability
to explain the variability in the response variable). Where no signals are listed, no signal-response
relationships reached an acceptable level of significance (p < 0.05). p-ERK1/2 at 12 hr is positively
correlated with A %apoptosis between 12-24 hr following treatment. These data suggest that ERK1/2
activity between 8 and 12 hr following treatment may have a role in promoting apoptosis following DNA
damage, and further supports a dual role for p-ERK1/2 in mediating both cell-cycle regulatory and
apoptotic responses following DNA damage. For further details on individual Time-Interval models in
this set, and on the full TI-SWR analysis, reference Supplemental Figure 3-16 through 3-25.
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